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Integrins are heterodimeric transmembrane proteins and have been shown to play a key 
role in insulin signalling and glucose metabolism. Integrin α7β1 is the predominant 
integrin in adult skeletal muscle, a tissue responsible for approximately 80% of insulin-
stimulated glucose uptake. Previous studies have demonstrated the role of integrin α7β1 
in the maintenance of skeletal muscle, but no studies have investigated it with a 
metabolic focus. In this thesis, we used an integrin α7 whole-body deletion mouse model 
(α7KO) to elucidate the role of integrin α7 in metabolism. 
In this study we showed that the deletion of integrin α7 resulted in leaner mice when fed 
either a chow or a high fat diet (HFD), as well as containing significantly less adipose 
tissue than controls when fed a HFD. Histological analysis showed that integrin α7KO 
mice suffered from significantly worse liver steatosis when fed a HFD compared to 
controls and had higher serum levels of indicative enzymes of liver damage. However, 
liver damage observed in integrin α7KO mice had no effect on bile acid production.  
Integrin α7KO mice were significantly more insulin sensitive and glucose tolerant than 
control mice. Protein quantification of skeletal muscle showed increased levels of 
pAkt(Ser473) and pAkt(Thr308) in integrin α7KO mice compared to controls when fed a 
HFD and were exacerbated when challenged with insulin. 
We demonstrated that the muscle-specific transgenic overexpression of the adult 
integrin α7 splice variants X2A and X2B rescued the insulin sensitive, glucose tolerant, 
and steatotic liver phenotype. However, splice variants X1A and X1B could not rescue 
the insulin sensitive or glucose tolerance phenotype, but partially rescued the steatotic 
liver phenotype. 
In this thesis, we have demonstrated that integrin α7 plays a fundamental role in diet-
induced obesity and metabolism. 
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1.1 The obesity pandemic 
Over the past 40 years, the world has transitioned from one where there were more than 
double the amount of people underweight than obese, to one in which there are more 
obese than underweight. If current trends are to continue, by 2025, almost 20% of the 
world will be classified as obese with a body mass index (BMI) of >30 kg/m2 (NCD Risk 
Factor Collaboration (NCD-RisC), 2016). Matters are worse in the United Kingdom. In 
2015, the UK was ranked 6th globally as having the largest percentage of obese adults 
(OECD, 2017). Current models predict that by 2030, 36% of men and 33% of women 
from the United Kingdom will be obese (World Health Organization, 2013).  
The causes of obesity are multifactorial, with a combination of environmental, epigenetic 
and genetic factors leading to obesity. The simplest conception of obesity is when 
ingested energy is greater than expended energy and excess energy is stored as mostly 
triglyceride in adipose tissue. However, these environmental factors are avoidable with 
the main causes being the increased ingestion of calorie-dense food and a reduction in 
physical activity in daily life (Brehm and D’Alessio, 2000). 
Obesity has been linked with a range of noncommunicable diseases including 
cardiovascular diseases, musculoskeletal disorders, cancer and type II diabetes mellitus 
(T2DM). The risk of these diseases increases with a greater BMI (World Health 
Organization, 2018). One of the greatest precursors of T2DM is insulin resistance 
(Taylor, 2012). In this study, the interplay between diet-induced obesity and insulin 






In 1921, Dr Frederick Banting began his experiments which led to the discovery of 
insulin. The removal of the pancreas from dogs resulted in diabetic-like symptoms. The 
administration of pancreas extracts to these dogs reversed the symptoms temporarily 
(Banting et al., 1922). A year later, the first human trial was completed on a diabetic 14-
year-old boy whose symptoms were reversed by the administration of Banting’s 
pancreas extract. The ability to restore health in such a dramatic fashion was described 
as “the raising of the dead”. The active compound in these extracts was identified and 
named ‘insulin’ for which Banting was awarded the Nobel Prize in 1923 (Quianzon and 
Cheikh, 2012). 
Insulin is a peptide hormone secreted by the β cells located in the islets of Langerhans 
found in the pancreas. It is secreted when blood glucose levels are elevated and 
oversees the controls of cellular glucose uptake, the regulation of carbohydrate, lipid and 
protein metabolism, and also affects cell division and growth. 
1.2.1 Insulin structure and synthesis 
Insulin is initially translated by pancreatic β cells as a single polypeptide precursor called 
preproinsulin. It is comprised of the signal peptide, insulin B-chain, C-peptide, and insulin 
A-chain. In the endoplasmic reticulum, proinsulin is formed by the enzyme signal 
peptidase, removing the signal peptide which causes proinsulin to adopt a 3-dimensional 
structure. Proinsulin is transferred to the Golgi apparatus, where the subsequent 
cleavage of the C-peptide forms the completed insulin dipeptide hormone. The mature 






Figure 1.1: Synthesis of insulin from preproinsulin in pancreatic β cells 
 
1.2.2 Insulin secretion 
The main stimulus of insulin secretion is elevated blood glucose, which is appropriate as 
insulin’s primary role is to regulate the concentration of blood glucose. β cells can detect 
changes in blood glucose concentration by clustering adjacent to vasculature. Elevated 
levels of blood glucose are detected by glucose diffusing into the β cells via glucose 
transporter-2 (GLUT2). Glucose is metabolised into pyruvate via glycolysis which is 
further metabolised to generate ATP. This increased ATP:ADP ratio causes ATP-
dependent potassium channels to close, depolarising the cell membrane. Depolarisation 
causes voltage-gated calcium channels to open, allowing Ca2+ to stimulate the 
movement of secretory granules containing insulin for release into the blood (Bonfanti et 





Figure 1.2: Summary of the process of insulin secretion in pancreatic β cells. Elevated blood 
glucose concentrations infiltrate the pancreas via GLUT2. Glucose undergoes glycolysis which 
results in the production of ATP. ATP-dependent K+ channels cause depolarisation of the cell 
resulting in an increase in intracellular Ca2+. Ca2+ is the primary trigger for exocytosis of the insulin-




1.2.3 Insulin signalling 
1.2.3.1 Insulin receptor 
Insulin mediates its actions by binding to the insulin receptor (IR) on various tissues 
whilst being transported via blood circulation. Mutant animal studies have demonstrated 
the crucial role the IR plays in vivo. The IR has been found to be essential for postnatal 
growth and metabolism, but is not required for foetal metabolism (Taylor, 1999; 
Sadagurski et al., 2006). Most tissue-specific knockouts of the IR led to T2DM-like 
conditions (Kulkarni et al., 1999). X-ray crystallography has been successfully utilised to 
determine the structure of the IR and also the mechanical link between insulin binding 
and activation (Hubbard, 1997; Scapin et al., 2018). 
The IR is a heterodimeric membrane glycoprotein composed of two α-chains, two β-
chains, a transmembrane helix, the juxtamembrane domain and the intracellular tyrosine 
kinase domain. Insulin binds to the extracellular α subunits which causes a 
conformational change. This change allows ATP to bind the β subunits intracellular 
domain, activating receptor autophosphorylation of tyrosine residues (Tavaré and Siddle, 
1993; Hubbard, 1997; Scapin et al., 2018). 
Insulin is not the only agonist of IR. The IR can also bind to insulin-like growth factors 
(IGF-1 and IGF-2). However, the affinity of IGF-1 is approximately 100-1000-fold lower 
than insulin (Andersen et al., 1992). But as IGF-1 circulation is approximately 100-fold 
higher than insulin, IGF-1 still plays a significant role in IR activation. 
1.2.3.2 Insulin receptor substrates 
Following activation of the IR by insulin, the auto-phosphorylated tyrosine residues act 
as docking sites for proteins, including the insulin receptor substrates (IRS). The IRS 
proteins are cytoplasmic adaptor proteins that transmit signals from the IR and IGF-1 





Both IRS-1 and IRS-2 are ubiquitously expressed  and are the primary mediators of 
glucose metabolism and insulin-dependent mitogenesis in most cell types (White, 2002). 
Deletion of IRS-1 resulted in impaired growth, decreased glucose tolerance and 
peripheral insulin resistance. However, it has been shown that IRS-2 can compensate 
for a lack of IRS-1 (Araki et al., 1994). Deletion of IRS-2 also resulted in insulin resistance 
but also a defect in pancreatic β cells (Kubota et al., 2000). IRS-3 shares homology with 
IRS-1 and IRS-2, however is specific to adipocytes. In contrast to IRS-1 and IRS-2, IRS-
3 deficient mice appear to have no obvious differing phenotype in terms of metabolism 
from control mice (Liu et al., 1999). Further studies demonstrated that IRS-3 localises to 
the nucleus and possesses transcription-regulating activity (Kabuta et al., 2002). IRS-4 
is restricted to the thyroid, brain, kidney and pancreatic β cells. IRS-4 is able to activate 
downstream proteins in the insulin signalling pathway in vitro but in vivo studies have 
shown there is no obvious phenotype in IRS-4 deficient mice (Tsuruzoe et al., 2001; 
Uchida et al., 2000). IRS-5 has been shown to be restricted to kidney and liver, whilst 
IRS-6 is restricted to skeletal muscle. However, both have limited function in signal 
transduction (Cai et al., 2003). 
All IRS proteins share a significant degree of homology. All contain an NH2-terminal 
pleckstrin-homology (PH) domain for phospholipid binding, which lies adjacent to a 
phospho-tyrosine-binding (PTB) domain, followed by a COOH-terminal tail which 
contains a variety of tyrosine, threonine and serine phosphorylation sites. The 
phosphorylation status of these sites regulate the downstream signalling proteins  (Sun 
et al., 1991; Yenush et al., 1998). It is this complex patterning of >50 serine, threonine 
and tyrosine residues in IRS-1 and IRS-2 which allows the intricate control of 
downstream effects. Most tyrosine phosphorylation sites have been shown to promote 
the effects of insulin stimulation. Phosphorylation of the tyrosine residues leads to the 
generation of binding sites for Src homology 2 (SH2) domain proteins. Activation of 




possible with the phosphorylation of tyrosine-612 and tyrosine-632 in humans (Esposito 
et al., 2001). In contrast to tyrosine sites, serine and threonine sites have been shown to 
reduce the effects of insulin signalling. Tumour necrosis factor alpha (TNFα) has been 
shown to inhibit insulin action by activating various kinases including, Jun NH(2)-terminal 
kinase (JNK). JNK phosphorylates serine-307, adjacent to the PTB-domain, and has 
been shown to reduce tyrosine phosphorylation by disrupting the IR/IRS-1 interaction 
(Aguirre et al., 2000; Solinas and Karin, 2010).  
1.2.3.3 Phosphoinositide 3-kinase 
PI3K is one of the key targets of the IRS proteins. It is a heterodimer composed of a 
p110 catalytic subunit and a p85 regulatory subunit which interacts with phosphorylated 
tyrosine residues of the IRS proteins. When PI3K is bound to IRS, it is brought close to 
its substrate phosphatidylinositol-4,5-bisphosphate (PIP2), which it phosphorylates to 
form phosphatidylinositol-3,4,5-triphosphate (PIP3) (Lietzke et al., 2000). PIP3 is 
subsequently able to regulate the AGC family of serine/threonine protein kinases 
including phosphoinositide-dependent kinase 1 (PDK1) (Alessi et al., 1997). PDK1, 
along with mTORC2, is able to phosphorylate Protein Kinase B/Akt, a critical signalling 
node of the insulin signalling pathway (Gao et al., 2014). 
Negative regulation of the insulin signalling pathway can also occur at the PI3K level. 
The lipid phosphatase, PTEN (phosphatase and tensin homolog deleted on 
chromosome 10) opposes the activity of PI3K by dephosphorylating PIP3 (Chalhoub and 
Baker, 2009).  
1.2.3.4 Protein kinase B/Akt 
Protein kinase B, or Akt as it will be referred to, is one of the key nodes of the insulin 
signalling pathway. As well as regulating nutrient metabolism, Akt is also heavily involved 
in a range of pathways which influence cell growth and apoptosis. The three isoforms of 




central serine/threonine kinase domain and a carboxyl-terminal regulatory domain. Akt 
isoform expression is dependent on tissue. Akt1 is ubiquitously expressed and has been 
shown to be the key isoform involved in lipid metabolism and the stimulation of glycogen 
synthesis in skeletal muscle, as well as the modulator of insulin function in adipocytes 
(Jiang et al., 2003; Bouzakri et al., 2006). Akt2 is expressed at a higher level in insulin-
responsive tissues including: adipose tissue, liver, and skeletal muscle. Akt3 has been 
shown to be expressed highest in the brain and other non-insulin sensitive tissues (Yu 
et al., 2015)  
PIP3 is able to bind to the PH domain of Akt and recruit it to the plasma membrane with 
the assistance of phosphatidylserine (PS) where it is phosphorylated on site 
Threonine308 by PDK1 (Wick et al., 2000; Huang et al., 2011). Phosphorylation of 
Threonine308 stabilises the activation loop in an active conformation and allows 
mTORC2 to phosphorylate at Serine473. The phosphorylation of Threonine308 and 
Serine473 of Akt results in full activation of the Akt kinase (Alessi et al., 2009; Liao and 
Hung, 2010). Fully activated Akt is then able to link insulin signalling with downstream 
regulators of glucose transporters. 
1.2.3.5 Glucose transporters 
Glucose is transported into cells by glucose transporters (GLUTs). GLUT4 is one of 14 
members of the GLUT family, a group of transmembrane hexose transporters, and is the 
most common GLUT in skeletal muscle and adipose tissue. GLUT4 is accompanied by 
GLUT1, GLUT5 and GLUT12 in skeletal muscle, and GLUT8, GLUT12, and proton-
coupled myo-inositol transporter (HMIT) in adipose tissue (Huang and Czech, 2007). 
However, it is only GLUT4 that has the characteristic of intracellular 
compartmentalisation in the insulin-unstimulated state that allows insulin to sensitively 
regulate glucose uptake (Bryant et al., 2002). In the absence of insulin, ~95% of GLUT4 
is distributed between the endosomes, the trans-Golgi network and heterogeneous 




et al., 2003). These vesicles contain a multitude of proteins including: transferrin 
receptor, insulin-responsive aminopeptidase (IRAP), sortilin, and low-density lipoprotein 
receptor-related protein-1 (LRP1) (Tanner and Lienhard, 1987; Larance et al., 2005). 
Once formed, these vesicles remain within unstimulated cells until stimulated by insulin 
(Bogan and Kandror, 2010). Upon stimulation by insulin, the translocation of GLUT4 to 
the cell surface can increase glucose uptake by 10-40 fold, dependent on the tissue 
(Bryant et al., 2002). Remarkably, GLUT4-deficient mice do not develop diabetes. 
Although not as sensitive to insulin, GLUT4-deficient mice are still effective at clearing 
glucose (Katz et al., 1995). This indicates that compensation by other GLUT isoforms 
occurs.  
As previously mentioned, Akt is the node which connects insulin and GLUT4 
translocation. Studies have demonstrated that Akt is required for an insulin-mediated 
prefusion step of the GLUT4 vesicle to within 250 nm of the plasma membrane. The 
main target for phosphorylated Akt in GLUT4 translocation is Rab GTPase-activating 
protein AS160/TBC1D4 and it has been shown that its activation is pivotal to the 
translocation process. Dominant-inhibitory mutation of AS160 leads to inhibition of 
insulin-stimulated exocytosis of GLUT4 (Zeigerer et al., 2004; Mîinea et al., 2005). 
Studies have also demonstrated that soluble N-ethlymaleimide-sensitive factor 
attachment protein receptor (SNARE) proteins, including Synip and CDP138, are 
downstream substrates of Akt and further regulate GLUT4 vesicle fusion with the plasma 
membrane (Min et al., 1999; Yamada et al., 2005). The fusion of the GLUT4 vesicle with 
the plasma membrane then allows GLUT4 to interact with extracellular glucose 
(Gonzalez and McGraw, 2006). 
1.2.3.6 Signalling through the MAP kinase pathway 
Although the primary role of insulin signalling is the uptake of glucose, insulin is also 
involved in other signalling pathways. One such pathway is the Ras/Raf/MEK/ERK 




with SH2 domains, including GRB2/SOS (Pruett et al., 1995). Upon activation, 
GRB2/SOS binds to Ras, a small GTP-binding protein, which exchanges GDP for GTP 
and undergoes a conformational change. Active Ras then phosphorylates Raf and 
recruits it to the cell membrane. Raf activates MEK 1/2 which consequently 
phosphorylates ERK 1/2. ERK 1/2 is responsible for a variety of functions throughout the 
cell, but the most significant is the control of gene transcription that control cell growth 





Figure 1.3: Summary of the insulin signalling pathway. Activation of the insulin receptor by 
insulin results in autophosphorylation of tyrosine residues in the β subunit. These residues result 
in the phosphorylation of the insulin-receptor substrates (IRS) and activation of phosphoinositide 
3-kiase (PI3K). This results in the conversion of phosphatidylinositol-4,5-bisphosphase (PIP2) to 
phosphatifylinositol-3,4,5-triphosphate (PIP3) and the activation of phosphoinositide-dependent 
kinase 1 (PDK1). PDK1 phosphorylates Akt resulting in the translocation of GLUT4-containing 




1.2.4 Defected insulin signalling 
1.2.4.1 Type I diabetes mellitus 
Type I diabetes mellitus (T1DM) is an autoimmune disease typically caused by the 
destruction of pancreatic β cells. Lack of pancreatic β cells results in severe 
hyperglycaemia due to lack of insulin production (Atkinson et al., 2014). Therefore, in 
patients with T1DM, hyperglycaemia is not caused by insulin signalling deficiency, but 
rather by a lack of production of insulin. In approximately 70-90% of T1DM incidences, 
pancreatic β cell loss is caused by autoimmunity and is known as type Ia diabetes 
mellitus (T1aDM). However in other cases, there are no detectable autoantibodies and 
the cause of β cell loss is currently unknown, termed type Ib diabetes mellitus (Maraschin 
et al., 2010). 
Patients with T1aDM possess autoantibodies for one or more of: insulin (IAA), glutamic 
acid decarboxylase (GADA), insulinoma-associated autoantigen 2 (IA-2A), and zinc 
transporter 8 (ZnT8A) (Bingley, 2010). Approximately 70% of patients with T1aDM have 
three or four of these markers, which typically appear years before symptomatic onset. 
Analysis of pancreata from patients with T1DM has demonstrated that approximately 
70% of islets are completely absent of insulin, with a remaining 20% being inflamed 
(Keenan et al., 2010). Of the remaining islets, they possess a normal population of other 
cells (Willcox et al., 2009). Studies have demonstrated that the predominant cell types 
causing the inflammation of islets are CD8(+) cytotoxic T cells followed by: macrophages 
(CD68(+)), CD4(+) cells, B lymphocytes (CD20(+)), and plasma cells (CD138(+)). 
1.2.4.2 Type II diabetes mellitus 
Type II diabetes mellitus (T2DM) is a chronic metabolic disorder with both genetic and 
environmental factors, the largest being obesity. It is estimated that by 2045, 693 million 
people will suffer from T2DM (International Diabetes Federation, 2017). 




malfunction of various metabolic tissues. Insulin resistance typically precedes T2DM by 
10 to 15 years. It is the combination of insulin resistance and pancreatic β cell impairment 
which results in T2DM. Proinflammatory cytokines have been associated with obesity 
and insulin resistance. As with T1DM, inflammation of the β cells can lead to impaired 
insulin production. Reduced insulin production results in hyperglycaemia, which has 
been associated with oxidative stress and further inflammation (Cerf, 2013). The 
progression of malfunction in metabolic tissues, which leads to insulin resistance, will be 




1.3 Metabolic tissues 
Metabolism is a complex system overseen by multiple organs. The development of 
obesity and insulin resistance is also multifaceted where the synergy of these tissues is 
disrupted. By understanding how these organs work in the metabolomic system, the 
intricacies of obesity and insulin resistance can be unravelled. 
1.3.1 Pancreas 
The primary function of the pancreas for the regulation of energy metabolism is the 
release of digestive enzymes and pancreatic hormones. The majority of the pancreas is 
made up of acinar cells which, along with the duct cells, secrete the ‘pancreatic juice’ 
composed of amylase, pancreatic lipase, and trypsinogen (Matull et al., 2006). The 
hormones of the pancreas are released by endocrine cells which cluster together to form 
the islets of Langerhans which make up only 1-2% of the organ (Baetens et al., 1979; 
Chandra and Liddle, 2009). Of the population of cells in the islets of Langerhans, 
glucagon-producing α-cells represent 15-20%; insulin-producing β-cells represent 3-5%; 
pancreatic polypeptide-producing γ-cells represent 3-5%, somatostatin-producing δ-
cells represent 3-10%, and ghrelin-producing ɛ-cells represent <1% (Katsuura et al., 
2002; Brissova et al., 2005). 
It is the combination of the blood glucose-increasing glucagon and the glucose-
decreasing insulin which facilitates normal glucose homeostasis. The stimulation and 
release of insulin has been discussed previously in Section 1.2.2. The secretion of 
glucagon follows a similar pattern in that it is controlled by glucose levels. Hypoglycaemia 
directly stimulates the pancreatic α cells to release glucagon (Quesada et al., 2006). 
Secretion of glucagon is facilitated by sodium and calcium channels by maintaining 
action potentials during hypoglycaemia. Ca2+ influx is increased by depolarisation and 
promotes glucagon secretion, supported by ATP-sensitive potassium channels 




receptor, expressed mostly in the liver and kidney (Svoboda et al., 1994). As expected, 
glucagon receptor-null mice have improved glucose tolerance and lower blood glucose 
levels caused by increased insulin sensitivity. However, prolonged fasting resulted in 
severe hypoglycaemia (Conarello et al., 2007; Gelling et al., 2003). 
1.3.2 Liver 
In normal fed conditions, ingested carbohydrates are broken down by glucosidases in 
the digestive tract to generate mostly glucose. Glucose is transported into tissues to 
function as the primary fuel in ATP production (Nordlie et al., 1999). This is facilitated via 
glycolysis where tissues with mitochondria use the catabolism of glucose to pyruvate to 
generate GTP, NADH and FADH2. These can function in electron transport chain-
oxidative phosphorylation, generating ATP (Rui, 2014). The glycolysis system is 





Figure 1.4: Summary of the glycolysis system. One molecule of glucose has two phosphate 
groups attached to it via ATP to form unstable fructose-1,6-bisphosphate. Fructose-1,6-
bisphosphate is broken down to form DHAP and glyceraldegyde-3-phosphate. DHAP is easily 
converted to glyceraldehyde-3-phosphate by triose phosphate isomerase. From the conversion 





The liver modulates glucose homeostasis by regulating various pathways of metabolism 
including glycogenesis, glycogenolysis, glycolysis, and gluconeogenesis (Rui, 2014). 
Energy is stored in the liver in the form of glycogen via glycogenesis in times of glucose 
and ATP surplus. This synthesis of glycogen from glucose takes place in the cytosol and 
requires an input of ATP and UTP. The key enzyme in glycogenesis is glycogen 
synthase, which facilitates the elongation of glycogen chains using one ATP molecule 
per glucose molecule incorporated into the glycogen chain (Miller and Larner, 1973). The 
process is promoted by insulin signalling via Akt which phosphorylates and inactivates 
glycogen synthase kinase-3 (GSK-3), a key inhibitor of glycogen synthase (Fang et al., 
2000). The formation of glycogen is critical for maintenance of normal blood glucose 
concentrations in times of short-term fasting, such as overnight whilst sleeping. The liver 
typically contains enough glycogen storage for 12-24 hours of fasting (Hers, 1976). 
Under fasting conditions, glycogen is converted to glucose via glycogenolysis via 
glycogen phosphorylase. This enzyme is the catalyst which removes glucose residues 
from glycogen chains, generating glucose 1-phosphate which is further converted to 
glucose 6-phosphate, via phosphoglucomutase. Glucose 6-phosphate can then be 
utilised in glycolysis. (Rhyu et al., 1984; Agius, 2015). 
As previously mentioned in Section 1.3.1, pancreatic α-cells release glucagon, a 
fundamental hormone in the regulation of blood glucose concentrations. The majority of 
glucagon receptors required to mediate the hormone’s effects are located in the 
hepatocytes. During hypoglycaemia, glucagon is released from the pancreas into the 
blood stream and is able to bind to the glucagon receptor. This results in a conformational 
change of the glucagon receptor leading to activation of two heterotrimeric G proteins: 
GSα and Gq (Burcelin et al., 1996). The activation of GSα leads to the activation of Protein 
Kinase A (PKA) via cAMP. PKA has a variety of functions in the liver but it is the main 
method by which glucagon regulates the production of glucose as summarised in Figure 




glycogen phosphorylase. This results in increased conversion of glycogen to glucose-1-
phosphate and glucose-6-phosphate. Studies have also demonstrated that glucagon 
increases glucose-6-phosphatase activity via PKA-mediated transcription of peroxisome 
proliferator-activated receptor-γ coactivator-1 (PGC-1), further promoting the conversion 
of glucose-6-phosphate to glucose (Striffler et al., 1984; Yoon et al., 2001). Furthermore, 
PKA has been found not only to promote glycogenolysis but also to impede 
glycogenesis. Glycogen synthase is only active when dephosphorylated, however, PKA 
is able to phosphorylate the enzyme (Ramachandran et al., 1983). By promoting 




Figure 1.5: Summary of the effects of glucagon on glycogenolysis and glycogenesis in the 
liver. Glucagon-activated PKA activates glycogen phosphrorylase kinase, further activating 
glycogen phosphorylase. PKA promotes transcription of proliferator-activated receptor-γ 
coactivator-1 which results in glucose 6-phosphatase activity. Glycogen synthase is deactivated 
by glucagon-dependent PKA. Green – Positively regulated by glucagon. Red – Negatively 





1.3.2.1 Hepatocyte insulin resistance 
Hepatocytes, like most other cells in the body, are vulnerable to becoming insulin 
resistant. Consequentially, there is decreased suppression of glycogenesis, resulting in 
increased blood glucose concentrations. Furthermore, this increased glucose in the 
blood is not taken up by insulin-sensitive tissues. 
Mice with hepatocyte-specific deletion of the insulin receptor completely lack the ability 
to suppress hepatic glucose production via insulin (Michael et al., 2000). Furthermore, 
these mice had extremely high circulating insulin levels due to impaired insulin clearance 
and production and resulted in modified insulin-regulated gene transcription, with 
increased expression of PEPCK, the rate limiting enzyme for gluconeogenesis. 
Together, the liver plays a paramount role in glucose homeostasis via glucagon and 
insulin. Slight modifications of the intricate pathways can result in adverse glucose and 
insulin signalling. 
1.3.3 Adipose tissue 
Typically, adipose tissue is classified into two subtypes: white and brown. The most 
abundant form of adipose tissue in mammals is white adipose tissue (WAT) and its 
primary cell type is the adipocyte. White adipocytes have a single unilocular lipid droplet 
and few mitochondria, whereas, brown adipocytes are multilocular and abundant in 
mitochondria (Cedikova et al., 2016) . 
The primary function of WAT is the storage and release of lipid/fatty acids in response to 
metabolic needs. Adipocytes are the primary cell type in adipose tissue and are 
commonly stored either subcutaneously or viscerally. Subcutaneous white adipose 
tissues (SWAT) makes up 80% of normal total body fat distribution and is typically found 
clustered around the abdomen and gluteofemoral regions (Lee et al., 2013b). 
Alternatively, adipose tissue is stored viscerally as visceral adipose tissue (VAT) which 




studies have demonstrated that SWAT has beneficial effects on metabolism. 
Transplantation of SWAT into VAT depots resulted in mice with a decrease in body 
weight, total fat mass, and glucose and insulin levels. Furthermore, these mice had 
markedly improved insulin sensitivity (Tran et al., 2008). 
1.3.3.1 Adipose tissue and metabolism 
White adipocytes mediate energy levels by storage of triglycerides (TGs) and the release 
of free fatty acids (FFAs). During times of hyperglycaemia, energy is stored as TGs 
through lipogenesis (Figure 1.6). Elevated glucose levels promote the release of insulin 
from pancreatic β-cells. Insulin binds to the insulin receptor and facilitates the 
translocation of GLUT4 and uptake of glucose through phosphorylation of Akt. Once 
glucose has been transported into the adipocyte, glycolysis takes place. Two of the by-
products of glycolysis are acetyl-coenzyme A (acetyl-CoA) and glycerol 3-phosphate 
which are crucial in lipogenesis. This results in increased production of acetyl-coenzyme 
A carboxylase (ACC), the rate-limiting enzyme of lipogenesis (O’Callaghan et al., 2001). 
Although adipocytes can produce FFAs, the majority used in the generation of TGs are 
taken from the blood stream, which are primarily generated in the liver (Jensen-Urstad 
and Semenkovich, 2012). To enable hydrolysis of the circulating TGs, lipoprotein lipase 
(LPL) is released from tissues that oxidise or store fatty acids including muscle and 
adipose tissue. Strict regulation of the production of LPL occurs as it is rate limiting for 
plasma TG clearance (Kersten, 2014). The final step in the esterification of FFAs to form 
TGs uses acyl CoA:diacylglycerol acyltransferase (DGAT). DGAT catalyses the covalent 
addition of a fatty acyl chain to diacylglycerol. Mice lacking DGAT2, the enzyme specific 
to adipose tissue, had reduced TG storage in all tissues and died shortly after birth 
(Harris et al., 2011).  
It times of energy needs, adipocytes are able to provide FFAs and glycerol via lipolysis 
(Figure 1.6). These freed FFAs can be used for energy via oxidation and glycerol can be 




activate PKA via cAMP. Adrenaline is released via the sympathetic nervous system 
during times of fasting and activates PKA via β-adrenergic receptor activation. (Leiter et 
al., 1984; Gelinas et al., 2008). TGs are initially converted to diglycerides (DGs) via the 
enzyme, adipocyte triglyceride lipase (ATGL) (Jiang et al., 2016). The second key 
enzyme is hormone-sensitive lipase (HSL) which is transported by phosphorylated 
perilipin, activated by PKA, and hydrolyses DGs to monoglycerides (MGs). MGs are 
further broken down by monoglyceride lipase into FFAs and glycerol, before being 





Figure 1.6: Summary of lipogenesis and lipolysis in adipocytes. Triglycerides (TGs) are 
stored via lipogenesis. Downstream activation of the insulin receptor causes the uptake of glucose 
via GLUT4. Acetyl-CoA induces the expression of Acetyl-CoA Carboxylase (ACC), a key enzyme 
in the conversion of free fatty acids (FFAs) to TGs. This is achieved by lipoprotein lipase (LPL) 
hydrolysing fatty acids from TGs before they are taken up by the adipocyte. These FFAs are 
converted to TGs via Acyl-CoA:diacylglycerol acyltransferase (DGAT).  Lipolysis involves the 
liberation of FFAs from stored TGs. Downstream activation of catecholamine-activated β-
adrenergic receptors phosphorylate perilipin via PKA and cAMP. Perilipin transports hormone-
sensitive lipase (HSL) to hydrolyse diglycerides (DGs) to monoglycerides (MGs) before being 




1.3.3.2 Brown adipose tissue function 
The main difference between white and brown adipose tissue (BAT) is whilst WAT stores 
energy in the form of triglycerides, BAT dissipates energy by generating heat through 
non-shivering thermogenesis (Figure 1.7). The process is initiated by the binding of 
secreted adrenaline to β3-adrenergic receptors, located on mature brown adipocytes. 
Epinephrine is secreted by the adrenal glands during hyperglycaemia and in response 
to cold exposure (Johnson et al., 1977; Schwartz et al., 1983). β-adrenergic signalling 
activates cAMP which leads to the activation of PKA (Kim et al., 2014). As discussed in 
Section 1.3.3.1, PKA can lead to the breakdown of triglycerides to FFAs. Although some 
FFAs are released, most are shuttled to the mitochondria to act as the substrate for 
thermogenesis. These fatty acids undergo β-oxidation with released acetyl-CoA being 
oxidised in the citric acid cycle (Williamson et al., 1969). Usually, the next step would be 
the movement of protons through ATP synthase to generate ATP. However, non-
shivering thermogenesis uses this stream of protons to sacrifice the production of ATP 
to produce heat via uncoupling protein 1 (UCP1). UCP1 is the key protein responsible 
for non-shivering thermogenesis and distinguishes WAT from BAT. UCP1 is a member 
of the mitochondrial carrier protein family and is located on the inner mitochondrial 
membrane. Its primary function is the uncoupling of proton transport from ATP production 
to fuel oxidation and the generation of heat (Fedorenko et al., 2012). 
It was long thought that non-shivering thermogenesis was specific to BAT until UCP1 
was detected in seemingly white adipocytes. However, these adipocytes were found to 
be of a distinct lineage of white adipocytes. Further studies also demonstrated that 
exposure of prolonged coldness and β-adrenergic agonist treatment resulted in them 
becoming more phenotypically brown (Cousin et al., 1992; Loncar, 1991). These unique 
adipocytes were termed ‘brite’ (brown-like-in-white) and appeared to populate WAT in 
sub depots (Nedergaard and Cannon, 2014). Several mouse studies have demonstrated 




brite adipocytes, mice showed resistance to obesity and improved insulin signalling 
(Kopecky et al., 1995; Cederberg et al., 2001; Seale et al., 2011). However, to date, no 






Figure 1.7: Summary of non-shivering thermogenesis pathway in brown/brite adipocytes. 
The mitochondria of brown and beige adipocytes are abundant in UCP1 (uncoupling protein 1). 





1.3.3.3 Adipose tissue as an endocrine organ 
Although adipose tissue is a crucial organ for the regulation of glucose, it has also been 
recognised as an important endocrine organ. Cytokines produced by adipose tissue, 
termed ‘adipokines’, are expressed by the non-adipocyte fraction of adipose tissue, 
namely resident immune cells. These adipokines have a spectrum of effects and can 
modulate the immune response, inflammation, glucose metabolism, insulin secretion, 
vascular growth, adipogenesis, and lipid metabolism (Fasshauer and Blüher, 2015). 
One of the primary adipokines secreted by adipocytes is leptin. Leptin is secreted by 
adipocytes proportionally to their TG levels and has shown to be expressed higher in 
SWAT than VAT (Fain et al., 2004). Discovered in 1994, leptin was found to be the 
product of the obese (ob) gene where the primary phenotype was the suppression of 
satiety (Zhang et al., 1994). Studies demonstrated that those with leptin deficiency 
(ob/ob) and those with a mutant leptin receptor (db/db) displayed increased food 
consumption, decreased energy expenditure, and severe obesity. 
Leptin mediates its effect on satiety by binding to the leptin receptor in the hypothalamus 
and influences pathways including the JAK-STAT pathway. The downstream effects of 
the JAK-STAT pathway include the inhibition of orexigenic neurons and regulating 
neuropeptides (Bjørbaek and Kahn, 2004). Furthermore, leptin has been shown to 
directly influence glucose homeostasis by binding to leptin receptor present on 
pancreatic β-cells, suppressing insulin secretion (Covey et al., 2006). 
The other key adipokine secreted by adipocytes is adiponectin. Whereas leptin 
suppresses insulin production, adiponectin enhances insulin sensitivity (Berg et al., 
2001). Adiponectin encourages adipocyte lipid storage, protecting other organs from lipid 
fat deposition (Fu et al., 2005). It has also been shown to suppress gluconeogenesis by 




1.3.3.4 Adipose tissue and insulin resistance 
The link between obesity and insulin resistance has been countlessly reproduced, 
demonstrating that adipose tissue likely plays a key role in the generation of insulin 
resistance. The hypertrophic expansion of adipocytes is a normal function to cope with 
increasing levels of FFAs. By adipocytes absorbing FFAs and storing as TGs, this 
protects other organs from ectopic fat depositions, causing lipotoxicity. Larger adipocytes 
are able to deal with an immediate influx of FFAs more efficiently than smaller adipocytes 
(Johannsen et al., 2014). However, adipocytes have a limit on by how much they can 
expand. Larger adipocytes can exhibit a hypoxic response resulting in the induction of 
hypoxic-response genes, oxidative stress, and inflammation (Netzer et al., 2015). 
The inflammatory response, caused by hypertrophic hypoxia, results in the invasion of 
WAT with macrophages (Dicker et al., 2013). These macrophages release a range of 
pro-inflammatory cytokines but also the promotion of TNFα, which results in further 
expression of cytokines in preadipocytes (Xu et al., 2003). In vivo studies have 
demonstrated that the neutralisation of TNFα in obese rats results in improved insulin 
signalling but unfortunately this has not been reproduced in humans (Hotamisligil et al., 
1994; Ofei et al., 1996). Chronic inflammation caused by hypoxic adipocytes is likely one 
of the key nodes in the development of insulin resistance, both locally and systemically.  
1.3.4 Skeletal muscle 
1.3.4.1 Skeletal muscle as a metabolic tissue 
In this section we will discuss the role skeletal muscle has as a metabolic tissue. The 
structure and function of the tissue will be further discussed in Section 1.4. 
Skeletal muscle makes up 40% of total body weight and is responsible for ~80% of 
insulin-stimulated glucose uptake, therefore it is no surprise that the tissue has a 
substantial influence on metabolism. Furthermore, as the primary function of skeletal 




physical activity is one of the key risk factors in the development of obesity. 
The major limiting step for the skeletal muscle to utilise and clear glucose is the 
translocation of the GLUT4 receptor. Insulin resistance involves the impairment of the 
IRS-PI3K-Akt pathway, resulting in reduced number of GLUT4 being transported to the 
cell surface. A number of reasons have been proposed for the generation of insulin 
resistance specific to skeletal muscle. Ectopic fat deposition in skeletal muscle has been 
suggested to be a significant contributor to the onset of insulin resistance, as well as 
decreased mitochondrial oxidative capacity. It has been suggested that this is due to the 
accumulation of intracellular fatty acyl CoA, diacylglycerol and ceramides (Lowell and 
Shulman, 2005). This accumulation may result in the decreased activation of PI3K via 
increased IRS-1 phosphorylation of the serine sites (Morino et al., 2005). 
It has also been suggested that the composition of skeletal muscle influences insulin 
sensitivity dependent on the ratio of type I:II fibres. Studies have demonstrated that 
patients with insulin resistance and higher blood pressure possess a large number of 
type II glycolytic fibres compared to type I fibres (Hernández et al., 2001). However, it is 
unclear how significant the composition of fibres is in comparison to other risk factors. 
Oxidative stress has also been proposed as a potential contributor to insulin resistance 
in skeletal muscle. Skeletal muscle has been shown to overproduce superoxide ions and 
hydrogen peroxide in insulin resistant models (Blendea et al., 2005). It has been 
suggested that the major contributor of reactive oxygen species (ROS) is excessive 
glucose and free fatty acid metabolism via mitochondrial electron leak. Although not 
specifically tested in myocytes, elevated ROS has been shown to impair insulin-
stimulated GLUT4 translocation in adipocytes, possibly via serine phosphorylation of 
IRS-1 (Rudich et al., 1998). 
As previously mentioned when discussing adipose tissue, skeletal muscle is susceptible 




inflamed, hypoxic adipocytes is TNFα. Studies have demonstrated that chronic 
inflammation caused by the secretion of TNFα results in insulin resistance in skeletal 
muscle (de Alvaro et al., 2004). This is most probably caused by the phosphorylation of 
serine sites on IR or IRS-1.  
Many mechanisms have been proposed as to what causes insulin resistance in skeletal 
muscle. Most probably, it is not due to one cause or one tissue but is in fact due to the 
malfunction of a variety of processes in many tissues. However, as skeletal muscle is 
responsible for such a large percentage of insulin-stimulated glucose, it is imperative that 




1.4 Skeletal muscle 
In humans, skeletal muscle is responsible for approximately 40% of the total body weight 
making it the largest organ in the body. Skeletal muscle, as an organ, is not restricted to 
mechanics via generation of force and movement of the skeleton. It is a complex tissue 
responsible for a range of metabolic functions and studies have demonstrated that it is 
responsible for approximately 80% of insulin-stimulated glucose uptake (Thiebaud et al., 
1982). In this section, we will discuss development, structure, and function of skeletal 
muscle. 
1.4.1 Development of skeletal muscle 
In the developing embryo, skeletal muscle is derived from the somites. Somites originate 
from the paraxial mesoderm, adjacent to the notochord and neural tube, and progress 
along the anterior to posterior axis (Christ et al., 2007). Subsequently, they are divided 
into the ventral sclerotome, which form the vertebrae and ribs, and dermomyotome which 
gives rise to the skeletal muscle of the trunk and limbs. The first signs of the committed 
development of muscle tissue (myogenesis) is the activation of myogenic factor Myf5 in 
some cells of the dermomyotome, termed ‘myoblasts’ (Ott et al., 1991). Developmental 
myogenesis is split into two phases. Primary myogenesis occurs at approximately E10.5 
– 12.5 in mice, where myoblasts positive for transcription factor paired box gene 3 (Pax3) 
proliferate and fuse to form the primary myotubes (Horst et al., 2006; Lee et al., 2013a). 
These primary myotubes are multi-nucleated and provide the templates for mature 
muscle. Secondary myogenesis occurs at E14.5 – 17.5 in mice, where Pax7+ myoblasts 
fuse to the primary myotubes to form secondary myotubes. These elongate and 
eventually separate to form multi-nuclear mature muscle fibres. Furthermore, within the 
mature muscle fibres reside a subset of Pax7+ progenitor cells, which form the adult 
muscle stem cells, termed ‘satellite cells’. It is these cells which mediate the adult muscle 




1.4.2 Structure of skeletal muscle 
Skeletal muscle is composed of parallel-aligned muscle cells, called myofibres, and are 
surrounded by connective tissue, the endomysium. Myofibres are composed of 
numerous myofibrils, arranged into the contractile apparatus named the sarcomere. 
These bundled myofibrils are surrounded by a plasma membrane called the 
sarcolemma, which is subsequently surrounded by a basement membrane (BM) 
(Frontera and Ochala, 2015). 
Muscle fibres are bundled into fascicles and are surrounded by the perimysium, spanning 
the length of the muscle. Nutrients essential for function are provide by the large network 
of arteries, veins, and capillaries throughout the muscle. 
Muscles are attached to the skeleton via the tendons. Tendons extend into the muscle, 
increasing the contact surface area, and form a collagen network with the perimysium 
(Passerieux et al., 2006). This strong connection permits muscles to transduce force via 
action potentials, allowing the skeletal muscle to perform its primary function, moving the 
skeleton. 
1.4.3 Function of skeletal muscle 
The primary function of skeletal muscle is to transduce force through tendons to the 
skeleton to enable mobility. The unit which enables contraction is the sarcomere, as 





Figure 1.8: Sarcomere unit. Composed of overlapping thick/myosin and thin/actin filaments. The 
A-band is made up thick filaments which are overlapped on both ends by thin filaments. The H-
zone consists of the part of the A-band that thin filaments do not reach. The M-line is a structural 
unit holding the thick filaments together and is composed of titin, myomesin, obscurin and Obsl1. 
The I-band is made up the thin filaments that do not extend into the A-band which also contains 
the darker Z-line. 
 
The sarcomere contracts using a sliding filament mechanism, made possible using the 
myosin heads found in abundance in thick filaments. During contraction, tropomyosin 
and troponin go through a conformational change dependent on Ca2+, moving them aside 
and exposing actin binding sites. Myosin heads bind to actin and go through a 
conformational change, causing the sarcomere to contract. This causes the H-zone and 
I-band to become shorter, however, the A-band remains the same size. 
However, without strong muscle attachment to the surrounding tissues, this contraction 
of muscle would be worthless. One major site of force transduction is the myotendinous 
junction (MTJ), the site where muscle joins with the tendon. Digit-like muscle projections 
intersperse with the tendon to form a strong bond. This is mediated by the connection of 




1.4.4 Basement membrane 
Basement membranes are a specialised form of extracellular matrix. They were first 
described in 1840 by Sir William Bowman where he describes them as a highly delicate, 
transparent and probably elastic sheath surrounding the muscle fibres (Bowman, 1840). 
Electron microscopy has revealed that the basement membrane is composed of two 
layers: the basal lamina (Figure 1.9A), which is linked directly to the sarcolemma, and 
an underlying fibrillar reticular lamina. As shown in Figure 1.9B, the basement membrane 
is made up of protein networks comprised by laminin and collagen IV (Col IV), with linker 
proteins such as perlecan and nidogen. 
 
Figure 1.9: Basal lamina. (A) Scanning electron micrograph of basal lamina isolated from chick 
embryo. Epithelial cells have been removed to expose basal lamina. (B) Diagram of the basal 
lamina with the its individual components. (Adapted from Alberts, 2002).  
 
One of the major constituents of the basement membrane, along with Collagen IV, are 
laminins comprising a family of heterotrimeric glycoproteins. They are involved in a wide 
variety of biological functions, including adhesion, differentiation, proliferation, migration, 
and survival. 




Currently, 12 distinct laminin subunits have been discovered, including 5 α, 3 β, and 3 γ 
chains. By combining these chains in different combinations, unique laminins can be 
created. The nomenclature of laminins has changed over the years. Isoforms are now 
named after their combination of α, β, and γ chains and designated, for example, laminin-
111 for α1 β1 γ1 (Aumailley et al., 2005). 
The most abundant form of laminin in the basement membrane of skeletal muscle is 
laminin-2 (containing laminin-211 and -221). Although not required for muscle 
development, laminin-211 is required for muscle integrity. Mutations in the laminin α2 
chain (LAMA2) resulted in a congenital muscular dystrophy (Helbling-Leclerc et al., 
1995). Patients display muscle and joint weakness, impaired motor development, and 
nervous system defects (Allamand and Guicheney, 2002). The functions of laminin-211 
in skeletal muscle are dependent on its ability to interact with the cell surface. This is 
achieved through the binding of laminin-211 to the transmembrane receptors. 
1.4.4.1 Transmembrane receptors 
It is the transmembrane receptors which allow adult skeletal muscle and the extracellular 
matrix to interact. The two major transmembrane receptors in adult skeletal muscle which 
link laminin to the basement membrane are the dystrophin-glycoprotein complex (DGC) 
and integrin α7β1 (which will be reviewed in greater detail in Section 1.5). 
The DGC is made up of several transmembrane and peripheral components to form a 
complex important in maintaining the integrity of skeletal muscle. The protein central to 
the DGC is dystroglycan, a large transmembrane glycoprotein, binding to laminin-211 in 
the BM through α-dystroglycan and to the intracellular dystrophin through β-dystroglycan 
(Ervasti and Campbell, 1993). The link is completed by dystrophin binding to actin, 
forming a strong bond between the BM and the muscle. In addition to dystroglycan and 
dystrophin, the DGC is composed of sarcoglycans (α, β, γ, and δ) and sarcospan. It is 





Mutations in the dystrophin gene were one of the first identified causes of muscular 
dystrophy, and have been identified in both Duchenne muscular dystrophy and the milder 
Becker muscular dystrophy (Worton and Thompson, 1988). The incidence of Duchenne 
muscular dystrophy and Becker muscular dystrophy is 1 in 5000 live male births and 1 
in 18450, respectively. Duchenne and Becker muscular dystrophies are X-linked, 
recessive diseases which lead to muscle weakness and degeneration. This can have 
major detrimental effects on breathing, the cardiac system, and general movement. 
Unfortunately, at this moment there is no cure for Duchenne muscular dystrophy, but 
through developing cardiac and respiratory treatments, more patients are surviving into 






The integrins were named due to their ‘integral membrane nature’ and ‘probable role in 
the integrity of both the extracellular matrix and the cytoskeleton’ (Tamkun et al., 1986). 
They are heterodimeric transmembrane adhesion receptors composed of an α and a β 
subunit. To date, 18 α and 8 β subunits have been discovered, however some of these 
can be expressed in varying splice forms (Figure 1.10) (Hynes, 2002a). It is the 
combination of α and β subunits which form unique integrins with varying functions.  
 
Figure 1.10: The integrin receptor family. Heterodimers composed of combinations of α and β 
subunits form unique integrins. Here they are classified into ligand specific families. Asterisks 
denotes subunits which can be expressed in different splice variants. (Taken from Hynes, 2002).  
 
1.5.1 Structure of integrins 
The integrin subunits span across the membrane. The extracellular α subunit is made 
up of a folded seven-bladed β-propeller, a thigh, and two calf domains (Springer, 1997). 
The seven-bladed β-propeller is present on all variations of the integrin α-subunit, and 




of the eighteen integrin α subunits possesses an I domain, which contains a metal ion-
dependent adhesion site (MIDAS) (Lee et al., 1995). The extracellular β subunit has a 
domain similarly structured to the I domain, thus named the I-like domain. The I-like 
domain plays a significant role in ligand binding for the remaining α subunits which don’t 
contain the I domain. The I-like domain is flanked by four EGF-like folds which then 
terminate with a β sheet domain. The structure of the integrin subunits is depicted in 
Figure 1.11. 
The extracellular and intracellular domains are linked by a transmembrane domains 
formed of α-helical coiled coils (Adair and Yeager, 2002). The domain is highly conserved 
in all α and β subunits and is thought to play a key role in the transition from an ‘inactive’ 
to ‘active’ state. 
Unlike the extracellular domains, no high-resolution X-ray crystallography of the 
intracellular domains has been completed. Instead, NMR data has been utilised. At 
present, there is controversy in the community as to how the intracellular α and β 
subunits interact with some researchers reporting a coiled coil construct, and some 
describing a salt bridge (Ulmer et al., 2001; Adair and Yeager, 2002). Although the 
intracellular domain of α subunits is diverse, the intracellular β subunit contains two well-
defined motifs: the membrane proximal NpxY and membrane distal NxxY motifs. These 





Figure 1.11: Summary of the integrin α- and β-subunit extracellular structure. (Taken from 
Campbell and Humphries, 2011). 
 
1.5.2 Integrin signalling 
Integrins are unique in that they can perform bidirectional signalling. Signals can be 
transduced from ligand to cell (outside-in) or intracellular stimuli can signal extracellularly 
(inside-out) as shown in Figure 1.12. 
1.5.2.1 Inside-out signalling 
Without intracellular stimuli, integrins exist in an inactive state with a bent conformation 
caused by the intracellular subunits of the integrin being bound together. Activation via 




straightened and stabilised conformation, allowing binding to their ligand. Two models 
have been proposed including the ‘switchblade model’, where integrins are only able to 
bind to ligands when activated, or the ‘deadbolt model’ which suggests that the extension 
of integrins is a result of ligand binding (Xiong et al., 2003; Luo et al., 2007). When 
integrins are active and bound to ligands, they cluster to form focal adhesions. These 
focal adhesions allow integrins to convey intracellular signals to the outside. 
1.5.2.2 Outside-in signalling 
Outside-in signalling can affect cellular growth, differentiation, and apoptosis, as well as 
other cellular events. However, integrins do not contain any intrinsic kinase activity. To 
resolve this, integrins rely on phosphorylation events cascaded by recruitment of proteins 
to their intracellular domains. Two key kinases associated with the intracellular subunits 
of the β domain are integrin-linked kinase (ILK), and focal adhesion kinase (FAK). 
ILK is a component of the ILK-PINCH-parvin (IPP) complex which binds to intracellular 
integrin β subunits (Legate et al., 2006). The IPP complex acts as a mediator between 
integrins and the actin cytoskeleton. The activation of the IPP complex is also associated 
with the phosphorylation of Akt, a key component of the insulin signalling pathway. 
However, the muscle-specific deletion of ILK results in improved insulin sensitivity in 
HFD-fed mice (Kang et al., 2016). It is also noteworthy that although ILK was originally 
dubbed a kinase, recent studies have suggested that ILK may not have intrinsic kinase 
abilities. Alone, ILK is not able to catalyse phosphorylation but as a component of the 
IPP complex, this is possible (Ghatak et al., 2013).  
FAK is a non-receptor tyrosine kinase which is autophosphorylated by its interaction with 
intracellular β subunits. This allows FAK to activate paxillin and Grb2/SOS (Hildebrand 
et al., 1995). Downstream of Grb2/SOS is the MAPK/ERK pathway which leads to the 
transcription of many genes involved in cell survival and proliferation. FAK is also a well-




The activation of FAK by the β integrin subunit causes PI3K to be recruited to the focal 
adhesion. This leads to downstream activation of Akt, a major contributor to the 
translocation of GLUT4. 
 
Figure 1.12: Summary of inside-out and outside-in integrin signalling. Inactivated integrins 
have a closed and bent conformation resulting in low ligand affinity. Inside-out signalling involves 
intracellular activators binding the β-subunit and causing a conformational change resulting in 
increased ligand affinity. Outside-in signalling involves conformational changes of the integrin 





1.5.3 Integrin expression during skeletal muscle development 
During the development and maintenance of skeletal muscle, the pattern of expression 
of integrins is tightly regulated (Figure 1.13). The integrins are mostly expressed at major 
areas of muscle function including the costameres, sarcolemma, neuromuscular junction 
(NMJ), and myotendinous junction (MTJ). However, the combination of α and β subunits 
varies throughout development. 
Either in development or adult skeletal muscle, α4, α5, α6, α7, αv, and β1 subunit 
expression has been verified. Integrin α4, α5, α6, and αv subunits are expressed during 
primary myogenesis but are no longer present in adult skeletal muscle. Integrin α4β1 
has been shown to mediate myoblast formation, via its ligand VCAM-1 (Rosen et al., 
1992).  
Integrin α7 is alternatively spliced resulting in two intracellular domains, α7A and α7B, 
and two extracellular domains, α7X1 and α7X2 (Song et al., 1993; Ziober et al., 1993). 
These intra- and extracellular splice variants form four unique integrin α7 splice variants. 
The only β subunit to interact with α7 is β1 which also has two variants, β1A and β1D 
(van der Flier et al., 1995). Studies have demonstrated that α7X1 and α7X2 are 
expressed in equal amount in mouse skeletal myoblast and adult cardiac muscle. 
However, α7X2 is the only extracellular domain expressed in adult skeletal muscle 
(Ziober et al., 1993). Of the intracellular domains, integrin α7B is the first to be induced 
in myoblasts and remains expressed throughout development into adult skeletal muscle. 
Integrin α7A is expressed at terminal differentiation and is weakly expressed in mature 
skeletal muscle (Yao et al., 1996a). Variance in the expression of integrin β1A and β1D 
also exists. Integrin β1A is ubiquitously expressed, whereas β1D is specific to skeletal 
and cardiac muscle. β1A is expressed during muscle development, but then replaced by 
the expression of β1D shortly after birth (van der Flier et al., 1995; Belkin et al., 1996). 
This strict patterning of integrins indicates that each subunit possesses distinct roles 






Figure 1.13: Summary of the expression of integrins during skeletal muscle development. 
During primary myogenesis β1A subunit is predominantly expressed but is reduced during 
secondary myogenesis and then completely replaced by β1D. Integrin α4, α5, α6, and αv are 
expressed during primary myogenesis but reduced and undetectable through secondary 
myogenesis. Integrin α7X1, α7X2 and α7B subunits are present during primary myogenesis. 
However, during secondary myogenesis, α7X1 is downregulated before being replaced by α7X2. 





1.5.4 Integrin α7β1 
Integrin α7β1 is the most prominent integrin in adult skeletal muscle, however, it is also 
detected in cardiac and smooth muscle. The association of skeletal muscle with the 
basement membrane is paramount for maintaining the sarcolemma and transmitting 
force from the muscle to the tendon. Integrin α7β1 is part of the team which maintains 
that link. 
The human integrin α7 gene (ITGA7) is composed of 27 exons and is situated on 
chromosome 12q13, in close proximity to the α5 and β7 subunit genes (Figure 1.14). 
The generation of different isoforms of integrin α7 is achieved through the splicing of 
different exons. These exons are homologous with those found in mice. The extracellular 
domains of integrin α7 are α7X1 and α7X2, which are composed of 1042 and 1038 aa 
respectively (Vignier et al., 1999). Studies have demonstrated that both integrin α7X1 
and α7X2 are expressed in equal amounts in mouse skeletal myoblasts and adult cardiac 
muscle, however, in adult skeletal muscle it is only α7X2 which is expressed as 
expression of α7X1 decreases post-secondary myogenesis. 
The two major intracellular domains of integrin α7 are α7A and α7B have been identified 
in humans and mice and are composed of 57 and 76 aa, respectively (Collo et al., 1993; 
Song et al., 1993). Integrin α7B is the first variant expressed during the development of 
skeletal muscle and remains expressed through to adulthood. The α7A variant is only 
induced at terminal differentiation and is then only weakly expressed in adult skeletal 
muscle. 
To date, four different intracellular isoforms have been discovered of the β1 integrin 
subunit (A-D) in humans. Integrin β1A is the most widely expressed isoform, present in 
all cell types except red blood cells (Belkin et al., 1996). Integrin β1B has been proposed 
to act as a negative regulator of cell adhesion during development and β1C inhibits cell 




be expressed in mice (Baudoin et al., 1996). Integrin β1D is the most prominent variant 
expressed in skeletal muscle and is expressed mainly around the junctions of skeletal 
muscle (Bozyczko et al., 1989) 
Surprisingly, no functional difference has been found between the intracellular α7A and 
α7B subunits (Echtermeyer et al., 1996; Yao et al., 1996b). However, the extracellular 
α7X2 variant favours binding to laminin-1, whereas α7X1 preferentially binds to laminin-
8, although equal affinity has been observed in α7X1 and α7X2 for laminin-2 (Ziober et 
al., 1997; Von der Mark et al., 2002).  
 
Figure 1.14: The integrin α7 gene and alternative splicing of the integrin α7 domains. 
Extracellular variant X1 contains exons 4, 5, and 7. X2 contains exons 4, 6, and 7. Intracellular 
variant A contains exons 25, 26, and 27. However, there is the formation of a stop codon after the 






1.5.5 Role of integrins in insulin sensitivity 
Diet-induced obesity has been consistently shown to be directly related to the onset of 
insulin resistance and glucose intolerance. Insulin signalling and glucose metabolism is 
a complex system with a range of organs participating in homeostasis. Increasing 
numbers of mouse models have been generated to further understand how this system 
is influenced by the integrins. 
One key model in investigating this interaction was the whole-body deletion of integrin 
α2β1. Integrin α2β1-null mice have improved insulin signalling, when fed a high fat diet 
compared to control mice (Kang et al., 2011a). Feeding a high fat diet to control mice 
resulted in increased levels of collagen III, a fibrillar-type collagen, and collagen IV, the 
main component of the skeletal basement membrane. Researchers believed that the 
improved insulin signalling in α2β1-null mice would be due to decreased collagen III and 
IV, but no difference was found compared to controls. However, the authors speculated 
that improved insulin sensitivity was due to increased muscle vascularisation, as shown 
by CD31 and von Willebrand factor staining.  
In contrast, the muscle-specific deletion of integrin β1 in mice resulted in a significant 
reduction in the insulin-stimulated glucose infusion rate (Zong et al., 2009). Yet, there 
was no difference in food intake, weight gain, fasting glucose, nor insulin levels 
compared to control mice. The study showed that there was no difference in GLUT4 
protein expression, but translocation was impaired due to defected insulin signalling via 
a reduction in Akt phosphorylation. 
Skeletal muscle is responsible for the vast majority of insulin-stimulated glucose uptake. 
However, no studies have investigated the role of integrin α7β1, the main integrin in adult 
skeletal muscle, in the context of metabolism. We hypothesised that a whole-body 
deletion of integrin α7 would result in a similar phenotype to that observed in the β1-





The role of integrin α7 has been researched extensively in terms of its role in muscle 
integrity and function, but no research has been completed on its role in metabolism. 
Studies have demonstrated that integrins can play a significant role in whole-body 
metabolism and insulin signalling. As skeletal muscle is responsible for approximately 
80% of insulin-stimulated glucose uptake, it is imperative that we investigate the role of 
integrin α7 in metabolism. We used the same whole-body integrin α7 deletion mouse 
model that has been used in many muscular dystrophy investigations. By using an in 
vivo model, the downstream effects of the deletion of integrin α7 on tissues where it is 
not expressed can be investigated. In this study, we aimed to answer the following 
questions: 
1) What effect does the deletion of integrin α7 have on insulin sensitivity and glucose 
tolerance? 
2) If the deletion of integrin α7 affects insulin sensitivity, how does it affect the insulin 
signalling pathway? 
3) Can the transgenic overexpression of any of the four splice variants of integrin 









2.1 Mouse lines 
2.1.1 Generation of integrin α7 knockout mouse 
Mice with a 129Sv background were selected for this study. Publications have 
demonstrated the varied susceptibility of different mouse strains to insulin-related 
diseases (Clee and Attie, 2007). C57BL strains have been used in a variety of metabolic-
related publications, however, studies have demonstrated that C57BL mice have an 
innate insulin secretion defect (Kaku et al., 1988; Toye et al., 2005). In contrast, 129 
strain mice maintain low insulin levels and are more glucose tolerant than other strains 
on both a chow and HFD (Almind and Kahn, 2004). Furthermore, obesity-related 
diseases including non-alcoholic fatty liver disease have been shown to be most 
consistently represented in 129Sv mice (Fengler et al., 2016). 
Integrin α7 deficient mice were produced by previous members of the Mayer laboratory 
before the start of this study. All splice variants were inactivated by the replacement of 
the signal sequence of exon one and 107 bp of the mature protein with a neomycin 
cassette via homologous recombination in embryonic stem cells as previously detailed 
(Mayer et al., 1997). 129Sv chimeric founder mice were produced using heterozygous 
embryonic stem cells, before being crossed to generate mice homozygous for the 
mutated α7 allele (α7KO). Male mice were used throughout this study to remove the 
variation in metabolism between sexes. Littermates were used as controls to reduce 
metabolism variation due to genetic background variance.  
2.1.2 Integrin α7 splice variant overexpressing transgenic 
mouse line 
Integrin α7 splice variant overexpressing transgenic mice were generated before the 
start of this study by previous members of the Mayer lab. Integrin α7 subunits were 




promotor was added 5’ to the integrin α7 cDNAs (Brennan and Hardeman, 1993). 
Linearised DNA was injected into the pronuclei of fertilised mouse embryos before being 
transferred to pseudopregnant females, generating founder mice. Mice positive for the 
transgene were detected by PCR using a sense primer hybridising with the HSA 
promotor.  
Mice with similar expression levels of the integrin α7 variants were selected to breed. 
These overexpressing mice were backcrossed for at least ten generations to the 129Sv 
background before crossing with heterozygous integrin α7-mutant mice to generate 
integrin α7-heterozygous mice overexpressing one of the four integrin α7 splice variants. 
These mice were further crossed with integrin α7-heterozygous mice to generate α7-
knockout mice overexpressing one of the four integrin α7 splice variants (α7-/-TG). 
2.2 Genotyping animals using Polymerase Chain 
Reaction (PCR) 
To genotype mice, mouse ear biopsies were taken and lysed overnight at 55OC in 
Proteinase K lysis buffer (Table 2.1). Lysate was diluted 1:10 in distilled H2O and used 
in PCR. The master mix for the PCR is detailed in Table 2.2. The touchdown programme 
used in genotyping PCR is detailed in Table 2.3.  
Table 2.1: Lysis buffer used for mouse ear/tail biopsy lysis 
Reagent Composition 
Proteinase K lysis buffer 
0.1M Tris-HCl, 0.2M NaCl, 0.2% (w/v) 





Table 2.2: Master mix for genotyping PCR 
Reagents Concentration Volume per 
reaction 
Forward and Reverse 
primer mix 
20pmol per primer 1µl 
10x buffer with detergent 100mM Tris-HCl (pH 8.8 at 25OC), 
500mM KCl, 0.8% (v/v) Nonidet P40, 
15mM MgCl2 
5µl 
dNTPs 25µM 0.5µl 
TOD (1:10 dilution) Unknown 2µl 
Sterile H2O (Fisher) N/A 38.5µl 
DNA (1:10 dilution) Unknown 3µl 
Total volume  50µl 
 
Table 2.3: Touchdown PCR programme 
Denaturation at 95OC for 5 min  
95OC for 1 min 
10 cycles Annealing at 65OC for 1 min (minus 1OC per cycle) 
Extension at 72OC for 1 min 
95OC for 1 min 
30 cycles 55OC for 1 min 
72OC for 1 min 
72OC for 10 min  









1 A7 – 981.rev CCA GAA TCG ATG GAG AAA CC 
5 A7 – 3588.rev 
GAT CGT CGA CTC TAG AAG ATG TTA GGC AGT 
GGC TGG 
6 A7 – 3206.seq CTC AGA GAT GCA TCC ACA GTG 
7 A7 – 719.seq TTC TGT GAG GGG CGC CCC CAG 
12 HSA.seq GCA CTA CCG AGG GGA ACC TG 
43 A7.39.seq GAG GGG TGC TGA GGT GAA AG 
44 A7.264.rev GCC GGT GGT AAG AAC AGT CC 
 
2.2.1 Agarose gel electrophoresis 
PCR products were mixed with 5x Orange G loading dye and loaded into 2% agarose 
gels, submerged in 1x TAE buffer (Table 2.5). Gels were run at a constant voltage of 
150V for approximately 40 minutes. Gels were then stained with 0.5µg/ml ethidium 
bromide for approximately 30 minutes before visualising in a UV trans-illuminator (UVP 
ChemiDoc-It®2 810 Imager). 
Table 2.5: Composition of reagents needed for gel electrophoresis 
Reagent Composition 
50x TAE buffer 40mM Tris acetate, 2mM EDTA (pH 8.5) 
5x Orange G loading dye 25ml glycerol, 5ml 10x TAE buffer, 0.25g Orange G 
powder, 50ml H2O 
 
2.3 Animal maintenance 




in individually-ventilated cages. Routine screens for contamination were completed. 
Mice were ear tagged and genotyped using ear biopsies. Unrequired mice were culled 
using a Schedule 1 approved method. Animals were separated by sex and housed until 
needed. 
2.4 Animal diet and food intake 
Under normal conditions, male mice were fed a chow diet (Rat and Mouse No.3 
Breeding, Special Diets Services). When 3 months old, animals were selected to either 
continue eating a chow diet or to be switched to a high fat diet (D12451, Research Diets 
Inc.) (Table 2.6). High fat diet pellets were weighed before being given to mice and then 
weighed after a week to measure food intake. 
Table 2.6: Breakdown of nutritional value of high fat diet 
  gm% Kcal% 
Protein  24 20 
Carbohydrate  41 35 
Fat  24 45 
 Total  100 
 kcal/gm 4.73  
 
2.5 Metabolic tests 
Intraperitoneal insulin and glucose tolerance tests were conducted initially on mice at 3 
months of age. Mice were then either fed a 45% fat diet or continued with a standard 




2.5.1 Intraperitoneal insulin tolerance test (IPITT) 
Mice were moved to a clean cage with no food, access to water ad libitum, and fasted 
for 6 hours. A basal glucose reading was measured by making a small pin prick incision 
at the tip of the tail and reading with a glucose meter (Alphatrak 2). Mouse weights were 
recorded and were then intraperitoneally injected with 0.75 U/kg of human insulin 
(Sigma) diluted in sterile phosphate-buffered saline (PBS). Further glucose readings 
were measured using the same method at 15 minutes, 30 minutes, 60 minutes and 120 
minutes. Mice were then given food and water ad libitum as before. 
2.5.2 Intraperitoneal glucose tolerance test (IPGTT) 
Mice were moved to a clean cage with no food, access to water ad libitum, and fasted 
for 16 hours. A basal glucose reading was measured by making a small pin prick incision 
at the tip of the tail and reading with a glucose meter. Mouse weights were recorded and 
were then intraperitoneally injected with 2 g/kg of 20% glucose solution (Sigma) in sterile 
PBS. Further glucose readings were measured using the same method at 15 minutes, 
30 minutes, 60 minutes and 120 minutes. Mice were then given food and water ad libitum 
as before. 
2.6 Dissection of mice 
Mice were sacrificed, and confirmed, via a Schedule 1 approved method, according to 
Home office guidelines. The tibialis anterior (TA) and gastrocnemius (GC) muscles were 
isolated and removed. For histological analysis, muscles were pinned onto parafilm to 
prevent contraction before being frozen in liquid nitrogen-cooled isopentane. For protein 
analysis, they were snap frozen in liquid nitrogen. 
Adipose tissue depots were isolated, weighed and dehydrated in increasing 
concentrations of ethanol. Dehydrated adipose tissue was embedded in paraffin wax for 





2.7.1 3’aminopropyl-triethocy silane (TESPA) coating of slides 
To aid tissue adhesiveness to slides, slides were coated with TESPA (Sigma) as shown 
in Table 2.7. Slides were dried in a 55OC incubator and then stored at room temperature 
until required. 
Table 2.7: Method of TESPA coating slides 
Reagent Incubation time 
Acetone 30 secs 
2% TESPA in acetone 1 min 
Acetone Quick immersion 
Acetone Quick immersion 
ddH2O Quick immersion 
 
2.7.2 Post fixation of liver for cryosectioning 
Livers were fixed, post dissection, in 4% paraformaldehyde solution in PBS for four hours 
at 4oC. Tissues were rinsed in PBS overnight at 4OC to remove excess 
paraformaldehyde. Livers were then incubated in 5% sucrose in PBS solution for four 
hours before being replaced with 20% sucrose solution in PBS overnight. Tissue was 
then frozen in Optimal Cutting Temperature (OCT) compound in moulds on dry ice.  
2.7.3 Paraffin embedding of adipose tissue 
Adipose tissue was fixed in 4% paraformaldehyde/PBS for four hours at 4oC. Tissue was 
rinsed in PBS overnight at 4OC to remove excess paraformaldehyde. Adipose tissue was 
then dehydrated and embedded in paraffin wax as shown in Table 2.8. Adipose tissue 
was then cast, using an embedding station (Microm EC350-2), in moulds filled with 




4OC before being sectioned on a microtome (Microm HM355S). 
Table 2.8: Paraffin embedding protocol 
Reagent Time tissue immersed 
30% ethanol 30 mins 
50% ethanol 30 mins 
70% ethanol 1 hour 
90% ethanol 1 hour 
95% ethanol 1 hour 
100% ethanol 3 x 30 mins 
Histo-clear (xylene substitute) 3 x 20 mins 
Paraffin wax (60OC) 2 x 2 hours 
 
2.7.4 Cryosectioning 
Frozen tissue was mounted onto a specimen holder using OCT. The specimen was 
maintained at a temperature of -24OC, whilst the blade was maintained at -26OC. 
Sections were cut 10µm thick and were collected on TESPA-coated slides. Four sections 
were collected on a single slide with every fifth being collected on a separate slide. The 
latter slide was used to gain an overall representation of the tissue. 
2.7.5 Microtome sectioning 
The microtome was filled with dH2O warmed to 42OC. Paraffin blocks were secured on 
the pre- cooled holder and were then sectioned 10µm thick. Slides were left to air dry 
before being stored at room temperature. 
2.7.6 Hematoxylin and Eosin staining 
Mayer’s hematoxylin (Merck) was prepared by dilution 1:1 in dH2O. A 0.1% (w/v) Eosin 




Solutions were filtered before use. 
If using paraffin embedded sections, slides were de-waxed in histo-clear (National 
Diagnostics) for 5 minutes. Sections were then rehydrated through descending 
concentrations of ethanol solutions. 
Slides were immersed in Mayer’s hematoxylin for 2 minutes before being submerged in 
flowing tap water for 10 minutes. Slides were then immersed in eosin for 30 seconds 
before being dehydrated through ascending concentrations of ethanol. Slides were 
submerged in fresh histo-clear twice for 7 minutes before being mounted with cover slips 
using DPX (Fisher). Slides were left to dry at room temperature and were then stored. 
2.7.7 Oil Red O staining 
Oil red o stock solution was prepared by dissolving 500mg of oil red o (Sigma) in 100ml 
of isopropanol overnight at room temperature. To make the working solution, 30ml of the 
prepared oil red solution was diluted in 20ml of dH2O and filtered with a 0.2µm filter. 
Sections were fixed with 4% PFA at room temperature for 10 minutes. Slides were 
immersed in running tap water for 5 minutes and rinsed with 60% isopropanol. Slides 
were submerged in working oil red o solution for 8 minutes at 55OC. Sections were then 
rinsed with 60% isopropanol and counterstained with hematoxylin solution for 1 minute. 
Slides were immersed in running tap water for 10 minutes and mounted with cover slips 
using gelvatol mounting medium. 
2.7.8 LipidTOX staining 
LipidTOX stain working solution was prepared 1:500 in PBS and kept on ice until needed. 
Every fifth section of tissue was captured on a slide to gain a better overall representation 
of the tissue resulting in 16 sections being captured. Sections were fixed with 4% PFA 




were incubated with LipidTOX working solution overnight at 4OC overnight in the dark 
followed by 3 x 5 minute PBS washes and mounted with cover slips using gelvatol 
mounting medium. 
2.7.9 Preparation of gelvatol mounting medium 
A 10ml solution of 0.1M KH2PO4 was adjusted with a 0.1M solution of Na2HPO4.H2O until 
the pH was 7.2. Of the resulting solution, 80ml was used to dissolve 0.64g of NaCl 
(0.14M) and 20g of polyvinylalcohol (Gelvatol, Type II, cold water soluble, Sigma P-8136) 
and left to mix overnight at room temperature. To this solution, 40ml of glycerol (Sigma) 
was added and was left to mix for a minimum of 16 hours. The solution was centrifuged 
at 12000 RPM for 15 minutes. The supernatant was decanted before ensuring the pH 
ranged between 6-7. The anti-bleaching agent, DABCO (Sigma), was added at a 
concentration of 25µg/ml. Syringes were filled with the final solution and stored at -20OC 
until required for mounting.  
2.8 Microscopy 
2.8.1 Imaging of muscle, liver and adipose tissue sections 
A Zeiss AxioPlan 2ie microscope was used to visualise sections. Brightfield or 
fluorescent images were captured using a 10x or 20x PlanNeofluar objective (0.6NA) 
and a Zeiss AxioCam HRm or HRc camera. 
Adipocyte size was calculated using the minimum Feret diameter and is the minimum 
distance between two parallel tangents of a shape, as shown in Figure 2.1. A 
standardised method of measurement has not been agreed on for measuring adipocytes. 
We tested different methods of measuring adipocytes including area, perimeter, 
minimum Feret diameter and maximum Feret diameter. By taking multiple sections of 
the same adipocyte and calculating the average measurement across sections it was 





Figure 2.1: Depiction of minimum and maximum Feret diameter (Taken from Sympatec, 
2008). 
 
2.9 Blood analysis 
2.9.1 Blood collection and serum isolation 
Blood was isolated from cervically dislocated animals by snipping the posterior of the 
heart. Samples were kept at 4OC overnight to allow clotting before spinning at 1,300 RCF 
at 4OC for 15 minutes. The supernatant/serum was isolated from centrifuged samples, 
snap frozen in liquid nitrogen and stored at -80OC until required. 
2.9.2 Alanine Transaminase (ALT) and Aspartate 
Transaminase (AST) assay 
Alanine Transaminase (ALT) and Aspartate Transaminase (AST) levels were measured 
in mouse serum samples using a Randox kit and analyser (Daytona) according to the 
manufacturer’s instructions. This work was kindly completed by the Vauzour Laboratory, 
Norwich Research Park. 
2.9.3 Bile acid analysis 




extraction cartridges (Waters) according to the manufacturer’s instructions. Extracted 
bile acids were analysed via liquid chromatography-mass spectrometry. This work was 
kindly completed by the Vauzour Laboratory, Norwich Research Park. 
2.10 Western blot analysis 
2.10.1 Protein extraction from tissue 
A standard RIPA lysis buffer (10mM Tris-Cl, 1mM EDTA, 0.5mM EGTA, 1% Triton X-
100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 140mM NaCl, 
1x cOmplete™ ULTRA protease inhibitor cocktail (Sigma), 1x PhosSTOP phosphatase 
inhibitor cocktail (Sigma)) was used to lyse tissue for immunoblotting. 
Gastrocnemius (GC) muscle was isolated post dissection and snap frozen in liquid 
nitrogen. Tissue was stored at -80OC until required for protein extraction. Frozen tissues 
were transferred to 2ml snap-cap Eppendorf tubes with 1ml of ice-cold RIPA lysis buffer. 
A metal bead was added to the tube before being homogenised in a TissueLyser II 
(Qiagen) at 30 Hz for 8 mins at RT. Lysates were left on ice for 15 minutes before being 
centrifuged at 4OC for 5 minutes at 14,000 RPM. The supernatant was removed before 
centrifugation again. The supernatant was collected and either used immediately or 
aliquoted and frozen on dry ice before storing at -80OC. 
2.10.2 Quantification of protein concentration in lysates 
The bicinchoninic acid (BCA) protein assay (ThermoFisher) was used to determine 
protein concentration in tissue lysates. Tissue lysate samples were diluted in RIPA buffer 
(1:10) to give a final volume of 25µl. Protein standards were made by diluting bovine 
serum albumin (BSA) in RIPA lysis buffer (0-2000µg/ml). The BCA working solution was 
made by mixing 50 parts of solution A with 1 part solution B. To a 96 well plate, 25µl of 
the diluted tissue lysates and protein standards was transferred to a well. To each 




30 minutes. The optical density of each sample was measured at 570nm using a 
VersaMax microplate reader (Molecular Devices). Samples were prepared in duplicate 
to obtain the average optical density. The standard curve was plotted of the protein 
standards and the gradient was used to calculate the value of the tissue lysate protein 
concentrations. 
2.10.3 Preparation of SDS-polyacrylamide gels and samples 
Glass plates were cleaned with 70% ethanol and rinsed with water before being stacked 
into gel chambers with 0.75mm spacers. Resolving gels (Table 2.9) were poured into the 
gel chambers and were levelled by pipetting a 200µl of water-saturated butanol on top. 
Gels were left at room temperature for 1 hour to allow to polymerise. 
Once the resolving gels had polymerised, the water-saturated butanol was poured off 
and gels were rinsed with distilled water. Stacking gels (Table 2.9) were poured over the 
resolving gels and well combs were slotted in until complete polymerisation. Gels were 
stored in their chambers in a sealed box with a damp piece of tissue at 4OC until required. 
Table 2.9: Components of resolving SDS-polyacrylamide resolving and stacking gels 
 Resolving gel Stacking gel 
Components 6% 8% 10% 12% 15% 5% 
H2O 2.6ml 2.3ml 1.9ml 1.6ml 1.1ml 680µl 
30% acryl-bisacrylamide mix 1.0ml 1.3ml 1.7ml 2.0ml 2.5ml 170µl 
1.5M Tris (pH 8.8) 1.3ml 1.3ml 1.3ml 1.3ml 1.3ml - 
1.5M Tris (pH 6.8) - - - - - 130µl 
10% SDS 50µl 50µl 50µl 50µl 50µl 10µl 
10% ammonium persulphate 50µl 50µl 50µl 50µl 50µl 10µl 





Samples were prepared for loading onto SDS-polyacrylamide gels by diluting in water 
and 2x Laemmli sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromophenol blue, 0.125M Tris-HCl) to give the required protein concentration. Samples 
were heated at 95OC for 5 minutes, cooled and loaded onto SDS-polyacrylamide gels. 
2.10.4 Immunoblotting 
Samples were prepared with 30μg of muscle lysate in 1x sample buffer and denatured 
at 95OC for 5 minutes under reducing conditions by the addition of 5% β-
mercapterethanol. SDS poly-acrylamide gels were cast depending on weight of protein 
desired. Samples were loaded into gels and were separated at 150V. Biorad broad range 
molecular range marker was used as a protein standard. Proteins were transferred onto 
PVDF membranes in 10mM sodium borate overnight at 200mA overnight at 4OC. 
Membranes were blocked in 5% NGS in PBS for 2 hours at RT. Appropriate primary 
antibody (Table 2.10) was diluted as per manufacturer’s instructions in 2% NGS in PBS-
T and incubated with blocked membranes overnight at 4OC. Membranes were washed 
and incubated with the desired housekeeping antibody for 1 hour at RT. Membranes 
were washed and incubated with diluted secondary antibody conjugated to horseradish 
peroxidase (Table 2.11). Further washes were completed in PBS-T before a final in PBS. 
Protein bands were visualised with Pierce ECL Western Blot substrate as per 




Table 2.10: Primary antibodies used for Western blotting 
Protein of interest Primary antibody Dilution Manufacturer 
Heat shock protein 
70 










Phospho-Akt (Ser473) (D9E) 






Phospho-Akt (Thr308) (244F9) 






P44/42 MAPK (Erk1/2) (137F5) 







Phospho-p44/42 MAPK (Erk1/2) 






Table 2.11: Secondary antibodies used for Western blotting 
Secondary Antibody Dilution Manufacturer 
Goat Anti-Rabbit IgG (H + L)-HRP Conjugate 
(#1706515) 
1:3,000 Bio-rad 
Anti-Mouse IgG (whole molecule)-
Peroxidase. Produced in Goat, IgG Fraction 
of Antiserum (#A5278) 
1:3,000 Sigma 
 
2.10.5 Quantification of immunoblot 
ECL stained membranes were visualised using a Molecular Imager ChemiDoc XRS+ 
Imaging System (Bio-rad). Protein bands were quantified using densitometry using 
Image Lab™ software (Bio-rad). Image Lab™ indicates when exposed images are 
overexposed. Proteins of interest were normalised against housekeeping bands to 





2.11.1 Faeces collection and sample preparation 
Freshly defecated faecal pellets were collected weekly and snap frozen. Pellets were 
diluted 1:10 in pre-reduced PBS. Pre-reduced PBS was generated by storing PBS in an 
anaerobic chamber overnight. Samples were vortexed for 60s to obtain a faecal slurry. 
Samples were centrifuged at 16000 RCF for 15 minutes at 4OC. In an Eppendorf tube, 
90μl of supernatant and 810μl of PBS were added before finally adding 100μl of NMR 
buffer (Table 2.12). Samples were vortexed briefly before being frozen at -20OC until 
analysis. 
Table 2.12: Composition of NMR buffer used in lysis of faecal pellets 
Reagent Composition 
NMR buffer 
0.26g NaH2PO4, 1.44g K2HPO4, 17mg 
TSP, 56.1mg NaN3, 100ml D2O 
 
2.11.2 NMR protocol 
High resolution 1H NMR spectra were recorded on a 600 MHz Bruker Avance 
spectrometer fitted with a 5 mm TCI cryoprobe and a 60 slot autosampler (Bruker). 
Samples were maintained at 300 K. Metabolites were identified using the Human 
Metabolome Database (www.hmdb.ca) and quantified using Chenomx® NMR Suite 






 CHAPTER 3: INSULIN SENSITIVITY AND 






Integrin α7β1 is the most abundant integrin in adult skeletal muscle. It is located along 
the sarcolemma but is highly enriched around the myotendinous junction and 
neuromuscular junction (Bao et al., 1993). Integrin α7β1 has been shown to play a 
fundamental role in muscle development and function, as well as a role in differentiation 
and migration processes during myogenesis (Song et al., 1993). Absence of integrin α7 
leads to a progressive muscular dystrophy starting shortly after birth and is located  
mainly in the soleus muscle and affects mainly the myotendinous junction (Mayer et al., 
1997). 
Previous studies have shown integrins to play a key role in insulin sensitivity. The 
muscle-specific deletion of β1 integrin in mice fed a chow diet resulted in decreased 
whole-body insulin sensitivity and glucose tolerance (Zong et al., 2009). The whole-body 
deletion of α2 integrin has been shown to reverse diet-induced muscle insulin resistance 
in high fat diet-fed mice (Kang et al., 2011b). Other studies have shown that whole-body 
deletion of integrin α1 resulted in hepatic insulin resistance in high fat diet-fed mice 
(Williams et al., 2015). 
As integrin α7 is the most abundant integrin in striated muscle, we decided to investigate 
the role of integrin α7 in insulin sensitivity and tissue histology. We used a whole-body 
deletion model of integrin α7 (α7KO) as almost all integrin α7 is expressed in the muscle. 
Integrin α7 was deleted as previously discussed in previously published papers and all 
mice used in this study were descendants of those founder mice produced (Mayer et al., 
1997). To delete the integrin α7 gene, 1 kb of genomic sequence was replaced, including 
the signal sequence of exon 1 and the first 107 bp of the mature protein, with a 
phosphoglycerate-kinase-neomycin (PGK-neo) cassette via homologous recombination 
in ES cells. Chimeric founder mice were produced using heterozygous ES cells, before 




In this chapter, we aimed to look at the whole-body effects of deleting integrin α7, 
including body weight and composition. We also looked at the effect deleting integrin α7 
had on insulin sensitivity and glucose tolerance. Finally, we investigated the effect the 
deletion of integrin α7 had on the histology of key tissues involved in insulin signalling 





3.2 The effect of integrin α7 deficiency on body weight 
and food consumption 
Preliminary studies showed that α7KO mice raised on the 129/Sv background, when fed 
a chow diet, weighed significantly less than controls. Three-month-old male α7KO mice 
had a mean weight of approximately 27.2g and controls had a mean weight of 
approximately 30.6g (Figure 3.1A). Apart from being leaner, mice appeared healthy. 
Preliminary studies demonstrated that chow-fed α7KO mice are more insulin sensitive 
than control mice (data not shown). In this study, we investigated the effect of feeding a 
high fat diet (HFD) to α7KO and control mice and observed to what extent this would 
affect body weight, insulin sensitivity and glucose tolerance. 
To investigate whether feeding α7KO and control mice a HFD had a greater effect on 
body weight than a chow diet, mice were fed a rodent diet with 45 kcal% fat for 12 weeks. 
Mice were separated into cages according to genotype and were given a weighed 
amount of HFD food. On a weekly basis, mouse weights were recorded to measure 
weight change over time (Figure 3.1B). 
Control mice, as expected, gained significant weight over 12 weeks of HFD feeding. 
Compared to Week 0 weights, control mice gained an additional 16% of body weight 
after the 12 weeks were completed. However, α7KO mice did not gain any significant 
weight over 12 weeks of HFD feeding. Compared to Week 0 weights, α7KO mice lost 
2% of their body weight after the 12 weeks were completed. Control mice first began to 
gain significantly more weight than α7KO mice after Week 7 and then continued until 
Week 12 (Figure 3.1B+C). This can be seen photographically in Figure 3.1E+F. 
As control mice gained more weight than α7KO mice over 12 weeks of HFD feeding, it 
was important to measure food intake to ensure this was not the reason for change in 
weight gain. On a weekly basis, the amount of food ingested by the mice was calculated 




Average food intake was normalised against the weight of the mice (Figure 3.1D). On a 
weekly basis, both control and α7KO mice consumed approximately 0.6g of HFD food 
per gram of body weight. This indicates that greater weight gain in the control mice is not 






Figure 3.1: Integrin α7 deficiency results in leaner mice when fed either a chow or a HFD. 
(A) Body weight of 3-month-old α7KO and control mice when fed a chow diet. The data are mean 
± SEM (n = 7). (B) Normalised weight of 3-month-old mice when fed a HFD for 12 weeks, 
compared to Week 0, chow-fed, body weight. The data are mean ± SEM (n = 7). (C) Normalised 
weight after 12 weeks of HFD feeding compared to Week 0, chow-fed, body weight. The data are 
shown as mean ± SEM (n = 7). (D) Average weekly food intake normalised against body weight 
(n = 3). (E+F) Photograph of (E) α7KO and (F) control mouse fed a HFD for 12 weeks. Statistical 





3.3 The effect of integrin α7 deficiency on insulin 
sensitivity and glucose tolerance 
When fed a HFD, control mice gained significantly more weight than α7KO mice. We 
decided to investigate whether this had an impact on insulin sensitivity and glucose 
tolerance. In this experiment, mice were aged to 3 months old where initial metabolic 
tests were performed. The Intraperitoneal Insulin Tolerance Test (IPITT) was used to 
measure insulin sensitivity and the Intraperitoneal Glucose Tolerance Test (IPGTT) was 
used to measure glucose tolerance. After initial metabolic tests, mice were fed a HFD for 
12 weeks before repeating the IPITT and IPGTT. We hypothesised that α7KO mice 
would be more insulin sensitive and more glucose tolerant than controls. 
3.3.1 Measuring insulin sensitivity in chow-fed and HFD-fed 
integrin α7KOs 
The reduced ability of α7KO mice to gain body weight when fed a HFD indicated that 
these mice would also remain insulin sensitive. Insulin tolerance tests were performed 
at 3 months and 6 months on a chow diet and HFD, respectively. Insulin tolerance testing 
of 3-month-old chow-fed mice showed that both α7KOs and controls were insulin 
sensitive (Figure 3.2A). Statistical analysis of time points during the IPITT showed that 
there was no significant difference between α7KOs and controls when fed a chow diet. 
Further insulin tolerance tests carried out on 6-month-old mice when fed a HFD for 12 
weeks showed that control mice became less insulin sensitive. However, 6-month-old 
HFD-fed α7KO mice remained insulin sensitive. Statistical analysis of α7KO and controls 
demonstrated a significant difference at time points: 30 mins, 60 mins and 120 mins 
(Figure 3.2B). 
Further comparison showed that when control mice were fed a HFD for 12 weeks, they 




showed they were significantly different after 60 mins of the IPITT and 120 mins (Figure 
3.2C). When comparing chow-fed α7KO mice to HFD-fed, statistical analysis showed 
there was only a significant difference at 120 mins (Figure 3.2D). 
The greatest difference in insulin sensitivity is seen between HFD-fed α7KO and control 
mice. However, all combinations of genotypes and diet showed that, although there is 
variance in the magnitude of insulin sensitivity, all are still insulin sensitive rather than 
insulin resistant. This is demonstrated by blood glucose levels reducing to some degree 





Figure 3.2: Integrin α7 deficiency causes insulin hypersensitivity on both a chow and HFD. 
(A) Following a 6-hour fast, IPITT performed using 0.75 U/kg of insulin on 3-month-old mice fed 
a chow diet. (B) Following a 6-hour fast, IPITT performed using 0.75 U/kg of insulin on 6-month-
old mice fed a HFD. (C) Comparison of insulin sensitivity of control mice when fed a chow diet vs 
a HFD. (D) Comparison of insulin sensitivity of α7KO mice when fed a chow diet vs a HFD. The 
data are mean ± SEM (n = 7). Statistical analysis was completed using an independent t-test. *p 


























































































3.3.2 Measuring glucose tolerance in chow-fed and HFD-fed 
integrin α7KOs 
Integrin α7KO mice were resistant to weight gain when fed a HFD as previously shown 
in this study. These mice were also shown to remain more insulin sensitive than controls. 
Therefore, we decided to investigate whether these mice also remained glucose tolerant. 
Glucose tolerance tests are used to measure the body’s ability to clear excessive 
glucose. Tests were performed at 3 months and 6 months on a chow and HFD, 
respectively. 
Glucose tolerance testing of chow-fed 3-month-old α7KO and control mice showed that 
both genotypes were similarly glucose tolerant. Statistical analysis showed that there 
was no difference between α7KO and control mice when fed a chow diet (Figure 3.3A). 
However, glucose tolerance testing of 6-month-old, HFD-fed α7KO and control mice 
revealed that although both genotypes remained glucose tolerant, α7KO mice were more 
glucose tolerant than controls. Statistical analysis showed that, at time points 15 and 30 
minutes, blood glucose levels were significantly higher in controls than α7KO mice 
(Figure 3.3B). 
Although there is no significant difference, further analysis demonstrated that there was 
a trend between the glucose tolerance in control mice that were fed a chow diet and 
those which were fed a HFD (15’ p=0.35, 30’ p=0.28) (Figure 3.3C). Additionally, there 
was no significant difference between chow-fed and HFD-fed α7KO mice (Figure 3.3D). 
This section of the study demonstrates that there is no difference in glucose tolerance 
between α7KO and control mice when fed a chow diet. However, when fed a HFD for 12 
weeks, α7KO mice are significantly more glucose tolerant than control mice. This is 
further reinforced by the trend of worsened glucose tolerance when comparing control 
mice on a chow and HFD. Analysis showed that α7KO mice were similarly glucose 





Figure 3.3: Integrin α7 deficiency increases glucose tolerance compared to control mice 
when fed a HFD. (A+B) Following a 16-hour fast, IPGTT performed using 2 g/kg on 3-month-old 
mice fed (A) chow diet and 6-month-old mice fed a (B) HFD. (C+D) Comparison of glucose 
tolerance of (C) control mice and (D) α7KO mice when fed a chow diet vs a HFD. The data are 





3.4 The effect of integrin α7 deficiency on adipose 
tissue depots 
As previously discussed, when α7KO mice were fed a 45% kcal HFD, they remained 
approximately the same body weight as when fed a chow diet. In contrast, control mice 
gained significantly more body weight than α7KO mice when fed a HFD. Increased body 
weight due to consumption of a HFD is usually due to the accumulation of adipose tissue. 
However, adipose tissue function differs depending on where in the body it is located. It 
was important to understand whether the increased body weight observed in control mice 
fed a HFD was due to increased adipose tissue and, furthermore, whether the distribution 
of this adipose tissue differed between control and α7KO mice. To investigate this, mice 
were fed a HFD for 12 weeks before tissue harvest. Adipose tissue depots were isolated, 
weighed and normalised against the animal’s total body weight. 
The four depots were chosen as they represented the two main categories of adipose 
tissue: subcutaneous and visceral. The mammary fat pad is accepted as being structural 
subcutaneous adipose tissue. The mesenteric and gonadal fat pads are representative 
of visceral adipose tissue. The inter-scapular fat pad can be separated into white and 
brown adipose tissue, though both are subcutaneous fat pads. 
Mammary, mesenteric and interscapular white fat pads from control mice, all weighed 
significantly more than α7KO (Figure 3.4A). When the combined weights of adipose 
tissue of control and α7KO mice were compared, it showed that control mice contained 
significantly more adipose tissue than α7KO mice (Figure 3.4B). 
However, as the body weight of α7KO and control mice were significantly different, it was 
important to calculate what proportion of the mice were adipose tissue to conclude 
whether control mice were ‘fatter’. As shown in Figure 3.4C, the visceral gonadal and 




mice. However, there was no significant difference between the: mammary, mesenteric 
or interscapular brown fat pads. Though, all white adipose tissue fat pads showed a trend 
of being larger in controls. Furthermore, when cumulating the total weight of the adipose 
tissue depots, there was significantly more in control mice (Figure 3.4D). Therefore, we 
can conclude that not only do control mice weigh more than α7KO mice when fed a HFD, 





Figure 3.4: Integrin α7 deficiency causes change in distribution and abundance of adipose 
tissue. (A) Adipose tissue depot weights from 6-month old, HFD-fed control and α7KO mice were 
compared. (B) Total adipose tissue weight from: mammary, mesenteric, gonadal, interscapular 
white and interscapular brown. (C) Adipose tissue depot weights normalised against total body 
weight. (D) Total adipose tissue from: mammary, mesenteric, gonadal, interscapular white and 
interscapular brown, normalised against total body weight. The data are mean ± SEM (α7KO n=7, 




3.5 The effect of integrin α7 deficiency on tissue 
histology and function 
As shown previously, α7KO mice weighed significantly less than control mice on both a 
chow and a HFD. Further analysis showed that not only were control mice heavier than 
α7KO mice, control mice had a higher percentage of body fat than α7KO mice. Both 
genotypes were insulin sensitive when fed a chow diet. In contrast, only α7KO mice 
remained hypersensitive to insulin when fed a HFD. Greater glucose tolerance was 
measured in HFD-fed α7KO mice compared to control, but no difference was observed 
when fed a chow diet. 
3.5.1 The role of integrin α7 in adipose tissue function 
Adipose tissue plays a vital role in normal metabolism by acting as an energy buffer 
during fluctuating energy availability and demand. Adipocytes, the main cell type in 
adipose tissue, can sequester excess circulating lipid in cytoplasmic lipid droplets during 
times of caloric surplus. Alternatively, during times of caloric need, lipid is released from 
lipid droplets into circulation to be used as an energy source. To possess this function, 
adipose tissue has a remarkable ability to change morphologically during times of 
overnutrition. This is achieved either via hypertrophy of individual adipocytes or 
hyperplasia from progenitors. To investigate this function, adipocyte size was measured 
in both α7KO and control mice. 
Firstly, adipose tissue was isolated from 6-month old HFD-fed mice before being fixed in 
4% PFA and rinsing overnight in PBS. Tissues were dehydrated in increasing 
concentrations of ethanol before being embedded in paraffin wax. Sections were stained 
with hematoxylin and eosin to visualise the nuclei, cytoplasm and extracellular matrix. 
Multiple images of the adipose tissue were captured to ensure that representation of the 
tissue was sampled and adipocyte sizes were measured using ImageJ software by 




pair of tangents). By using minimum Feret diameter, the error from irregularly shaped 
adipocytes is reduced. The mean minimum Feret diameter was calculated for each 
mouse and was then averaged to give an overall mean. Generalised Estimating 
Equations were used to estimate the SEM by considering the number of adipocytes from 
each individual biological sample.  
Interestingly, there was no significant difference between mean minimum Feret diameter 
of the mammary and interscapular white subcutaneous, nor the mesenteric visceral, 
adipose tissue sites between control and α7KO mice (Figure 3.5). However, the mean 
minimum Feret diameter of the gonadal visceral adipose tissue depot was significantly 
smaller in α7KO mice compared to control. 
Further to the results shown in Figure 3.4, this demonstrates that there are not only less 
gonadal visceral adipocytes in α7KO mice, but the adipocytes that are present are 
significantly smaller than controls. The deletion of integrin α7 not only alters the 





Figure 3.5: (A) Mean minimum Feret diameter of adipocytes isolated from HFD-fed α7KO and 
control adipose tissue. The data are mean ± SEM (n=3 mice). Statistical analysis was measured 
using generalised estimating equations. (B+C) Hematoxylin and eosin staining of paraffin-




3.5.2 The role of integrin α7 in skeletal muscle histology 
Previous studies have demonstrated the role integrin α7 has in skeletal muscle 
regeneration and homeostasis. However, histological analysis has not been conducted 
before where the focus has been the role of integrin α7 in metabolism. Obesity and 
insulin resistance has been associated with chronic inflammation, therefore the 
dysregulation of skeletal muscle histology could be a factor in the variance of insulin 
sensitivity in α7KO and control mice. As integrin α7 is the most abundant integrin in 
skeletal muscle, the primary tissue of glucose uptake, it was necessary to investigate the 
histology of skeletal muscle.  
The tibialis anterior (TA) muscle was isolated and pinned to parafilm before being frozen 
in liquid nitrogen-cooled isopentane. TA muscle was sectioned in a cryostat at 10 μm 
thick. Sections were stained with hematoxylin and eosin.  
As previously shown by Mayer et al., histological analysis of TA muscle from chow-fed, 
6-month-old, α7KO mice showed evidence of a mild myopathy (Mayer et al., 1997). The 
combination of variable muscle fibre size and centrally located nuclei is a pattern that is 
typically found in muscular dystrophies (Figure 3.6). Histological staining revealed 
evidence of mononuclear cell infiltration and muscle fibre necrosis around the 
myotendinous junction in α7KO mice, whereas control mice showed no signs of 
degeneration or regeneration. 
In 6-month-old, HFD-fed α7KO and control mice, there was very little difference when 
comparing to their chow-fed counterparts. There appeared to be no deposits of lipid and 
we observed a similar level of centrally-located nuclei in α7KO chow-fed muscle 
compared to α7KO HFD-fed muscle. 
From the H&E-stained muscle sections we can conclude that there is no change in 




reiterated the previously recorded differences between control and α7KO mice. We 
observed a greater population of centrally-located nuclei in the α7KO mice compared to 






Figure 3.6: Hematoxylin and eosin staining of frozen muscle sections. (A) Control mice possess a regular muscle fibre pattern with peripherally located nuclei. (B) 
α7KO mice possess muscle fibres of a variable size. Many of these fibres contain centrally located nuclei with increased endomysial connective-tissue deposition 
(asterisk). There is also an apparent influx of mononuclear cell infiltration around the myotendinous junction (arrow). (C) HFD-fed control mice appear similar 




3.5.3 Ectopic fat deposition in α7KO skeletal muscle 
Lipid that is stored in tissues other than adipose tissue is defined as ‘ectopic fat’. Ectopic 
fat depositions in the skeletal muscle are associated with reduced insulin sensitivity and 
are typically found between muscle fibres. Small lipid droplets can also be found 
throughout the muscle cells (intramyocellular lipid deposition) from insulin resistant 
specimens. To determine the presence of lipid deposition in either chow or HFD-fed 
α7KO and control mice, we stained muscle sections with Oil Red O, a stain used to 
detect neutral triglycerides and lipids. 
In neither control or α7KO 6-month old, chow-fed mice was there evidence of ectopic fat 
depositions in the skeletal muscle, nor was there evidence of intramyocellular lipid 
deposition. This was to be expected as the storage of lipid in the skeletal muscle is an 
abnormal observation which should not occur in control, normally-fed mice. 
Both control and α7KO 6-month old, HFD-fed mice showed some degree of ectopic lipid 
deposition in the skeletal muscle (Figure 3.7). All depositions appeared to lie between 
the muscle fibres with no evidence of intramyocellular lipid deposition. Muscle fibres 
appeared histologically normal around lipid deposits. 
ImageJ software was used to quantify the amount of lipid in skeletal muscle from the Oil 
Red O-stained sections. Images were ‘deconvoluted’ to separate the red stain from the 
rest of the image, the area of the red stain was quantified and the mean coverage per 
mm2 of skeletal muscle was calculated. No significant difference in abundance of lipid in 






Figure 3.7: Oil Red O staining of frozen muscle sections. (A) TA sections from control chow-
fed mice and (B) α7KO chow-fed mice. No presence of lipid detected. (C) TA sections from control 
HFD-fed mice and (D) α7KO HFD-fed mice show some degree of lipid deposition. (E) 
Quantification of Oil Red O staining shows no significant difference in abundance of lipid between 
control and α7KO muscle. The data are mean ± SEM (n=3). Statistical analysis was completed 




3.5.4 The role of integrin α7 in liver histology 
Investigating the role of α7 integrin in muscle, with a focus on metabolism, suggested 
that there was only a slight difference between α7KO and control mice when fed a HFD. 
One of the other key organs involved in insulin signalling and glucose metabolism is the 
liver. The liver is involved in a range of glucose metabolic processes including 
glycogenesis, glycogenolysis, glycolysis and gluconeogenesis (Han et al., 2016). The 
liver is a major site of glucose utilisation during the post-prandial period where this 
absorbed glucose is phosphorylated and stored as glycogen. The liver is then able to 
release glucose systemically when needed (Adeva-Andany et al., 2016). 
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent diseases 
associated with obesity and insulin resistance. Steatosis is the main phenotype of this 
disease but portal and lobular inflammation, apoptotic hepatocellular injury, Mallory-
Denk bodies, megamitochondria and fibrosis are also key symptoms of NAFLD liver 
histology which can lead to non-alcoholic steatohepatitis (NASH), liver cirrhosis and 
finally, hepatocellular carcinoma (Kleiner and Makhlouf, 2016; Kitade et al., 2017).  
3.5.5 Histology of liver 
To investigate whether the deletion of integrin α7 affected the liver histology, we isolated 
liver from chow-fed and HFD-fed, 6-month-old mice. Livers were fixed and cryoprotected 
before being sectioned and stained with H&E to observe general histology. 
As expected, chow-fed control and α7KO livers were very similar histologically. We saw 
no evidence of steatosis or inflammation when fed a chow diet. In contrast, livers isolated 
from HFD-fed α7KO mice showed unexpected results compared to control livers. Insulin 
resistance has been shown to be pivotal for the progression of NAFLD. H&E staining 
showed that HFD-fed control mice suffer from macrovesicular steatosis (lipid droplets 
large enough to distort the nucleus) (Figure 3.8C+D). Unexpectedly, insulin sensitive 




degree. HFD-fed α7KO mice had apparent portal and lobular inflammation whereas 
control mice did not (data not shown). However, neither HFD-fed α7KO or control mice 
livers appeared to contain Malloy-Denk bodies, megamitochondria or fibrosis from H&E 
analysis. This indicated that α7KO livers are at a later stage of NAFLD than controls but 
have not progressed into the NASH or cirrhosis stage.  
These results are controversial as NAFLD is not normally associated with insulin 
sensitivity. The causes of insulin resistance tend to cause NAFLD so one phenotype 
without the other is uncharacteristic. Therefore, it was important to confirm the level of 






Figure 3.8: Hematoxylin and eosin staining of frozen liver sections.(A+B) Chow-fed (A) control and (B) α7KO liver show normal liver histology. (C) HFD-fed, 
control liver shows mild steatosis with evidence of ectopic lipid deposition (arrow). (D) HFD-fed, α7KO liver shows macrovesicular steatosis through accumulation 




3.5.6 Ectopic fat deposition in α7KO liver 
Histological staining of liver sections from HFD-fed α7KO and control mice with H&E 
produced evidence of ectopic lipid droplets. This is acknowledged as a common 
phenotype in sufferers of insulin resistance. Surprisingly, there appeared to be more lipid 
deposition in HFD-fed α7KO mice compared to control. This was controversial as 
previous tests demonstrated α7KO HFD-fed mice were insulin sensitive and lean. 
Therefore, it was important to confirm that the ‘holes’ observed in H&E-stained liver 
sections were lipid droplets. 
Liver sections were fixed and cryoprotected before being frozen in Optimal Cutting 
Temperature (OCT) Compound. Livers were cryosectioned and stained with HCS 
LipidTOX™ Green neutral lipid stain. HCS LipidTOX™ Green neutral lipid stain was used 
rather than Oil Red O, as the red stain of Oil Red O was difficult to distinguish from the 
natural red hue of liver. The LipidTOX™ neutral lipid stain has an extremely high affinity 
for neutral lipid droplets and can be observed and quantified using fluorescence 
microscopy. HCS LipidTOX™ Green neutral lipid-stained liver images were quantified 
using ImageJ software. 
As was expected from previous H&E stained liver sections, there was no quantifiable 
amount of lipid found in chow-fed α7KO or control mice (Figure 3.9). HFD-fed, α7KO 
mice contained approximately 0.13μm2 of lipid per 1μm2 of liver. Whereas in equivalent 
control mice, only 0.03μm2 of lipid was present per 1μm2 of liver. Statistical analysis 
showed that there was significantly more lipid in 6-month old, HFD-fed α7KO mice 





Figure 3.9: HSC LipidTOX™ Green neutral lipid stain of frozen liver sections. (A) Chow-fed control liver. No evidence of lipid deposition (B) α7KO chow-fed. 
No evidence of lipid deposition. (C+F) Section with no lipid stain to ensure fluorescence is specific to lipid. (D) HFD-fed control mice. Some lipid deposition. (E) 
HFD-fed α7KO liver. Major lipid deposition. (G) Comparison of mean area of lipid/area of liver between 6-month old, HFD-fed control and α7KO livers. The data 




3.6 The role of integrin α7 in liver function 
3.6.1 Liver enzymes in α7KO and control mice 
We have demonstrated that livers from HFD-fed, α7KO mice contained significantly more 
lipid than controls. Ectopic lipid deposition in the liver is usually an indicator of liver 
damage, therefore, it was necessary to determine if these fatty livers were damaged and 
to quantify the extent to which they were damaged. 
Alanine transaminase (ALT) and Aspartate transaminase (AST) are transaminase 
enzymes important in amino acid metabolism. ALT and AST are commonly used 
clinically to determine liver health. Although ALT is predominantly found in the liver, AST 
is also found in the heart, skeletal muscle, kidneys, brain and red blood cells. As a result 
of this, ALT is a better indicator of liver damage whereas AST may be increased due to 
other tissues (Limdi and Hyde, 2003). 
Blood was isolated from HFD-fed α7KO and control mice in a fed state. Serum was 
isolated from these samples and snap frozen in liquid nitrogen. Serum samples were 
analysed using a Randox system and an ALT and AST assay kit as per manufacturer’s 
instructions. 
Analysis of ALT enzyme showed levels of 106.86 U/L in HFD-fed control mice, whereas 
in α7KO mice there were concentrations of 225.65 U/L. Although there was a trend of a 
greater concentration of ALT present in α7KO serum, it was not shown to be statistically 
significant (Figure 3.10A). Analysis of enzyme AST showed that there was a significantly 
greater concentration in HFD-fed α7KO mice compared to controls. Control animals had 
a mean concentration of 587.89 U/L, whilst α7KO mice had a mean concentration of 
1635.29 U/L (Figure 3.10B). 
This elevation of circulating liver enzymes is a key indicator of tissue damage. However, 
as previously mentioned, AST is not specific to the liver. Therefore, this indicates that 





Figure 3.10: ALT and AST enzyme analysis of serum collected from HFD-fed α7KO and 
control mice. (A) ALT quantification of HFD-fed α7KO and control mice. (B) AST quantification 
of HFD-fed α7KO and control mice. The data are mean ± SEM (n = 3). Statistical analysis was 
completed using an independent t-test. NS p > 0.05, * p < 0.05


























3.6.2 Bile acid production in α7KO and control mice 
We have shown that livers from HFD-fed, α7KO mice contain significantly more lipid than 
controls and that there were greater amounts of circulating liver enzymes, indicating liver 
damage. Therefore, it was necessary to investigate whether α7KO liver function had 
been affected from this influx of lipid deposition. As α7KO animals do not gain weight 
when fed a HFD, we hypothesised that the production of bile acids in the liver may have 
been affected. 
Bile acids are a group of water-soluble steroids, formed from cholesterol. They play a 
significant role in the absorption and digestion of fat and fat-soluble proteins. 
Chenodeoxycholic acid and cholic acid are referred to as the primary bile acids and are 
the most abundant. They are produced in the hepatocytes of the liver before being 
conjugated to glycine or taurine in the canaliculi of the liver. It is the glycoconjugates and 
tauroconjugates which increase the amphipathic nature of bile acids and are the major 
solute in bile. In the colon, they are deconjugated by bacterial enzymes to form 
secondary bile acids which are then recycled in the liver by reconjugation to either glycine 
or taurine, or are excreted in faeces (Stamp and Jenkins, 2008).  
By quantifying the total, and the categories of bile acids, we are able to analyse if and 
where there is an effect caused by the deletion of integrin α7. A change in primary bile 
acid levels indicates a potential issue with the production in hepatocytes. Variance in the 
levels of glycoconjugates and tauroconjugates indicates there may be an issue with the 
transporters of bile acids. Finally, a change in the levels of secondary bile acids would 
suggest there was a change in the microbiota required to recycle bile acids. 
Serum was isolated from blood samples collected from animals and was analysed via 
LC-MS. Analysis showed that there was no significant difference in the total amount of 
serum bile acids between α7KO and control animals when fed either a chow or HFD. 




chow or a HFD (Figure 3.11A).  
Total bile acids were broken down into categories of: primary, secondary, glycol-
conjugated and tauro-conjugated, to investigate whether the proportions of bile acids 
were affected. Statistical analysis showed that there was no significant difference in any 
of these categories when comparing genotype and diet (Figure 3.11B). 
This investigation confirmed that increased lipid deposition in the liver does not affect 
total bile acid production regardless of genotype or diet. Neither does it affect the 
conversion of primary bile acid to secondary bile acid. The difference in weight gain 





Figure 3.11: Bile acid analysis of serum collected from chow-fed and HFD-fed animals. (A) 
Total bile acid concentration from serum. (B) Breakdown of total bile acids into: primary, 
secondary, glycoconjugated and taurogconjugated. The data are mean ± SEM (Control Chow n 
= 3, α7KO Chow n = 4, Control HFD n = 6, α7KO HFD n = 5). Statistical analysis was completed 


































































































In this chapter, we aimed to investigate the effect the deletion of integrin α7 had on the 
whole-body metabolic phenotype in mice. We successfully utilised a previously 
generated mouse line with a whole-body deletion of integrin α7. We ran metabolic tests 
on male control and α7KO at 3-months old before feeding a HFD for 12 weeks. Metabolic 
tests were conducted on mice post-HFD. Tissues of metabolic interest including skeletal 
muscle, adipose tissue and liver, were isolated and analysed.  
Absence of integrin α7 has been shown to cause a novel form of muscular dystrophy in 
vivo (Mayer et al., 1997). Integrin α7 is the most abundant integrin in skeletal muscle and 
has been demonstrated to be involved, but not crucial, in the differentiation and migration 
process during muscle development. Histopathological analysis shows that deletion of 
integrin α7 results in impaired function of the myotendinous junction. Although many 
studies have been completed to investigate the role of integrin α7 in myogenesis and 
muscle function, no studies have sought to investigate its impact on metabolism. 
The integrins, and their downstream effectors, have been shown to be implicated in the 
regulation of insulin action. Skeletal muscle has been recognised to be responsible for 
approximately 75% of all insulin-stimulated glucose uptake (Brennan et al., 2016). 
Therefore, we hypothesised that integrin α7 would be involved in skeletal muscle’s 
response to insulin. 
3.7.1 Body weight and composition 
The deletion of integrin α7 resulted in mice that weighed significantly less than control 
mice when fed a chow diet. However, it was unclear whether this reduction in body weight 
was due to a reduction in muscle mass caused by the novel myopathy seen in the α7KO 
model. Surprisingly, when control and α7KO mice were fed a HFD for 12 weeks, α7KO 




gained significant amounts of body weight. It was important to investigate whether this 
lack in gain of body weight was due to reduced consumption of food compared to control 
mice. Mice were separated according to genotype and food was weighed alongside 
weekly mouse weigh-ins to calculate the average food ingested per mouse. Interestingly, 
there was no significant difference in the amount of food consumed between genotypes 
when normalised against mouse weight. 
To understand whether the reason HFD-fed α7KO mice were lighter than control mice 
was due to less adipose tissue, we isolated adipose tissue from four different depots. 
We chose two subcutaneous depots (mammary and interscapular) and two visceral 
depots (gonadal and mesenteric). Overall, we found that there was significantly less 
adipose tissue in HFD-fed α7KO mice. The main difference was in the gonadal depot 
with there also being significantly less interscapular white adipose tissue. 
We further analysed the adipose tissue depots by observing the histology of the 
adipocytes. Calculating the mean minimum Feret diameter demonstrated no difference 
in the mammary, mesenteric or interscapular white adipose tissue. However, gonadal 
adipocytes were shown to be significantly smaller in HFD-fed α7KO mice. Thus, the 
deletion of integrin α7 results in leaner mice when fed either a chow or HFD. It also 
causes significantly smaller adipocytes in visceral gonadal adipocytes.  
3.7.2 Insulin sensitivity and glucose tolerance 
IPITT and IPGTTs were performed on 3-month old chow-fed control and α7KO mice. 
Mice were fed a HFD for 12 weeks before undergoing further metabolic tests. There was 
no significant difference between control and α7KO mice in terms of insulin sensitivity 
when fed a chow diet. However, when fed a HFD for 12 weeks, control mice became 
less insulin sensitive as they gained weight and α7KO mice remained insulin sensitive 




A similar trend was observed with glucose tolerance tests. Chow-fed α7KO and control 
mice were no different in terms of glucose tolerance when fed a chow diet. However, 
α7KO mice were significantly more glucose tolerant than controls when fed a HFD. 
Therefore, the deletion of integrin α7 results in mice remaining insulin sensitive and 
glucose tolerant when fed either a chow or a HFD. 
3.7.3 Muscle histology 
As previously mentioned, the deletion of integrin α7 results in a novel form of muscular 
dystrophy (Mayer et al., 1997). This was reiterated in the H&E images shown in this 
chapter. Though no studies have investigated integrin α7 with metabolism being the 
focus, intramyocellular fat deposition has been shown to be a factor of obesity and insulin 
resistance (Greco et al., 2002). 
No evidence of intramyocellular fat deposition was seen in H&E or Oilred O-stained 
images of frozen chow-fed TA muscle in control or α7KO mice. There were small 
amounts of adipose deposition in both control and α7KO HFD-fed muscle but there was 
no significant difference between the mouse models. Therefore, a HFD causes some 
muscle fat deposition, however, there is no difference in the extent of deposition between 
control and α7KO mice. 
3.7.4 Liver histology and function 
NAFLD is a general term which ranges from the deposition of lipid in the liver, to 
progressive Non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular 
carcinoma (HCC) (Benedict and Zhang, 2017). NAFLD is the most common form of liver 
disease and typical involves steatosis and fat accumulation in the liver. Progression of 
NAFLD leads to NASH, which includes distortion of hepatocytes, inflammation, and 
fibrosis. Further progression of the disease eventually results in liver cirrhosis, and 




The histology of the liver in chow- and HFD-fed control and α7KO mice was investigated 
using H&E staining. No evidence of steatosis or inflammation was observed in chow-fed 
mice. However, when fed a HFD, control livers began to show evidence of 
macrovesicular steatosis (lipids large enough to distort the nuclei of the liver). 
Surprisingly, the lean, α7KO, insulin-sensitive mice possessed livers which were 
suffering from macrovesicular steatosis more evident than seen in control mice. 
Furthermore, the HFD-fed α7KO livers showed evidence of portal and lobular 
inflammation. Further investigation of fat deposition in livers showed that HFD-fed α7KO 
livers possessed significantly more lipid deposition than controls. Therefore, the deletion 
of integrin α7 results in a later stage of NAFLD than control mice when fed a HFD. 
Liver function was analysed by measuring the levels of key liver enzymes in the blood 
serum. There was a trend of greater alanine transaminase (ALT) levels in HFD-fed α7KO 
mice and significantly more aspartate transaminase (AST) levels. Unfortunately, 
although ALT is predominantly found in the liver, AST is found in a range of tissues 
(Gowda et al., 2009). Therefore, we cannot conclude that these elevated serum enzymes 
are solely caused by liver damage. 
To further investigate the function of the liver we analysed the levels of bile acids in blood 
serum. The liver is responsible for the generation of bile acids which assist nutrient 
absorption and expulsion of toxic metabolites (Chiang, 2013). Clinical studies have 
demonstrated the link between NAFLD and bile acid homeostasis dysregulation. 
Patients with NASH have been found to have four-fold elevated serum tauroconjugates 
and glycoconjugates (Kalhan et al., 2011). This increase in serum bile acid levels is 
suggested to be due to increased cholesterol 7α-hydroxylase (CYP7A1) expression (Puri 
et al., 2017). We quantified the total amount of bile acids but also broke them down into 
four main categories: primary, secondary, glycoconjugates and tauroconjugates. Results 
showed that there was no significant difference when fed either a chow or a HFD. 




levels are not different in the intestines of the animals, therefore affecting nutrient 
absorption. 
3.7.5 Summary table 
Table 3.1: Table summarising the results from Chapter 3, comparing control and α7KO 
mice. ↓ comparatively significantly lower, ↑ comparatively significantly higher 
 Chow diet High fat diet 
 Control α7KO Control α7KO 
Body weight - ↓ - ↓ 
Insulin 
sensitivity 
- No difference - ↑ 
Glucose 
tolerance 
- No difference - ↑ 
Adipose tissue 
weight 
- ↓ - ↓ 



















- No difference - No difference 








- - - ↑ 
Serum liver 
enzymes 
- - - ↑ 
Serum bile 
acids 





 CHAPTER 4: ANALYSING THE 






The development of disease is often caused by interplay between genetic, epigenetic 
and environmental factors. This has been shown to be the case with metabolic diseases 
where both environmental factors (diet and exercise) and genetic factors (shown in 
genome wide association studies) impact the onset of disease (Imamura and Maeda, 
2011). Changes in insulin sensitivity have been shown to be affected by a wide range of 
factors including: altered insulin signalling, accumulation of adipose tissue, oxidative 
stress and inflammation (Koves et al., 2008; Erion and Shulman, 2010; Lee and Lee, 
2014). However, many of these changes can be influenced by the ingestion of varied 
diets and how the body absorbs nutrients from food. The quantification and analysis of 
small molecules in a biological sample have been termed the study of metabolomics. By 
analysing samples at a specific time and condition, it offers a snapshot of the metabolic 
status of the subject (Milburn and Lawton, 2013).  
Integrins have been shown to play a role in the absorption of nutrients on both a whole-
body and cellular level. The deletion of RGD-binding protein α8β1 from gastrointestinal 
smooth muscles resulted in enhanced gastric contraction, faster gastric emptying and 
more rapid transport of food from the small intestine. This resulted in lean mice due to 
malabsorption (Khalifeh-Soltani et al., 2016). Integrin α7 is ubiquitously expressed by 
various types of smooth muscle, including those found along the gastrointestinal tract 
and is crucial for the differentiation of smooth muscle (Yao et al., 1997). Therefore, it is 
possible that the HFD-fed, lean, insulin sensitive integrin α7KO model we have 
generated is influenced by altered nutrient absorption. 
We sought to investigate whether the deletion of integrin α7 from chow-fed or HFD-fed 
control or α7KO mice resulted in a change of metabolic profile. Control and α7KO mice 
were housed separately as they are coprophagous animals, to prevent sharing of 




(NMR). Concentrations of individual metabolites were calculated from spectral peaks 
and were analysed using MetaboAnalyst 4.0. We used a variety of both exploratory and 
functional statistical analysis to explore both the individual and group effects of 





4.2 Clustering of metabolites according to genotype in 
chow-fed mice 
We used Partial Least Squares Discriminant Analysis (PLS-DA) as an exploratory 
method to cluster the metabolomic profiles of faeces collected from control and α7KO 
mice. PLS-DA links two data matrices: X (raw data) and Y (genotype category) and 
explores the maximal covariance of the data (Gromski et al., 2015). From this data, a 
predictability performance value (Q2) can be calculated to estimate the predictive ability 
of a model. The closer the Q2 value is to 1, the better the predictability (Szymańska et 
al., 2012). Additionally, we used clustered heatmapping to visually observe clustering of 
specific metabolites between genotypes. 
Clustering of metabolomic profiles from control and α7KO mice fed a chow diet is shown 
in Figure 4.1A. Visually, there appears to be little variation in the metabolomic profile of 
chow-fed α7KO mice. However, there is a large variance in the profile of chow-fed control 
mice. This is demonstrated by the calculated Q2 value of -1.69. This Q2 value indicates 
there is poor predictability between the chow-fed control and α7KO model in terms of 
metabolomics. 
To explore the difference in individual metabolites between chow-fed control and α7KO 
faecal metabolomic profiles, we performed a Student’s T-Test (Figure 4.1B). Statistical 
analysis demonstrated that there was no significant difference between any individual 
metabolites measured. Full readout can be seen in Appendix Table 10.1. 
A heatmap was generated, as shown in Figure 4.1C, to visually display different 
distribution patterns of metabolites between control and α7KO groups. However, the 
heatmap demonstrated the variance within genotypes previously reported in PLS-DA 
analysis. The varied results of these exploratory analyses make drawing conclusions 
about the difference between the metabolomic profiles of faeces from control and α7KO 





Figure 4.1: Exploratory analysis of metabolomic profiles from faeces collected from chow-
fed control and α7KO mice. (A) PLS-DA analysis score plots of metabolomic profiles. Dots 
represent individual mouse samples. Coloured oval represents 95% confidence region of 
genotype. (B) Visual representation of Student’s T-Test of individual metabolites. (C) Heatmap 




4.3 Functional analysis of metabolites in chow-fed mice 
We employed Metabolite Set Enrichment Analysis (MSEA) to measure whether there 
was any difference in clusters of metabolites between control and α7KO metabolomic 
profiles. MSEA bypasses the need for individual metabolites to be evaluated individually 
for significance and to all pass a significance test. This allowed us to identify subtle but 
consistent changes amongst a group of related compounds which may, otherwise, go 
undetected. 
MSEA was performed using a generalised linear model to estimate a Q-statistic for each 
metabolite. The Q-statistic values the correlation between the metabolite concentrations 
and the clinical outcome summarises the ranking of pathways changed between the 
metabolomic profile of faeces from chow-fed control and α7KO mice  
Figure 4.2). However, as shown in Appendix Table 10.2, none of these pathways are 
significantly different. Therefore, with the combination of results from exploratory and 
functional analyses of the metabolomic profile of faeces collected from chow-fed control 
and α7KO mice, we can conclude that there is no significant difference caused by the 













Raw p FDR 
Glycerolipid Metabolism 25 1 60.299 20 0.0693 0.8294 
Selenoamino Acid 
Metabolism 
28 2 40.607 20 0.0815 0.8294 
Glutathione Metabolism 21 3 37.181 20 0.8784 0.8294 
Bile Acid Biosynthesis 65 1 37.653 20 0.1951 0.8294 
Porphyrin Metabolism 40 1 37.653 20 0.1951 0.8294 
 
Figure 4.2: Summary plot for Metabolite Set Enrichment Analysis (MSEA) of metabolomic 




4.4 Clustering of metabolites according to genotype in 
HFD-fed mice 
Following 12 weeks of HFD feeding, faecal samples were collected from the same mice 
discussed in the previous section of this chapter. Samples were extracted and measured 
in the same manner and were analysed using the same exploratory and functional 
analyses. Unfortunately, one control sample contained insufficient material to complete 
analysis. To compensate for this, the Missing Value Imputation function in 
MetaboAnalyst 4.0 was employed to replace sample values with the mean value of the 
remaining two to allow statistical testing. 
PLS-DA was used to measure the clustering of HFD-fed samples to measure the 
predictability of the control and α7KO samples (Figure 4.3A). As before in chow-fed mice, 
there was positive clustering of the α7KO metabolomic profile but a large variation in 
control mice. A Q2 value of -0.1778 was calculated, indicating that, again, HFD-fed 
control and α7KO models have a poor predictability in terms of metabolomics.  
To explore the difference between individual metabolites we performed a Student’s T-
Test (Figure 4.3B). As shown in chow-fed control and α7KO mice, there was no 
significant difference between any individual metabolites measured. Full readout can be 
seen in Appendix Table 10.3. 
To visually display different distribution levels in control and α7KO metabolomic profiles, 
a heatmap was generated (Figure 4.3C). This further demonstrated the variance in the 
HFD-fed metabolomic profile. There is a large variance between the two measured 
samples which makes the addition of a calculated mean sample nonbeneficial. This 
variation, again, makes concluding differences or similarities between control and HFD 






Figure 4.3: Exploratory analysis of metabolomic profiles from faeces collected from HFD-
fed control and α7KO mice. (A) PLS-DA analysis score plots of metabolomic profiles. Dots 
represent individual mouse samples. Coloured oval represents 95% confidence region of 
genotype. (B) Visual representation of Student’s T-Test of individual metabolites. (C) Heatmap 




4.5 Functional analysis of metabolites in HFD-fed mice 
As there were no single metabolites in the metabolomic profile of faeces from HFD-fed 
control and α7KO that were significantly different, it was important to look at the slight 
changes in groups of metabolites. Functional analysis was completed via MSEA in 
MetaboAnalyst 4.0. 
A summary plot of the MSEA analysis is shown in Figure 4.4. There was very little overlap 
with affected pathways from chow-fed mice. Though, the butyrate metabolic pathway 
was shown to be significantly altered. The combination of the elevation of adenosine 
monophosphate, butyrate and succinate in control mice provides evidence that the 
butyrate metabolic pathway is significantly less active in α7KO mice. However, it is not 
possible to say whether this pathway is truly significantly different due to the variance 
and incomplete data set of HFD-fed control mice. The full readout of the MSEA can be 
seen in Appendix Table 10.4. With the combination of exploratory and functional 
analyses completed on the metabolic profiles of faeces from HFD-fed control and α7KO 













Raw p FDR 
Butyrate Metabolism 19 3 32.065 20 0.0280 0.5141 
Mitochondrial Electron Transport 
Chain 
19 2 41.465 20 0.0839 0.5141 
Ketone Body Metabolism 13 1 54.631 20 0.0932 0.5141 
Oxidation of Branched Chain Fatty 
Acids 
26 1 54.631 20 0.0932 0.5141 
Phytanic Acid Peroxisomal 
Oxidation 
26 1 54.631 20 0.0932 0.5141 
 
Figure 4.4: Summary plot for Metabolite Set Enrichment Analysis (MSEA) of metabolomic 





Development of metabolic diseases, including obesity and insulin resistance, are due to 
interplay between generic, epigenetic and environmental factors. It has been widely 
shown that the onset of insulin resistance is linked with obesity, however, the mechanism 
is still not completely understood. One such method of investigation is termed: 
‘metabolomics’, in which small molecules that are involved in metabolic functions, 
deemed ‘metabolites’, are measured in biological samples (Goodacre et al., 2004). 
Metabolomics uses both qualitative and quantitative analysis where either non-target or 
targeted metabolite profiling is conducted. Non-targeted profiling is able to identify a large 
number of metabolites, whereas, targeted profiling uses existing knowledge of 
metabolomic pathways and can accurately quantify those selected metabolites. 
In this study we isolated faecal pellets from both chow- and HFD-fed α7KO and control 
mice. Samples were prepared and analysed using NMR spectroscopy. Peaks were 
identified and quantified before being analysed by MetaboAnalyst 4.0. We used a variety 
of statistical tests to highlight differences between the metabolomic profile of α7KO and 
control mice. 
4.6.1 The metabolomic profile of chow-fed integrin α7 deficient 
mice 
Using PLS-DA, we aimed to construct a model to visually separate α7KO and control 
samples based on their metabolomic profile. Unfortunately, due to the variance in the 
metabolomic profile of control mice, the predictability value of our model (Q2) was -1.69, 
indicating a very poor predictability between chow-fed control and α7KO mice. Of the 
samples we had, Student’s T-Testing demonstrated that there was no significant 
difference between any of the individual metabolites measured, nor did visually 




We continued analysis of chow-fed control and α7KO metabolomic profiles by employing 
MSEA. The purpose of MSEA is to detect slight changes in a pattern of metabolites that 
may not be significantly different when compared individually. However, no pathways 
were found to be significantly different. The pathway which was most different according 
to statistical analysis was the glycerolipid metabolism pathway. In chow-fed α7KO mice 
we observed increased levels of glycerol excreted in the faeces. Other studies have 
demonstrated that increased glycerol levels are a characteristic of the onset of diabetes 
(Diao et al., 2014). Clearly, control chow-fed mice are not diabetic but this reduced 
circulation of glycerol in α7KO mice could suggest protection from the development of 
the disease.  
4.6.2 The metabolomic profile of HFD-fed integrin α7 deficient 
mice 
We continued our investigation by isolating faecal samples from mice fed a HFD for 12 
weeks. We proceeded to use the same statistical analysis as previously used on chow-
fed samples. 
Unfortunately, due to a sampling error we were only able to obtain two useable samples 
from HFD-fed control mice. To make statistical testing possible, we utilised 
MetaboAnalyst 4.0’s Missing Value Imputation function which creates a false sample 
based on the average of the two real samples. PLS-DA was used to generate a model 
to visually separate HFD-fed α7KO and control samples based on their metabolomic 
profile. However, due to the variance in the control metabolomic profile, the model had 
a very low predictability value. Student’s T-Testing of individual metabolites showed that 
no individual metabolites and heatmap visualisation revealed no clustering. 
We employed MSEA analysis to identify significantly different pathways between HFD-
fed control and α7KO metabolomic profiles. Curiously, the butyrate metabolism pathway 




acid in controls indicated that butyrate metabolism had been altered. Studies in humans 
demonstrate that those suffering from type I or type II diabetes have increased levels of 
AMP and butyric acid (Zeng et al., 2011; Dudzinska, 2014). However, studies have also 
demonstrated that sufferers from type I diabetes do not possess altered succinic acid 
levels (Oresic et al., 2008). However, it is worth mentioning that the mechanisms of type 
I and type II diabetes are vastly different. 
Interestingly, ingested butyrate glycerides has been shown to alter body fat deposition 
via regulation of gene expression (Yin et al., 2016). Increased ingestion of butyrate 
glycerides in broiler chickens resulted in a significant decrease in abdominal fat 
compared to total body weight. THRSP, EGR-1, and downstream genes of PPAR-α were 
significantly altered in chickens fed increased butyrate glycerides. THRSP is a 
transcription factor regulator of lipogenesis and adipo-genesis. EGR-1 induces 
expression of IGF-2, PDGF and FGF. However as shown in our data, α7KO mice had 
reduced levels of butyric acid contrasting that found in the study of Yin et al.  
Although we see a difference in one pathway in HFD-fed chow and α7KO mice it is still 
uncertain as to whether this result can be trusted. As previously mentioned, a false 
sample was generated to make statistical analysis possible. Therefore, further samples 
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Two of the main signalling pathways activated by integrins in skeletal muscle are the 
mitogen-activated protein kinase (MAPK) and the Akt pathways. The MAPK pathway is 
made up of three families of kinases: extracellular signal-regulated kinase (ERK), Jun N-
terminal kinase (JNK) and p38 (Johnson and Lapadat, 2002). Activation of ERK is 
initiated by extracellular stimuli that can be induced via integrins (Yee et al., 2008). There 
are two isoforms of ERK: ERK1 and ERK2, with differing roles. The deletion of ERK1 
resulted in viable mice with no overt phenotype, whereas ERK2 deficient mice died in 
utero around embryonic day 6.5 (Pagès et al., 1999; Hatano et al., 2003). ERK1 and 
ERK2 have been shown to be involved in the synthesis of proteins in skeletal muscle but 
also in the regulation of insulin sensitivity (Zhang et al., 2011). The crosstalk of integrins, 
MAPK and insulin sensitivity is still not fully understood. Therefore, ERK has been a 
candidate of interest during this study. 
Akt consists of three isoforms: Akt1, Akt2 and Akt3. All are ubiquitously expressed but 
vary in expression depending on the tissue (Yu et al., 2015). Deletion of Akt1 resulted in 
foetal and postnatal growth defects but possessed normal insulin sensitivity and glucose 
tolerance (Cho et al., 2001a). In contrast, Akt2 deficient mice were less insulin sensitive 
and glucose tolerant than controls (Cho et al., 2001b). Akt3-deficient mice had 
completely normal metabolism, with no change in insulin sensitivity or glucose tolerance, 
however, Akt3 levels in adipocytes were increased by insulin (Barthel et al., 1998; Easton 
et al., 2005). The phosphorylation of Akt on the serine 473 and threonine 308 site is 
involved in insulin signalling and the translocation of GLUT4. Integrin β1 has been shown 
to be involved in the phosphorylation of Akt1 on the serine 473 site, demonstrating the 
link between integrins and insulin signalling (Velling et al., 2004).  
As has already been discussed in this study, the insulin sensitivity of α7KO mice is higher 
compared to control mice when fed either a chow or a HFD for 12 weeks. This was 




Chapter 3 in greater detail.  
Integrins play a clear role in insulin sensitivity, however, the exact molecular mechanism 
that results in increased insulin sensitivity has still not been concluded. As skeletal 
muscle is responsible for approximately 80% of all insulin-stimulated glucose uptake, we 
sought to investigate what effect the deletion of integrin α7 has on the insulin signalling 
pathway. We achieved this by quantifying protein expression via Western blotting of 
various nodes of the insulin signalling pathway from α7KO and control mice fed a chow 





5.2 ERK and Akt signalling in chow-fed integrin α7 
deficient mice 
As previous data in Chapter 3 has shown, α7KO mice are significantly more insulin 
sensitive than control mice when fed a chow diet and, to a greater extent, when fed a 
HFD for 12 weeks. However, we sought to investigate the mechanism of how integrin α7 
deficiency results in insulin sensitivity. To understand this, we investigated the insulin 
signalling pathways in α7KO and control mice. 
In this study, we isolated the gastrocnemius (GC) muscle from 6-month-old mice fed 
either a chow or a HFD. GC muscles were lysed in RIPA buffer with protease and 
phosphatase inhibitors. Samples were prepared under reducing conditions before being 
loaded and run through SDS polyacrylamide gels. Gels were transferred overnight onto 
membranes before being blocked. Membranes were probed with antibodies against pan-
Akt, pAkt(Ser473), pAkt(Thr308), ERK1/2, pERK1/2(Thr202/Tyr204), as well as heat 
shock protein 70 as a loading control protein. Membranes were washed and probed with 
secondary antibodies before being visualised via enhanced chemiluminescence.  
As shown in Figure 5.1, total levels of Akt (including Akt1, Akt2 and Akt3) were not 
different between chow-fed α7KO and control GC muscle lysates. There was also no 
significant difference between the total levels of ERK1 and ERK2 between chow-fed 
α7KO and control GC muscle lysates. 
To quantify the activation of insulin signalling, we calculated the ratio of pAkt:Akt. As 
previously discussed, total activation of Akt requires phosphorylation on sites: Serine473 
and Threonine308. There was no significant difference in normalised ratios of 
pAkt(Ser473):Akt between control and α7KO mice. Neither was there a difference in 
pAkt(Thr308):Akt. Phosphorylated levels of ERK were undetectable so at this moment 
we cannot comment on the ERK signalling pathway in chow-fed α7KO and control mice. 
This data replicates that of the insulin sensitivity tests discussed in Chapter 3 where there 

















































































































































Figure 5.1: Quantification of total and phosphorylated ERK and Akt in chow-fed control 
and α7KO GC muscle. Immunoblot analysis of total Akt, pAkt(Ser473), pAkt(Thr308), total 
ERK1/2 and pERK1/2(Thr202/Tyr204) in chow-fed control and α7KO GC muscle lysates. Bar 
charts represent densitometry of Western blots. The data are mean ± SEM (n = 4). Statistical 




5.3 ERK and Akt signalling in HFD-fed integrin α7 
deficient mice 
Chow-fed α7KO and control mice have similar insulin sensitivity which is further 
supported by a lack of difference between Akt and ERK signalling. However as discussed 
in Chapter 3, we found that when α7KO mice are fed a HFD, they remain insulin 
sensitive, whereas control mice become less insulin resistant. To investigate this 
phenotype further, we analysed protein lysates from HFD-fed α7KO and control mice. 
Concurrent with results in chow-fed mice, there was no significant difference in levels of 
total Akt between HFD-fed α7KO or control mice (Figure 5.2). However, we observed 
significantly higher ratios of pAkt(Ser473):Akt and pAkt(Thr308):Akt in α7KO mice 
compared to controls. This data replicated that of HFD-fed mice in Chapter 3 in terms of 
insulin sensitivity. HFD-fed α7KO mice have a significantly higher level of basal 
phosphorylated Akt in GC muscle further demonstrating their insulin sensitivity. 
Interestingly, we observed a significantly higher level of total ERK2 in HFD-fed α7KO 
mice. Levels of pERK1 were undetectable, however, there was a significantly lower ratio 


























































































































































Figure 5.2: Quantification of total and phosphorylated ERK and Akt in HFD-fed control and 
α7KO GC muscle immunoblot. Immunoblot analysis of total Akt, pAkt(Ser473), total ERK1/2 
and pERK1/2(Thr202/Tyr204) in HFD-fed control and α7KO GC muscle. Bar charts represent 
densitometry of Western blots. The data are mean ± SEM (n = 7). Statistical analysis was 




5.4 ERK and Akt signalling in insulin-challenged chow-
fed integrin α7 deficient mice 
To further investigate the effect the deletion of integrin α7 has on insulin signalling, we 
sought to explore how challenging mice with insulin would affect phosphorylation levels. 
By challenging mice with insulin, we would be able to observe a snapshot of the insulin 
signalling pathway at its most active. Mice were intraperitoneally injected with 0.75 U/kg 
of insulin and were sacrificed 15, 30, 60 or 120 minutes later. GC muscles were isolated, 
lysed and immunoblotted for pAkt and Akt to determine optimal timing. We calculated 
the largest levels of pAkt to be at time point 60 minutes (data not shown). 
Chow-fed control and α7KO mice were intraperitoneally injected with 0.75 U/kg of insulin. 
GC muscle was harvested after 60 minutes and snap frozen in liquid nitrogen. Protein 
lysates were prepared with phosphatase and protease inhibitors before being run under 
reducing conditions through SDS polyacrylamide gels. Gels were transferred overnight 
before being blocked. Membranes were probed with antibodies against insulin receptor 
β, p-insulin receptor β(Tyr1361), pan-Akt, pAkt(Ser473), pAkt(Thr308), ERK1/2, 
pERK1/2(Thr202/Tyr204) and heat shock protein 70 as a loading control protein. 
Membranes were washed and probed with secondary antibodies before being visualised 
via enhanced chemiluminescence. Protein bands were measured using densitometry 
and are shown in Figure 5.3. 
In agreement with non-insulin challenged and chow-fed conditions, there was no 
significant difference in the total amount of Akt in insulin-challenged (Figure 5.3) GC 
muscle. Unexpectedly, there was no difference between the calculated ratio of either 
pAkt(Ser473):Akt or pAkt(Thr308):Akt. Curiously, we measured significantly greater 
levels of ERK1 in insulin-challenged, chow-fed α7KO GC muscle. However, there was 
no difference in between control and α7KO mice in terms of the calculated pERK1:ERK1 




and no difference was found in the calculated pERK2:ERK2 ratio. Furthermore, we 
detected no difference in the total levels of insulin receptor between control and α7KO 
GC muscle. Expectedly, there was no difference either in the calculated p-insulin 






























































































































































































































































Figure 5.3: Quantification of total and phosphorylated ERK, Akt and Insulin Receptor in insulin-challenged, chow-fed control and α7KO GC muscle 
immunoblot. Immunoblot analysis of total Akt, pAkt(Ser473), pAkt(Thr308), total ERK1/2, pERK1/2(Thr202/Tyr204), total insulin receptor and phospho-insulin 
receptor in insulin-challenged chow-fed control and α7KO GC muscle. Bar charts represent densitometry of Western blots. The data are mean ± SEM (n = 4). 





5.5 ERK and Akt in insulin-challenged HFD-fed integrin 
α7 deficient mice 
As discussed in Chapter 3, α7KO remain significantly more insulin sensitive than control 
mice when fed a HFD. This is reinforced by significantly higher levels of pAkt(Ser473) 
and pAkt(Thr308) in α7KO GC muscle lysates compared to controls. We sought to 
investigate whether this observation is reflected when challenging HFD-fed control and 
α7KO mice with insulin. 
Significantly higher levels of total Akt were measured in insulin-challenged HFD-fed 
α7KO GC muscles lysates compared to control (Figure 5.4). Curiously, this was not the 
case in non-insulin-challenged mice. Further reinforcing the insulin tolerance tests 
discussed in Chapter 3 and the non-insulin-challenged HFD-fed immunoblots, 
significantly higher levels of pAkt(Thr308):Akt were measured in α7KO mice. In contrast, 
no difference was measured in pAkt(Ser473):Akt levels between α7KO and control mice.  
Quantification of ERK1 in a7KO and control HFD-fed insulin-challenged GC muscle 
showed that there was no difference in levels. In contrast to our data from HFD-fed non-
insulin challenged mice, there was no difference in the calculated ratio of pERK1:ERK1. 
Furthermore, we found that there was no difference in levels of ERK2 or the ratio of 
pERK2:ERK2. Unfortunately, immunoblotting of the insulin receptor or p-insulin receptor 
was unsuccessful in these lysates.  
To summarise, we see no change in ERK pathway in HFD-fed insulin challenged mice. 
Interestingly, we see no difference in the phosphorylation of Akt on the Serine473 site 
between α7KO and control mice but hugely more phosphorylation on the threonine308 
site. This further supports our data from Chapter 3 suggesting deletion of integrin α7 





































































































































































































Figure 5.4: Quantification of total and phosphorylated ERK and Akt and in insulin-challenged, HFD-fed control and α7KO GC muscle immunoblot. 
Immunoblot analysis of total Akt, pAkt(Ser473), pAkt(Thr308), total ERK1/2 and pERK1/2(Thr202/Tyr204) in insulin-challenged HFD-fed control and α7KO GC 






Insulin resistance is strongly associated with metabolic syndrome, a cluster of symptoms 
that increases a patient’s risk of developing heart disease and diabetes mellitus. These 
symptoms include obesity, hypertension, hyperglycemia, and dyslipidemia (Hoffman et 
al., 2015). The primary function of insulin signalling is the uptake of glucose and energy 
homeostasis predominantly in muscle, liver and adipose tissue. Imbalance of the 
modulation of this pathway can lead to a variety of diseases (Saltiel and Kahn, 2001). 
Unlocking the secrets of this pathway is essential to understanding how to treat these 
diseases. 
Integrins are involved in a wide variety of signal transduction events modulating a variety 
of cellular functions including migration, proliferation and apoptosis (Cary et al., 1999). 
Many of these downstream effectors of integrin signalling overlap with the insulin 
signalling pathway, including FAK and integrin-linked kinase (ILK) (Hynes, 2002a; Moser 
et al., 2009). Therefore, it is no surprise that the deletion of integrin α7 may influence 
some of the downstream effects of the insulin signalling pathway. 
In this study we analysed the protein lysates of gastrocnemius (GC) muscle from chow- 
and HFD-fed control and α7KO mice to investigate the effect the deletion of integrin α7 
had on the insulin signalling pathway. To exacerbate this effect, we challenged the mice 
with 0.75 U/kg of insulin before isolating the GC muscle 60 mins later. We highlighted 
the Akt and ERK1/ERK2 signalling pathway as ideal candidates to investigate the insulin 
signalling pathway. Protein quantification was achieved by Western blotting and 
densitometry. 
5.6.1 The effect of integrin α7 deficiency in the insulin 
signalling of non-insulin-challenged mice 




investigate the basal insulin signalling in our models. We immunoblotted for: total Akt, 
pAkt(Ser473), pAkt(Thr308), ERK1, ERK2, pERK1 and pERK2. 
In chow-fed mice, we discovered that there was no difference in the total levels of Akt, 
ERK1 or ERK2 between chow and α7KO GC muscle. Furthermore, when calculating the 
normalised ratios of the phosphorylated:total protein, we found that there was no 
significant difference in the values of pAkt(Ser473) or pAkt(Thr308). This was 
unsurprising as insulin tolerance tests, performed in Chapter 3, demonstrated that there 
was no significant difference in insulin sensitivity between the chow-fed model. Levels of 
phosphorylated ERK1 or ERK2 were undetectable. 
In HFD-fed mice, we found, again, that there was no difference in total levels of Akt 
between control and α7KO GC muscle. Interestingly, when calculating the 
phosphorylated:total Akt ratios, we found that there was a significantly higher proportion 
of pAkt(Ser473) and pAkt(Thr308) in α7KO mice compared to controls. In contrast to our 
chow-fed data, there was significantly higher levels of total ERK2 in α7KO mice. 
However, this result was inversed with a significantly higher proportion of ERK2 being 
pERK2 in control mice. This data further suggests the glucose uptake branch of insulin 
signalling is more sensitive in HFD-fed α7KO mice. 
5.6.2 The effect of integrin α7 deficiency in the insulin 
signalling of insulin-challenged mice 
To investigate the insulin signalling pathway in its most active state, we injected mice 
intraperitoneally with 0.75 U/kg of insulin before isolating the GC muscle after 60 
minutes. This would allow us to see a ‘snapshot’ of the insulin signalling pathway during 
active signalling. 
In chow-fed mice, we observed a similar result to that of non-insulin-challenged mice 
with no difference in the amount of total Akt. Unsurprisingly, we also found no difference 




pAkt(Thr308). In contrast to our data in chow-fed mice, we detected significantly higher 
levels of total ERK1 in α7KO GC muscle. However, the administration of insulin should 
have no impact on total levels of ERK in such a small time, therefore, this result is 
inconclusive. In insulin-challenged mice we were able to detect phosphorylated levels of 
ERK1 and ERK2. However, the ratio of phosphorylated:total protein demonstrated that 
there was no significant difference between control and α7KO GC muscle levels. We 
also measured no significant difference in the total amount of insulin receptor or the ratio 
p-insulin receptor:total insulin receptor protein. This data supports our non-insulin-
challenged data and our insulin tolerance data from Chapter 3.  
In HFD-fed mice, we found that there was no significant difference in the total amount of 
ERK1 or ERK2 but, in contrast to non-insulin-challenged mice, a greater level of total Akt 
in α7KO mice. As mentioned previously, the administration of insulin should have no 
bearing on the total amount of Akt in such a short amount of time. Unfortunately, efforts 
to detect levels of insulin receptor or p-insulin receptor were unsuccessful in this study. 
Our data also showed that there was no difference in the proportion of pERK1 and 
pERK2 compared to their total protein values. In contrast to non-insulin-challenged data, 
we found that there was no significant difference in the ratio of pAkt(Ser473):Akt. 
However, we detected a greatly higher ratio of pAkt(Thr308):Akt in insulin-challenged, 
HFD-fed α7KO mice compared to controls. This further supports the idea of the deletion 





 CHAPTER 6: RESCUING THE INTEGRIN Α7 
DEFICIENCT PHENOTYPE WITH THE 





Integrin α7β1 is the predominant integrin in skeletal, cardiac and smooth muscle cells. 
Mice deficient for integrin α7 develop a novel mild myopathy with disruption of the 
myotendinous junction. However, there is variation in the integrin α7 subunits with two 
cytoplasmic variants (α7A and α7B) and two extracellular variants (α7X1 and α7X2) 
(Ziober et al., 1993). The α7A cytoplasmic variant is only expressed weakly in mature 
skeletal muscle, whereas α7B is expressed in cardiac and skeletal muscle (Velling et al., 
1996). The α7X1 and α7X2 variants are expressed at equal levels in skeletal muscle 
development and adult heart but only α7X2 can be found in adult skeletal muscle (Ziober 
et al., 1993). Through the combination of these cytoplasmic and extracellular variants, 
four integrin α7 splice forms are generated: α7X1A, α7X1B, α7X2A and α7X2B. This has 
been discussed in more detail in Section 1.5.4 
Table 14: Expression of integrin α7 isoforms in adult (Von der Mark et al., 2002). 
Integrin α7 isoform Adult Expression 
α7X1 Cardiac muscle 
α7X2 Cardiac and skeletal muscle 
α7A Skeletal muscle 
α7B Cardiac, smooth, and skeletal muscle 
 
Integrin α7β1 has been shown, in vitro, to play a crucial role in myoblast migration but 
also plays a pivotal role for skeletal muscle function and integrity, in vivo, by acting as a 
laminin receptor (Echtermeyer et al., 1996; Mayer et al., 1997; Von der Mark et al., 2002). 
However, due to the occurrence of alternative splice variants, the role of integrin α7 is 
probably more complicated than previously believed. 




discussed in this thesis. We sought to investigate whether the overexpression of any of 
the four integrin α7 splice variants were able to rescue the α7KO phenotype. To 
investigate the role of the integrin α7 splice variants in diet-induced obesity, we used α7 
deficient mice crossed with transgenic mice that use the Human Skeletal Alpha Actin 
(HSA) promoter to drive the expression of each of the four possible combinations of 
integrin α7 splice variants in all intra- and extracellular combinations. These mice were 
previously selected in our lab by ensuring that each of the four possible splice variants 
was expressed at similar levels in each of the founder mice. 
6.2 The effect of integrin α7 splice variant 
overexpression on body weight 
As previously discussed, α7KO mice are significantly leaner than control mice when fed 
a chow diet. When α7KO and control mice were fed a HFD, control mice gained weight 
but α7KO mice remained lean. To investigate whether the overexpression of any of the 
integrin α7 splice variants could rescue the α7KO phenotype, integrin α7 deficient mice 
overexpressing one of the four splice variants were each fed a HFD for 12 weeks and 
their body weights were measured over time (α7-/-TG). 
When fed a chow diet, α7-/-X1A, α7-/-X1B and α7-/-X2B were all found to weigh significantly 
less than both α7KO and, to a greater extent, control mice. The reduction in body weight 
of the X2B splice variant overexpressing mouse was particularly surprising as X2B is the 
predominant splice variant of integrin α7 found in adult skeletal muscle. There was no 
significant difference of body weight in α7-/-X2A mice compared to α7KO or control (Figure 
6.1A). 
As previously discussed, when α7KO mice were fed a HFD, they did not gain weight and 
remained significantly lighter than control mice. However, when integrin α7 splice variant 




α7KO trait of gaining weight. Integrin α7 splice variant: α7X1B, α7X2A and α7X2B all 
had a comparable ability to gain weight as that of control mice. Interestingly, integrin 
α7X1A mice gained significantly more normalised weight than control mice also. 
Together, this data shows that there is no difference between embryonic and adult 





Figure 6.1: Integrin α7 splice variant overexpression affects chow-fed weight but rescues 
weight gain after HFD. (A) Body weight of chow-fed α7KO, control and integrin α7 deficient mice 
overexpressing one of the four integrin α7 splice variants. (B) Normalised weight over 12 weeks, 
when fed a HFD, compared to week 0, chow fed body weight. The data are mean ± SEM (α7KO 
n = 7, Control n = 7, α7-/-X1A n = 4, α7-/-X1B n = 5, α7-/-X2A n = 6, α7-/-X2B n = 3). (*) significantly 
different from α7KO. (+) significantly different from control. */+ p < 0.05, **/++ p < 0.01, ***/+++ p < 




































































































6.3 The effect of integrin α7 splice variant 
overexpression on insulin sensitivity and glucose 
tolerance 
As previously discussed, α7KO mice are hyper insulin sensitive when fed either a chow 
or a HFD compared to control mice. Weight gain was rescued by overexpression of 
integrin α7 splice variants, therefore we sought to investigate whether the 
overexpression of any of the four splice variants of integrin α7 could also rescue the 
hyper insulin sensitive phenotype of α7KO and result in a phenotype more comparable 
to a control mouse. In this experiment, mice were aged to 3 months and initial metabolic 
tests were performed. The IPITT was used to measure insulin sensitivity and the IPGTT 
was used to measure glucose tolerance. Thereafter, mice were fed a HFD for 12 weeks 
before IPITT and IPGTT were repeated. 
6.3.1 Measuring insulin sensitivity in chow and HFD-fed 
integrin α7 splice variant overexpressing mice 
Insulin tolerance tests were performed at 3 months and 6 months old mice on a chow 
and HFD, respectively. When fed a chow diet, there was no significant difference in 
insulin sensitivity between control and α7-/-X1A mice. However, α7KO mice were slightly, 
but significantly, less insulin sensitive than α7-/-X1A (Figure 6.2A). In contrast, when fed a 
HFD for 12 weeks, α7-/-X1A mice became significantly more insulin sensitive than control 
mice (Figure 6.2B). There was no difference between α7-/-X1A and α7KO mice showing 
that overexpression of integrin α7 X1A splice variant did not rescue the insulin sensitive 
phenotype of α7KO mice.  
There was no significant difference between control and α7-/-X1B insulin sensitivity when 
fed a chow diet. However, α7KO mice were significantly less insulin sensitive than α7-/-
X1B mice (Figure 6.2C). Although, when fed a HFD, α7-/-X1B become significantly more 




6.2D). Therefore, the overexpression of α7 integrin X1B splice variant does not rescue 
the insulin sensitive phenotype. 
When α7-/-X2A mice are fed a chow diet, it is unclear whether their insulin sensitivity is 
more similar to α7KO or control mice. During the IPITT, α7-/-X2A mice reacted at various 
points similarly to either α7KO or control mice (Figure 6.2E). Therefore, it is not possible 
to draw conclusions of the integrin α7 X2A splice variant’s ability to rescue the insulin 
sensitive phenotype when fed a chow diet. However, when fed a HFD for 12 weeks,     
α7-/-X2A mice were significantly less insulin sensitive than α7KO mice with no significant 
difference from controls (Figure 6.2F). Thus, integrin α7 X2A splice variant is able to 
rescue the insulin sensitive phenotype of α7KO mice, when fed a HFD, and is much more 
comparable to controls. 
Surprisingly, when α7-/-X2B mice were fed a chow diet, they were significantly less insulin 
sensitive than control and, , α7KO mice (Figure 6.2G). Overexpression of integrin α7 
X2B splice variant is the only example of the four splice variants to significantly reduce 
insulin sensitivity to less than control mice. This effect was exacerbated when α7-/-X2B 
were fed a HFD for 12 weeks. HFD-fed α7-/-X2B were significantly less insulin sensitive 
than both α7KO and control mice. Therefore, integrin α7 X2B splice variant is able to 
rescue the insulin sensitive phenotype of α7KO mice on both a chow and HFD. 
In contrast to our HFD-fed weight-gain experiments, only the integrin α7 splice variants: 
α7X2A and α7X2B predominantly found in adult skeletal muscle were able to rescue the 
insulin sensitive phenotype of α7KO mice. Overexpression of integrin α7 splice variants: 
α7X1A and α7X1B did not contribute to rescue the α7KO phenotype most probably as 
α7X1 is only expressed during the initial stages of myogenesis. However, it was 


































































Figure 6.2: IPITT of α7KO, control and integrin α7 splice variant overexpressing mice on a 
chow and a HFD. (A, C, E, G) Following a 6 hour fast, IPITT was performed using 0.75 U/kg of 
insulin on chow fed α7KO, control and (A) A7-/-X1A, (C) A7-/-X1B, (E) A7-/-X2A and (G) A7-/-X2B mice. 
(B, D, F, H) Following a 6 hour fast, IPITT was performed using 0.75 U/kg of insulin on HFD-fed 
α7KO, control and (B) A7-/-X1A, (D) A7-/-X1B, (F) A7-/-X2A and (H) A7-/-X2B mice. The data are mean 
± SEM (α7KO n = 7, Control n = 7, α7-/-X1A n = 4, α7-/-X1B n = 5, α7-/-X2A n = 6, α7-/-X2B n = 3). 
Statistical analysis was completed using an independent t-test. (*) integrin α7 splice variant 
overexpressing mouse significantly different from α7KO. (+) integrin α7 splice variant 





6.3.2 Measuring glucose tolerance in chow and HFD-fed 
integrin α7 splice variant overexpressing mice 
Following insulin sensitivity testing via IPITT, glucose tolerance was measured using an 
IPGTT on a chow and HFD at 3 months and 6 months of age, respectively. It is difficult 
to predict if the overexpression of α7 integrin splice variants affect the glucose tolerance 
of mice when fed a chow diet as there was no difference in the glucose tolerance of 
α7KO and control mice when fed a chow diet. When α7-/-X1A mice were fed a chow diet, 
glucose tolerance was significantly higher than both chow-fed α7KO and control mice 
(Figure 6.3A). However, when fed a HFD, there was no significant difference between 
α7-/-X1A glucose tolerance and that of α7KO or control mice (Figure 6.3B).  
There was no significant difference in glucose tolerance between chow-fed α7-/-X1B mice 
and α7KO or control mice (Figure 6.3C). However, when fed a HFD, α7-/-X1B were 
significantly more glucose tolerant than control mice and comparable with α7KO mice 
(Figure 6.3D).  
On a chow diet, α7-/-X2A mice were significantly more glucose tolerant than α7KO mice 
(Figure 6.3E). When fed a HFD, there is no significant difference between α7-/-X2A mice 
and α7KO or control mice (Figure 6.3F). Glucose tolerance of α7-/-X2A mice appears to 
fall between that of α7KO and control mice.  
When α7-/-X2B mice were fed a chow diet, IPGTT tests showed that they were 
significantly less glucose tolerant than control animals (Figure 6.3G). Data interpretation 
suggests that α7-/-X2B mice are also less glucose tolerant than α7KO mice. Interestingly, 
when fed a HFD, α7-/-X2B mice became significantly less glucose tolerant than α7KO 
mice (Figure 6.3H). Our data further indicates that these mice are also slightly less 
glucose tolerant than control mice.  
To summarise, it is not possible to conclude whether overexpression of integrin α7 X1A 




between α7KO and control values. Integrin α7 X1B is not able to the rescue the α7KO 
phenotype. However, data suggests that as seen in insulin sensitivity tests, integrin α7 
X2B splice variant overexpression is able to the rescue the glucose tolerance phenotype 



































































































Figure 6.3: IPGTT of α7KO, control and integrin α7 splice variant overexpressing mice on 
a chow and a HFD. (A, C, E, G). Following a 16 hour fast, IPGTT was performed using 2 g/kg of 
glucose on chow fed α7KO, control and (A) A7-/-X1A, (C) A7-/-X1B, (E) A7-/-X2A and (G) A7-/-X2B 
mice. (B, D, F, H) Following a 16 hour fast, IPGTT was performed using 2 g/kg of glucose on 
HFD-fed α7KO, control and (B) A7-/-X1A, (D) A7-/-X1B, (F) A7-/-X2A and (H) A7-/-X2B mice. The data 
are mean ± SEM (α7KO n = 7, Control n = 7, α7-/-X1A n = 4, α7-/-X1B n = 5, α7-/-X2A n = 6, α7-/-X2B 
n = 3). Statistical analysis was completed using an independent t-test. (*) integrin α7 splice variant 
overexpressing mouse significantly different from α7KO. (+) integrin α7 splice variant 




6.4 The role of integrin α7 splice variants in liver 
histology 
As previously discussed in Chapter 3, the deletion of integrin α7 resulted in higher levels 
of liver steatosis compared to control mice when fed a HFD. We sought to investigate 
whether the overexpression of α7 integrin splice variants under the control of the muscle-
specific HSA promotor would rescue the steatosis phenotype in α7KO mice. 
Liver sections were fixed and cryoprotected before being frozen in OCT compound. 
Livers were cryosectioned and stained with HCS LipidTOX™ Green neutral lipid stain. 
The LipidTOX™ neutral lipid stain has an extremely high affinity for neutral lipid droplets 
and can be observed using fluorescence microscopy. Unfortunately, quantification of 
fluorescence was not possible due to time constraints.  
Surprisingly, ectopic fat depositions were present in mice overexpressing integrin α7 X1A 
and X1B splice variants, albeit to a lesser extent that α7KO mice (Figure 6.4). However, 
whereas α7KO mice livers showed macrovesicular steatosis, integrin α7X1A and X1B 
overexpressing mice seem to be suffering from less severe early steatosis.  
Interestingly, there was no evidence of lipid deposition in α7-/-X2A or α7-/-X2B mice (Figure 
6.4) livers when fed a HFD. Livers appeared identical to those from HFD-fed control 
mice. This is extremely surprising as, previously discussed, the overexpression of 
integrin α7 splice variants in these models is done so under the control of the muscle-
specific HSA promotor. 
Remarkably, the muscle-specific overexpression of integrin α7 splice variants can 
change the histology of liver. Therefore, any change is not due to the presence of integrin 
α7 in liver but as a downstream effect of the reintroduction of the specific splice variants 






Figure 6.4: HCS LipidTOX™ Green neutral lipid stain of frozen liver sections from HFD-fed 





Integrin α7β1 is the sole β1 integrin expressed throughout muscle development and 
adulthood. Previously, mice deficient for integrin α7 have been shown to suffer from a 
novel form of muscular dystrophy (Mayer et al., 1997). Integrin α7 has also been 
investigated as a possible therapeutic of Duchenne muscular dystrophy, a disease 
caused by a lack of dystrophin. Remarkably, transgenic overexpression of the integrin 
α7 X2B splice variant in dystrophin deficient mice ameliorates some of the dystrophic 
phenotype (Burkin et al., 2001).  
As previously discussed in this thesis, integrin α7 deficient mice are: lean, insulin 
sensitive and glucose tolerant on both a chow and HFD. At this time, no metabolically-
focused studies have been conducted on integrin α7. Furthermore, no studies have 
investigated the roles of the four possible integrin α7 splice variants. In this chapter, we 
sought to investigate whether transgenic overexpression of any of the four possible 
integrin α7 splice variants in an α7 deficient model would be successful in rescuing the 
integrin α7 deficient phenotype. 
6.5.1 Integrin α7 splice variants and their effect on body weight 
Using integrin α7 deficient mice transgenically overexpressing each of the integrin α7 
splice variants, we investigated body weight and the ability of the mice to gain weight 
when fed a HFD. We showed that integrin α7 deficient mice overexpressing the α7X1 
splice variant are leaner than both α7KO and control mice when fed a chow diet. 
However, when fed a HFD, the overexpressing α7X1 mice successfully rescue the ability 
to gain weight by gaining significantly more than α7KO mice when normalised against 
starting weight. This was unexpected as the α7X1 splice variant is usually only expressed 
during primary myogenesis before decreasing and finally becoming absent in adult 
skeletal muscle. Integrin α7X2A was successfully able to rescue the lean phenotype of 




Overexpression of α7X2A was also successful at rescuing the ability to gain weight of 
α7KO mice when fed a HFD. Unexpectedly, integrin α7X2B was not able to rescue the 
lean phenotype of α7KO mice as data showed that mice were significantly leaner than 
α7KO and control mice. However, the integrin α7X2B splice variant was successful at 
rescuing the ability of α7KO mice to gain weight. This outcome was surprising as it is the 
X2B splice variant that is most predominantly found throughout myogenesis and adult 
skeletal muscle. Therefore, by transgenically overexpressing this splice variant, it was 
expected that this model would mostly resemble a wildtype model compared to the other 
splice variant models. Furthermore, as the expression pattern of integrin α7X2B is more 
similar to X2A than X1A and X1B, it was expected that the overexpression of integrin 
α7X2B would resemble the phenotypes of the X2A model. 
6.5.2 Integrin α7 splice variants and their effect on insulin 
sensitivity and glucose tolerance 
Following from our experiment measuring weight gain, we sought to investigate whether 
any of the four splice variants would be able to rescue the α7KO insulin sensitive and 
glucose tolerant phenotype. One limitation in this investigation was there is no significant 
difference in the glucose tolerance levels of chow-fed control and α7KO mice. Therefore, 
it is not possible to measure a rescue in these conditions. 
Curiously, when either the X1A or X1B splice variants were overexpressed in chow-fed 
α7KO mice, they were significantly less insulin sensitive than α7KO mice. However, 
when fed a HFD, α7-/-X1A and α7-/-X1B mice had very similarly insulin sensitivity to α7KO 
mice and were significantly more insulin sensitive than controls. This trend continued 
when testing glucose tolerance. X1A or X1B overexpression resulted in significantly 
more glucose tolerant mice when fed a HFD compared to control mice. 
It was unclear what effect the overexpression of integrin α7 X2A splice variant had on 




α7KO mice at varying moments. However, when fed a HFD, mice were significantly less 
insulin than α7KO mice. Furthermore, we observed a trend of worsened glucose 
tolerance in HFD-fed mice, but statistical testing demonstrated that it was not significant. 
Interestingly, in both chow- and HFD-fed conditions, integrin α7 deficient mice 
overexpressing the X2B splice variant were significantly less insulin sensitive than α7KO 
mice. This trend continued in glucose tolerance of HFD-fed mice. Integrin α7-/-X2B mice 
were significantly less glucose tolerant than α7KO mice. 
From our data, It is unclear what effect the α7X1A and X1B splice variants have on insulin 
sensitivity due to their conflicting results under chow- and HFD-fed conditions. However, 
it is clear that they cannot rescue the α7KO glucose tolerant phenotype. At this moment, 
we cannot conclude whether the α7X2A splice variant is able to rescue the insulin 
sensitive α7KO phenotype. However, evidence suggests it is possible to rescue the 
glucose tolerant phenotype. We can conclude that the only splice variant able to rescue 
the insulin sensitive and glucose tolerant α7KO phenotype in both chow- and HFD-fed 
conditions is the X2B splice variant. This is unsurprising as α7X2B is the predominant 
splice variant found in adult skeletal muscle and most closely resembles a control model.  
6.5.3 Integrin α7 splice variants and their effect on liver 
histology 
As discussed in Chapter 3, non-alcoholic fatty liver disease (NAFLD) is one of the most 
prevalent diseases associated with obesity and insulin resistance. Early signs of this 
disease include the accumulation of lipid in the liver, termed steatosis. Remarkably, 
integrin α7 deficient mouse livers possessed significantly higher levels of steatosis than 
control mice when fed a HFD. We sought to investigate whether the overexpression of 
any of the splice variants could rescue this phenotype. 
When investigating the level of liver lipid, integrin α7 deficient mice overexpressing the 




x1A and α7-/-X1B mouse livers are still steatotic but less so than α7KO livers. 
Overexpression of the X2A and X2B splice variants appeared to completely ameliorate 
the α7KO fatty liver phenotype with no evidence of any lipid deposition. It is important to 
remember that the transgenic overexpression of these four possible splice variants is 
controlled by the muscle-specific HSA promotor. Therefore, it is surprising that any of the 
four possible integrin α7 splice variants had any effect on the liver. Consequently, we 





6.5.4 Summary table 
Table 6.15: Table summarising the results from Chapter 6. ↓ - lower body weight, ↑ - higher 
body weight, ✓ - successfully rescues phenotype, X – unsuccessfully rescues phenotype, N/A – 






























α7KO - ↓ 
Control - ↓ 
✓ N/A N/A 
X1B 
α7KO - ↓ 
Control - ↓ 




? N/A N/A 
X2B 
α7KO - ↓ 
Control - ↓ 






α7KO - ↑ 
Control - ↑ 
X X X 
X1B 
α7KO - ↑ 
Control – No 
difference 
X X X 
X2A 
α7KO - ↑ 
Control – No 
difference 
✓ ? ✓ 
X2B 
α7KO - ↑ 
Control – No 
difference 












Significant studies in the past have demonstrated important insights into the pathological 
changes and abnormalities associated with integrin α7 deficiency in mice and humans 
(Mayer et al., 1997; Hayashi et al., 1998; Nawrotzki et al., 2003). Mounting evidence has 
suggested that integrins play a key role in diet-induced obesity and insulin signalling. 
Integrin α7 is the most predominant integrin in adult skeletal muscle, a tissue which is 
responsible for ~80% of insulin-stimulated glucose uptake (Thiebaud et al., 1982). 
Remarkably, no metabolically focused studies have been completed involving integrin 
α7. In this study, we aimed to investigate what effects the deletion of integrin α7 would 
have on diet-induced obesity and insulin signalling. 
7.1.1 Integrin α7-deficient mice are lean and insulin sensitive 
We sought to investigate what effect a HFD would have on the progression of diet-
induced obesity and its downstream effects on α7KO mice. In this study, we used an 
integrin α7 whole-body deletion model (α7KO) and were fed either a standard chow diet 
or a HFD for 12 weeks. Control mice, as expected, gained weight when fed a HFD, but 
α7KO mice remained lean. These results suggested that HFD-fed α7KO mice would 
remain insulin sensitive. 
IPITTs revealed that α7KO mice were significantly more insulin sensitive than controls 
when fed a HFD, but no difference in insulin sensitivity was seen when fed a chow diet. 
Similarly, IPGTTs showed a marked improvement in the glucose tolerance of α7KO mice 
compared to control mice when fed a HFD. Again, no difference was observed when fed 
a chow diet. 
Our data seems to contradict those reported in striated muscle-specific integrin β1-
deficient mice (Zong et al., 2009). Zong et. al generated a muscle-specific knockout of 




carrying the Muscle Creatine Kinase (MCK) promotor driving Cre-recombinase 
(MCKItgβ1 KO). MCKItgβ1 KO mice were reported to have normal weight gain, fasting 
glucose and insulin levels compared to controls. However, euglycemic (EU) clamp tests 
revealed that smaller volumes of glucose were required to keep MCKItgβ1 KO mice in a 
euglycemic state. The glucose turnover of MCKItgβ1 KO mice was also markedly 
decreased during EU clamp tests. These data indicated that MCKItgβ1 KO mice were 
insulin resistant. Zong et al. reported that the whole-body insulin resistant phenotype was 
a direct result of impaired insulin signalling specifically in skeletal muscle and that liver 
and adipose tissue were fully functional. It is difficult to compare our α7KO model with 
the MCKItgβ1 KO model. Firstly, although the authors generated a muscle-specific 
knockout, the MCK promotor does not become active until birth. Therefore, the 
development of skeletal muscle is completely normal until birth whereas, in the α7KO 
model, integrin α7 will never have been expressed. Secondly, it is important to remember 
that although α7β1 is the predominant integrin in adult skeletal muscle, other β1 integrins 
are expressed at varying timepoints, albeit to a lesser degree. The tenascin-C-binding 
α9β1 is mildly expressed, as well as αvβ1 (deHart et al., 2008; Sinanan et al., 2008). 
Therefore, the effect observed in the MCKItgβ1 KO model could be a result of 
deficiencies of several β1-containing integrins. 
Previous studies have already outlined the morphological differences in integrin α7-
deficient mouse muscle but not with a metabolic focus (Mayer et al., 1997). We stained 
frozen TA muscle sections with H&E and Oil Red O to investigate histological differences 
between α7KO and control muscle. As previously shown by Mayer et al., α7KO mouse 
muscles contained fibres with a greater variance in diameter. Many of these fibres 
contained centrally located nuclei, indicating past damage and regeneration. The most 
startling difference was the increased infiltration of mononuclear cells around the 
myotendinous junction demonstrating signs of necrosis. Oil Red O staining showed 




Depositions of lipid within skeletal myocytes are known as intramyocellular lipid 
depositions and have been strongly associated with insulin resistance (Anastasiou et al., 
2009; Li et al., 2015). All evidence of lipid deposition was found outside the muscle fibres 
and not within in both α7KO and control mice. Furthermore, there was no significant 
difference in the amount of lipid-deposition in the muscle between α7KO and control TA 
muscle suggesting the α7KO phenotype is not caused by changes in the level of lipid 
deposition in the muscle.  
As previously discussed, α7β1 binds to the extracellular matrix (ECM) via laminin-211 
and laminin-221. Remodelling of the ECM has been linked with obesity and insulin 
resistance with increased inflammation and transforming growth factor-β (TGF-β) found 
in obese humans and has been replicated in α2β1-deficient mice (Kang et al., 2011b; 
Watts et al., 2013). Integrin α2β1 differs from α7β1 in that it is a collagen receptor. It 
preferentially binds to Type I collagen and is predominantly expressed on epithelial cells 
(Kirchhofer et al., 1990; Edelson et al., 2004). Whole-body deletion of integrin α2 resulted 
in increased insulin-stimulated glucose uptake during a hyper-insulinemic EU clamp 
(Kang et al., 2011b). Furthermore, HFD-fed control mice had higher expression of 
collagen III and IV. Increased collagen III was associated with increased transcription, 
whilst increased levels of collagen IV were due to reduced matrix metalloproteinase 9 
(MMP9) activity. This has also been observed in obese, insulin-resistant humans (Berria 
et al., 2006). It was hypothesised that the accumulation of collagen III in the interstitial 
space would act as a physical barrier impeding insulin and glucose transport to the 
myocyte. Furthermore, it was suggested that the deletion of integrin α2, a positive 
regulator of collagen I expression, would result in less ECM accumulation in HFD-fed 
models as shown in vitro (Ivaska et al., 1999). However, collagen staining showed that 
there was no difference between integrin α2-deficient and control mice meaning the 
‘physical barrier’ hypothesis is unlikely. It is also unlikely that deletion of integrin α7 




have investigated the structure of the basal lamina in α7KO mice and have reported no 
physical differences compared to control mice (Han et al., 2009). 
A further hypothesis, involving remodelling of the ECM, is that an increase in muscle 
ECM may impair neovascular growth and vascular function. Obesity and insulin 
resistance has been strongly linked with endothelial dysfunction, caused by an 
imbalance of vasodilating and vasoconstricting factors (Harrison, 1997). Studies have 
also shown that insulin acts as a vasoactive hormone and its signalling action produces 
nitric oxide (NO) (Scherrer et al., 1994). A progressive resistance to insulin also results 
in less production of NO which has been associated with reduced muscle number of 
capillaries resulting in a smaller surface area of insulin signalling and glucose transport, 
exacerbating the insulin resistant phenotype (Solomon et al., 2011). This hypothesis was 
acknowledged by Kang et al. who demonstrated that their HFD-fed α2β1-deficient mouse 
possessed significantly higher muscle vascularisation. Previously, our lab and others 
have demonstrated a partial embryonic lethal phenotype in α7KO mice (Mayer et al., 
1997; Flintoff-Dye et al., 2005). Approximately 68% less α7KO mice are born than 
expected. This was shown to be due to altered vascular smooth muscle in α7KO 
embryos. Curiously, the α7KO embryos which died in utero suffered from vascular 
smooth muscle hypoplasia, however, those that survived had vascular smooth muscle 
hyperplasia. It has been suggested that this hyperplasia may compensate for the 
absence of integrin α7 in these cells (Flintoff-Dye et al., 2005).  Unfortunately, our study 
did not allow for us to investigate this particular area of interest but is a viable direction 
of investigation in the future. 
Another key player in the maintenance of the vasculature is the pericyte. Pericytes are 
cells which wrap around capillaries, offering support to the microvessels (Mandarino et 
al., 1993). Pericytes are also involved in communication with endothelial cells via contact 
and paracrine signalling and defects result in compromised vascular integrity (Eilken et 




pericytes positive for integrin α7, and were identified as myofibroblastic pericytes 
(Malhotra et al., 2012). These myofibroblastic pericytes have been associated with 
increased renal fibrosis (Chang et al., 2012). Although we did not measure the presence 
of fibrosis in this study, the mechanism by which myofibroblastic pericytes work could be 
influencing our α7KO phenotype. As we did not use a muscle-specific deletion of integrin 
α7, it is possible that these small subpopulations of integrin α7-expressing cells are 
having a larger effect on the α7KO phenotype than previously thought.  
7.1.2 Integrin α7-deficiency results in increased insulin 
signalling 
We continued our investigation as to why α7KO mice were more insulin sensitive than 
control mice by analysing the insulin signalling pathway via protein quantification. The 
gastrocnemius (GC) muscle was isolated from chow- and HFD-fed a7KO and control 
mice. We also challenged a sample of mice with insulin before isolation of the GC muscle 
to observe a ‘snapshot’ of the insulin signalling pathway in an activated state. 
We observed significantly higher levels of pAkt on both the Serine473 and Threonine308 
sites in HFD-fed α7KO non-insulin-challenged GC muscles compared to controls, whilst 
lower levels of pERK2 were detected in the knockout. However, no difference was seen 
when fed a chow diet. Similarly, we saw no differences in the amount of phosphorylated 
proteins in chow-fed insulin-challenged mice, but the levels of pAkt on the Threonine308 
site in HFD-fed α7KO were significantly elevated when challenged with insulin. 
Countless studies have demonstrated that the activation of Akt is dependent on both the 
Serine473 and Threonine308 phosphorylation sites. However, more recent studies have 
begun to dissect the complex signalling of Akt and have discovered that phosphorylation 
of either serine, threonine or both is required for different functions of the pathway (Kilic 
et al., 2017; Kitamura et al., 1998; Vincent et al., 2011; Wang et al., 2008). Beg et al. 




Serine474 or Threonine309 site. They showed that phosphorylation of Threonine309 but 
not Serine474 is required for GLUT4-mediated glucose uptake. Furthermore, inhibition 
of both sites completely blocked GLUT4 translocation (Beg et al., 2017). Therefore, this 
indicates that increased phosphorylation on the Threonine308 site in α7KO mice results 
in increased GLUT4-mediated glucose uptake. 
Our results conflict with those of recent studies investigating the effect integrin α7 has 
on skeletal muscle signalling. Boppart  et al. investigated the effect of transgenic 
overexpression of integrin α7X2B, the main adult integrin α7 splice variant, in a mouse 
model of Duchenne muscular dystrophy (mdx/utr-/-) termed utr-/-/mdxα7X2B mice (Boppart 
et al., 2011). They reported a significant increase in p70S6K(Thr389) and pAkt(Ser473). 
Integrin β1 has been shown to associate with ILK, which authors hypothesised causes 
the downstream phosphorylation of Akt on the Serine473 site. Although, they could not 
detect significant increases in ILK activity in utr-/-/mdxα7X2B mice. However, controversy 
still surrounds ILK if it is an active kinase. Although showing homology with protein 
kinases, some key residues are not present for catalysis in eukaryotes (Ghatak et al., 
2013; Hanks et al., 1988). ILK has been dubbed a ‘pseudokinase’, only able to exhibit 
kinase-like behaviour through the IPP complex (Ghatak et al., 2013). Furthermore, in this 
study, the authors did not investigate the levels of pAkt(Thr308) in utr-/-/mdxα7X2B mice, 
a key element of the insulin signalling pathway. It is also difficult to compare our models 
as change in investigated protein levels could be caused primarily due to the lack of 
dystrophin and utrophin.  
Another kinase associated with integrins is FAK, which has been shown to localise with 
integrin receptors when attached to the ECM (Hanks et al., 1992). Reduced levels of 
phosphorylated FAK have been observed in insulin resistance myocytes in vitro (Bisht 
et al., 2007). Furthermore, increasing FAK levels in insulin-resistant myocytes improved 
insulin sensitivity and glucose tolerance in vivo (Bisht and Dey, 2008). Recent studies, 




upstream like previously believed (Wang and Basson, 2011). Therefore, alterations in 
FAK level could be a biproduct of altered phosphorylation levels of Akt in insulin resistant 
models. 
In this study we have focused on insulin-dependent signalling, but it is important to note 
that insulin stimulation is not the only method of glucose uptake. A second distinct 
pathway in skeletal muscle is the contraction-stimulated pathway reliant on activation of 
AMPK (Mackenzie and Elliott, 2014). Exercise, via the contraction of skeletal muscle, 
has been shown to increase the rate of glucose uptake via GLUT4 translocation. Muscle 
contractions increase the demand for energy, causing the ratio of AMP:ATP to increase, 
stimulating AMPK. AMPK then phosphorylates TBC1D1 allowing dissociation of Rab 
proteins and GLUT4 translocation to the cell surface (O’Neill, 2013). PI3K is a key node 
in the insulin signalling pathway and its inhibition has been demonstrated to inhibit 
insulin-stimulated but not contraction-stimulated glucose uptake, further distinguishing 
the two pathways (Yeh et al., 1995). In vivo studies showed that although insulin 
stimulation leads to phosphorylation of Akt, muscle contraction does not (Brozinick and 
Birnbaum, 1998). However, although insulin-dependent and -independent glucose 
uptake act separately, evidence suggests that contraction-induced signalling may 
sensitise insulin-mediated signalling. Activation of AMPK has been shown to 
phosphorylate IRS-1 on the Serine789 site. This resulted in a 65% increase in PI3K 
activity in C2C12 myotubes (Jakobsen et al., 2001). This demonstrates a possible direct 
link between exercise and insulin signalling. In this study, we focused primarily on insulin-
dependent signalling. However, it is clear that contraction-induced glucose transport 
could be altered in integrin α7-deficient mice. Future studies should focus on the effects 




7.1.3 Integrin α7-deficiency alters adipose tissue location and 
structure 
As previously mentioned, when α7KO mice were fed a HFD, they remained lean whilst 
control mice gained weight. To ensure this was not due to differences in satiety, we 
confirmed that mice were ingesting the same weight of diet normalised to their body 
weight. 
To further understand the body composition of the α7KO mice, we compared the weight 
of a selection of adipose tissue depots to the overall body weight. We found that α7KO 
mice had significantly less adipose tissue in relation to their overall body weight. Further 
dissection of results demonstrated that α7KO mice contained less visceral gonadal 
adipose tissue and subcutaneous interscapular white adipose tissue. Furthermore, 
gonadal adipocytes were significantly smaller than controls. 
The normal response of adipose tissue to nutrient surplus is through adipocyte 
hypertrophy and hyperplasia via ECM remodelling and increased vascularisation 
(Catalán et al., 2012). The link between the excessive accumulation of adipose tissue 
and metabolic diseases has been excessively documented. However, the mechanism 
by which this occurs in still unclear. The importance of ECM remodelling is signified by 
the accumulation of collagen VI in the adipose tissue of obese humans (Pasarica et al., 
2009). Excessive build-up of fibrotic collagen deposition acts as a physical barrier in 
adipocytes and prevent the expansion of the cells required to accommodate nutrient 
surplus (Sun et al., 2014). This restriction of expansion results in the secretion of 
proinflammatory cytokines, leading to fibrosis, and the necessity to store lipid in other 
tissues (Keophiphath et al., 2009). This was confirmed by the deletion of collagen VI in 
ob/ob mice which resulted in unrestricted expansion of adipocytes and improved whole-
body energy homeostasis (Khan et al., 2009). There is no evidence that integrin α7 is 




are directly influenced by its deletion. It is more likely that these changes occur due to 
an indirect effect of skeletal muscle. 
In this study, we have primarily focused on white adipose (WAT) and brown adipose 
tissue. The primary function of WAT is the storage of excess energy as triglyceride whilst 
BAT specialises in heat production via non-shivering thermogenesis (Coelho et al., 
2013). However, a third type of adipocyte, termed ‘brite’, appears morphologically as 
WAT until stimulated via cold exposure or the ingestion of a HFD. (García-Ruiz et al., 
2015; Giralt and Villarroya, 2013). Following stimulation, brite adipocytes adopt a 
morphology more similar to BAT and begin to generate heat via UCP1 This 
transformation is termed ‘browning’. During oiur study, we generated preliminary data 
suggesting browning in WAT in α7KO but not control mice. When fed a HFD, in multiple 
instances we found subcutaneous evidence of brite adipocytes in histological analysis of 
subcutaneous adipose tissue. However, these observations were not consistent enough 
to be reported in this study. Studies have demonstrated the link between increased 
‘browning’ of adipocytes and improved glucose and lipid homeostasis (Cousin et al., 
1992; Kajimura et al., 2015). By increasing the population of energy-dissipating 
adipocytes, excess energy is used in heat generation rather than being stored in WAT 
or ectopically. Recent studies have demonstrated the distinct lineage of white and brown 
adipocytes. Interestingly, brown adipocytes are now believed to be closer in relation to 
myocytes than white adipocytes due to their common precursors expressing Pax3, Pax7 
and Myf5, whilst white adipocytes are negative for all of these markers (Seale et al., 
2008). The lineage of brite adipocytes has proved to be even more complicated. 
Depending on the adipose tissue they are located in, brite adipocytes have been shown 
to be positive or negative for Pax3 and Myf5, indicating further separation of lineages 
(Xue et al., 2007). Unfortunately, our study could not investigate the effect of the deletion 
of integrin α7 on the generation of brite adipocytes. However, preliminary data suggests 




confirmed the link between increased brite adipocyte populations and improved glucose 
metabolism. Therefore, this could be a possible mechanism as to why integrin α7-
deficient mice remain more insulin sensitive than controls. 
As previously mentioned, adipose tissue releases various cytokines, termed 
‘adipokines’, to communicate with other organs. Many of the released adipokines are 
pro- or anti-inflammatory and their dysregulation has been associated with insulin 
resistance. The pivotal adipokines associated with the onset of insulin resistance are 
leptin and adiponectin. The pro-inflammatory adipokine, leptin, is produced by 
adipocytes proportionally to their triglyceride content to regulate satiety. However, 
obesity has been linked to leptin resistance (Münzberg et al., 2004). This resistance to 
leptin results in increased inflammation from excessive production and increase food 
ingestion (Myers et al., 2010). Although we did not measure leptin levels of α7KO mice, 
we propose that our data showing that α7KO mice consume no more food than controls 
as evidence of no difference in leptin signalling.  
7.1.4 Altered liver morphology in integrin α7-deficient mice 
In this study, we discovered that the livers from HFD-fed insulin-sensitive mice contained 
significantly more steatosis than control mice. This was confirmed via histological 
staining and fluorescent lipid staining. However, evidence suggests that non-alcoholic 
fatty liver disease (NAFLD) is the hepatic branch of metabolic syndrome and studies 
suggest it is very rare to see NAFLD without insulin resistance (Kitade et al., 2017; 
Manco, 2011). 
As discussed with other tissues, the ECM of the liver expands with the ingestion of a 
HFD. Studies have demonstrated increased expression of α-smooth muscle actin 
(αSMA) in hepatic stellate cells and collagen in the sinusoidal space of mice fed a HFD 
(Dixon et al., 2013). Human studies have also reported increased expression of collagen 




completely understood how ECM remodelling in the liver contributes to insulin 
resistance. It has been suggested that, as the liver can clear 40% of insulin via a first 
pass of the receptor-mediated process, patients with liver damage will continue to 
circulate elevated insulin levels, leading to insulin resistance (Field, 1973) 
We further confirmed the damage of livers from HFD-fed α7KO mice by measuring 
alanine transaminase (ALT) and aspartate transaminase (AST) in blood serum. We 
measured more ALT and AST in α7KO mice, indicating steatosis. However, although 
confirmed to be excellent markers of hepatic injury, it is important to note that these 
enzymes are also found in other tissues, albeit to a lesser extent. Although ALT is mostly 
specific to the liver, AST is also found in skeletal muscle, kidneys, brain, pancreas, lungs, 
leucocytes, and red blood cells (Pratt and Kaplan, 2000).  Therefore, although there is 
evidence supporting liver damage, the release of ‘liver’ enzymes into the blood may also 
be due to other tissue damage, including skeletal muscle. 
We sought to investigate whether the liver damage seen in HFD-fed α7KO mice also 
affected the production of bile acids. Bile acids are a group of water-soluble steroids 
which aid the absorption of fat-and fat-soluble proteins synthesised in the hepatocytes 
of the liver. Increased levels of bile acids have been shown to protect from obesity and 
insulin resistance. Therefore, we sought to investigate whether bile acid levels were 
altered in α7KO mice. However, our data suggests there is no difference between serum 
bile acid levels in α7KO compared to controls. Nevertheless, in our study we only 
analysed bile acid levels in the serum. To truly understand whether bile acid levels are 
altered, levels from multiple locations including the liver and the gut will need to be 
analysed. 
Six integrins have been detected in the liver: α1, α2, α3, α4, α5 and α6; all of which 
associate with the β1 subunit, however only α1β1 and α5β1 are expressed in 




of integrins on liver histology. Williams et al. demonstrated that deletion of collagen-
binding integrin α1 resulted in severe hepatic insulin resistance in HFD-fed mice. 
However, lipid deposition was no different from chow-fed levels in α1-null mice. It has 
been suggested that this phenotype is possibly due to enhanced α5β1 signalling to 
compensate for the lack of integrin α1. The fibronectin receptor, integrin α5β1, has been 
shown to be involved in embryonic myogenesis and is expressed at the adult MTJ until 
postnatal day 10. However, in the absence of integrin α7 the expression of α5β1 is 
continually expressed at the MTJ and regenerated muscle fibres. The persistence of 
α5β1 results in the deposition of fibronectin in the basement membrane of integrin α7-
deficient adult muscle fibres. It is thought that this α5β1-fibronectin link is weaker than 
the α7β1-laminin link and results in the myopathy observed in integrin α7-deficient mice 
(Nawrotzki et al., 2003). It is unclear how the expression of integrin α7 results in the 
reduction of integrin α5. It is also unknown whether this effect is confined to the skeletal 
muscle. Although speculative, if not specific to skeletal muscle, the deletion of integrin 
α7 could result in maintained or increased expression of integrin α5 in the liver, leading 
to a similar effect observed in integrin α1-deficient mice. 
7.1.5 Deletion of integrin α7 does not alter the metabolomic 
profile 
Integrin α7 is vital to the differentiation of smooth muscle cells along the gastrointestinal 
tract. These smooth muscle cells maintain organ dimensions and can generate 
contractions to move along bolus. In our study, we aimed to detect whether a deletion of 
integrin α7 would alter the metabolomic profile of mice fed both a chow or a HFD. We 
analysed faecal pellets from α7KO and control animals and measured their metabolomic 
profile via NMR. Results from chow-fed control and α7KO mice indicated that there was 
no difference of the metabolomic profile between mice. However, at this moment, no 
conclusions can be drawn from HFD-fed mice. Due to a laboratory error, the 




software we used, MetaboAnalyst 4.0, possesses an algorithm to generate a ‘false 
sample’ from other data to make statistical analysis possible. However, due to the huge 
variance, no reliable outcome could be concluded. 
Recently, there has been increased interest in identifying biomarkers in the metabolomic 
profiles of sufferers of insulin resistance and obesity. By identifying key biomarkers, this 
would make early treatment easier. To date, four categories of metabolism have been 
identified as potential candidates of biomarkers: amino acid, lipid, carbohydrate, and 
nucleotide metabolism (Park et al., 2015). Countless studies have provided evidence of 
unique metabolites which can act as early markers of metabolomic disorder. It is 
important that further analysis be completed on integrin α7 deficient mice to determine 
whether they possess any of these. 
7.1.6  Integrin α7 splice variants rescue the integrin α7-
deficient phenotype 
Throughout this study, we have reported numerous phenotypes in the α7KO mouse 
model. As mentioned, four possible splice variants of integrin α7 are expressed at varying 
times throughout development. Previous studies have demonstrated that overexpression 
of the adult forms of integrin α7 reduced the development of myopathy in mice deficient 
for dystrophin and utrophin (Burkin et al., 2001). We sought to investigate whether 
transgenic overexpression of any of the four possible splice variants in the α7-deficient 
model could rescue the phenotypes discovered during our study. 
The expression of transgenic integrin α7 splice variants was promoted by the HSA 
promotor. HSA promoter activity begins on embryonic day 9.5 and is specific to skeletal 
muscle (Leu et al., 2003). Therefore, all expression of the transgene was specific to 
skeletal muscle. Random insertion of the transgenic gene into the genome resulted in 
varying degrees of protein expression but past protein expression experiments have 




During our study, we discovered that when fed a chow diet, curiously, α7KO mice 
overexpressing: X1A, X1B or X2B were significantly leaner than both α7KO and control 
mice. However, overexpression of any of the four splice variants rescued the ability to 
gain weight when fed a HFD. Further studies confirmed that only the X2A and X2B adult 
variants of integrin α7 were able to rescue the insulin sensitive phenotype on a HFD. 
Furthermore, only the X2B splice variant was found to rescue glucose tolerance with X2A 
data being inconclusive. Previous studies have demonstrated it is integrin α7X2 and β1D 
which provide the strong connection between the muscle and tendon in adult skeletal 
muscle. Integrin α7X1 is more transiently expressed during early stages of regeneration. 
Integrin α7A and α7B are both expressed in adult skeletal muscle, although α7B is more 
predominant (Ziober et al., 1993). Consequently, we can assume that each of the splice 
variants has specific functions in skeletal muscle function. Therefore, it is not surprising 
that the predominant adult splice variant of integrin α7 is the variant that was able to 
rescue the weight gain phenotype, insulin sensitivity and glucose tolerance. 
We reported that the deletion of integrin α7 resulted in the onset of liver steatosis when 
fed a HFD. Surprising data in our study demonstrated that the transgenic expression of 
adult integrin α7 splice variants X2A and X2B could rescue the fatty liver phenotype in 
HFD-fed α7KO mice, but not the overexpression of X1A or X1B. Integrin α7-null mice 
overexpressing transgenic α7X2A or α7X2B showed no signs of lipid deposition when 
fed a HFD and were comparable to controls. Curiously, α7KO mice overexpressing 
α7X1A and α7X1B showed a partially rescued phenotype. As transgenic expression was 
linked to the HSA promotor, we can be sure that this rescue is not due to integrin α7 
being expressed in liver. We postulate that the novel muscular dystrophy induced by the 
deletion of integrin α7 may be having downstream effects on the liver. The increase of 
pro-inflammatory cytokines has been linked with muscular dystrophies. Increased TNFα, 
an important regulatory of chronic inflammation, has been measured in the regenerating 




Increased levels of interleukin-6 have also been observed the serum of patients of DMD, 
a cytokine with both pro- and anti-inflammatory properties (Rufo et al., 2011). Elevated 
systemic pro-inflammatory cytokines have been associated with the onset of NAFLD 
(Kumar et al., 2012). We can presume that the reduced development of muscular 
dystrophy by the overexpression of integrin α7X2B could also be observed in those 
overexpressing α7X2A. The amelioration of the dystrophic phenotype may also result in 
the reduction of pro-inflammatory cytokines released by the muscle, thus preventing 





Figure 7.1: Summary diagram depicting the key findings from this study and possible 




7.2 Future Studies 
During this study, we have identified the main metabolic differences between control and 
α7KO mice. However, it is unclear whether there is a difference in glucose uptake 
between the models. In vitro assays can be performed on myocytes to determine 
whether glucose translocation is affected. The gold standard for measuring glucose 
uptake is using radio-labelled 2-deoxy-D-glucose (3H-2DG) (Yamamoto et al., 2015). 
Unlike glucose, the 2-deoxyglucose 6-phosphase (DG6P) formed from 3H-2DG cannot 
be rapidly metabolised leading to an accumulation of DG6P, therefore isotope efflux is 
decreased. Myocytes are incubated with 3H-2DG before uptake is measured using a 
liquid scintillation counter. By comparing uptake of glucose in myocytes, this would 
highlight whether α7KO mice are leaner and more insulin sensitive due to altered glucose 
uptake. 
It could be possible that α7KO mice are leaner due to differences in exercise patterns. 
To investigate this further, future studies should include the use of “metabolic cages”. 
Although we measured food intake throughout this study, “metabolic cages” are able to 
measure food and water intake in real time, energy expenditure via O2 consumption and 
CO2 production, and movement. This would highlight whether any changes in leanness 
and insulin sensitivity are due to differences in activity. 
We observed differences in liver histology between control and α7KO mice. However, 
further investigations into how the liver is altered should be explored. The deposition of 
ECM proteins is one of the main responses to NAFLD, but it was unclear to see exactly 
how the liver histology differed between control and α7KO mice from H&E staining alone. 
Immunohistochemistry staining for fibronectin should be conducted to observe the 
differences in the ECM of the livers. Staining for α-smooth muscle actin should also be 
performed to quantify liver fibrosis. 




resistance. To more accurately measure inflammation in tissues including liver and 
muscle, a CD68 stain should be used to measure monocyte infiltration. Pro-inflammatory 
serum cytokines should also be measured to estimate the degree of inflammation. 
Production of TNF-α and IL-1β have been shown to be linked to the progression of insulin 





7.3 Concluding remarks 
In this thesis, we have demonstrated the pivotal effect integrin α7 has on metabolism. 
Our novel data shows that the deletion of integrin α7 results in lean and insulin sensitive 
mice. Furthermore, phenotypes of the deletion of integrin α7 are not constricted to the 
skeletal muscle but are also shown in adipose tissue and liver. We have demonstrated 
that the transgenic overexpression of the integrin α7 splice variants can rescue some of 
the phenotypes observed in integrin α7-deficient mice. Our study, along with others’, has 
demonstrated the critical role integrins play in metabolism and insulin signalling. Our data 










α7KO – Integrin α7-deficient mouse  
ACC – Acetyl-coenzyme A carboxylase 
Acetyl-CoA – Acetyl-coenzyme A 
ADP – Adenosine diphosphate 
ATP – Adenosine triphosphate 
BAT – Brown adipose tissue 
BM – Basement membrane 
BMI – Body mass index 
cAMP – Cyclic adenosine monophosphate 
DG – Diglyceride 
DGAT - Diacylglycerol acyltransferase 
DGC – Dystrophin-glycoprotein complex 
ECM – Extracellular matrix 
ERK – Extracellular signal-regulated kinase 
EU – Euglycemic 
FAK – Focal adhesion kinase 
FFA – Free fatty acid 
GC – Gastrocnemius 




GSK-3 – Glycogen synthase kinase-3 
HFD – High fat diet 
HMIT – Proton-couple myoinositol transporter 
HSL – Hormone-sensitive lipase 
IGF – Insulin-like growth factor 
ILK – Integrin-linked kinase 
IPGTT – Intraperitoneal glucose tolerance test 
IPITT – Intraperitoneal insulin tolerance test 
IPP – ILK-PINCH-Parvin 
IR – Insulin receptor 
IRS – Insulin receptor substrate 
JNK – Jun NH(2)-terminal kinase 
LPL – Lipoprotein lipase 
MAPK – Mitogen-activated protein kinase 
MG – Monoglyceride 
Myf5 – Myogenic factor 5 
NAFLD – Non-alcoholic fatty liver disease 
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PGC-1 - Peroxisome proliferator-activated receptor-γ coactivator-1 
PH – Pleckstrin-homology 
PI3K – Phosphoinositide 3-kinase 
PIP2 - Phosphatidylinositol-4,5-bisphosphate 
PIP3 - Phosphatidylinositol-3,4,5-triphosphate 
PKA – Protein kinase A 
PTB – Phospho-tyrosine binding 
PTEN – Phosphatase and tensin homolog detected on chromosome 10 
ROS – Reactive oxygen species 
SH2 – Src homology 2 
SWAT – Subcutaneous white adipose tissue 
T2DM – Type II diabetes mellitus 
TA – Tibialis anterior 
TG – Triglyceride 
TNFα – Tumour necrosis factor alpha 
UCP1 – Uncoupling protein 1 
VAT – Visceral adipose tissue 
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Table 10.1: Student's T-Test results from metabolomic profile analysis of faeces collected 
from chow-fed control and α7KO mice 
 t.stat p.value -LOG10(p) FDR 
Glycerol -2.4648 0.069332 1.1591 0.72228 
Alanine -2.4037 0.074058 1.1304 0.72228 
Ethanol -2.0292 0.11232 0.94954 0.72228 
Ornithine -1.7281 0.15903 0.79851 0.72228 
Hypoxanthine 1.7132 0.16183 0.79094 0.72228 
Methanol -1.6801 0.16823 0.77411 0.72228 
Glycine -1.5542 0.1951 0.70975 0.72228 
Lactate -1.5484 0.19646 0.70674 0.72228 
Aspartate -1.5261 0.20169 0.69531 0.72228 
Tyrosine -1.4922 0.20992 0.67795 0.72228 
Phenylalanine -1.4497 0.22073 0.65614 0.72228 
Leucine -1.4026 0.23339 0.63191 0.72228 
Urocanate -1.4 0.2341 0.6306 0.72228 
Galactose -1.3763 0.24074 0.61845 0.72228 
Tryptophan -1.3699 0.24259 0.61513 0.72228 
Isoleucine -1.3236 0.25621 0.59141 0.72228 
1,3-Dihydroxyacetone 1.3093 0.26057 0.58407 0.72228 
Fumarate -1.3055 0.26175 0.58212 0.72228 
Glutamine -1.2899 0.26662 0.57411 0.72228 
Asparagine -1.2896 0.26671 0.57396 0.72228 
Valine -1.259 0.27651 0.55829 0.72228 
Methionine -1.231 0.28577 0.54399 0.72228 
Threonine -1.2102 0.29282 0.5334 0.72228 
3-Phenylpropionate -1.1501 0.3142 0.5028 0.72228 
Arabinose -1.1373 0.3189 0.49634 0.72228 
Lysine -1.1227 0.32441 0.4889 0.72228 
Histidine -1.1092 0.32955 0.48207 0.72228 
AMP -1.066 0.34649 0.46031 0.72228 
Valerate -1.0595 0.3491 0.45705 0.72228 
Ferulate -1.0213 0.36484 0.43789 0.72969 
5-Aminopentanoic acid -0.92625 0.40674 0.39068 0.77387 
Proline -0.90242 0.41786 0.37897 0.77387 
Pyruvate -0.85561 0.44044 0.35611 0.77387 
Isobutyrate 0.85476 0.44086 0.3557 0.77387 
Glutamate -0.83353 0.45142 0.34542 0.77387 
Acetoin -0.75153 0.49413 0.30616 0.80078 
Xylose -0.73896 0.50095 0.30021 0.80078 
GTP -0.72761 0.50716 0.29486 0.80078 
lactaldehyde_ifr -0.59394 0.58451 0.23321 0.89925 
Dimethylamine 0.5 0.64333 0.19157 0.92706 




Propionate -0.41417 0.7 0.1549 0.92706 
Alpha-ketoisovaleric acid -0.361 0.73636 0.13291 0.92706 
Cytidine monophosphate 0.34874 0.74487 0.12792 0.92706 
Butyrate -0.31415 0.76911 0.11401 0.92706 
Glucose -0.28488 0.78988 0.10244 0.92706 
Uracil -0.28333 0.79098 0.10183 0.92706 
Formate 0.25889 0.8085 0.092322 0.92706 
malic_acid -0.25623 0.81041 0.091293 0.92706 
Trimethylamine -0.25482 0.81142 0.090752 0.92706 
2-Oxoisocaproate -0.24373 0.81943 0.086489 0.92706 
Ribose -0.2397 0.82234 0.084946 0.92706 
2-methylbutyric_ifr -0.21997 0.83666 0.077449 0.92706 
Choline -0.19528 0.85469 0.068192 0.92706 
Methylamine -0.1822 0.86429 0.06334 0.92706 
Acetate -0.18088 0.86526 0.062854 0.92706 
Xanthine 0.14479 0.89188 0.049693 0.93882 
Fructose 0.11933 0.91077 0.040592 0.94217 
Nicotinate 0.062017 0.95352 0.020668 0.96528 




Table 10.2: Results from Metabolite Set Enrichment Analysis of metabolomic profiles of faeces collected from chow-fed control and α7KO mice 
 Total Cmpd Hits Statistic Q Expected Q Raw p FDR 
Glycerolipid Metabolism 25 1 60.299 20 0.069332 0.82948 
Selenoamino Acid Metabolism 28 2 40.607 20 0.081585 0.82948 
Glutathione Metabolism 21 3 37.181 20 0.18784 0.82948 
Bile Acid Biosynthesis 65 1 37.653 20 0.1951 0.82948 
Porphyrin Metabolism 40 1 37.653 20 0.1951 0.82948 
Urea Cycle 29 8 31.285 20 0.20005 0.82948 
Catecholamine Biosynthesis 20 1 35.761 20 0.20992 0.82948 
Thyroid hormone synthesis 13 1 35.761 20 0.20992 0.82948 
Spermidine and Spermine Biosynthesis 18 2 35.11 20 0.20998 0.82948 
Glycine and Serine Metabolism 59 8 30.77 20 0.22849 0.82948 
Alanine Metabolism 17 5 29.827 20 0.22873 0.82948 
Nucleotide Sugars Metabolism 20 1 32.138 20 0.24074 0.82948 
Purine Metabolism 74 9 25.018 20 0.24076 0.82948 
Phenylalanine and Tyrosine Metabolism 28 5 27.401 20 0.2516 0.82948 
Glutamate Metabolism 49 8 26.92 20 0.26173 0.82948 
Ammonia Recycling 32 9 26.888 20 0.2698 0.82948 
Arginine and Proline Metabolism 53 8 25.121 20 0.28899 0.82948 
Threonine and 2-Oxobutanoate Degradation 20 1 26.802 20 0.29282 0.82948 
Tryptophan Metabolism 60 4 26.868 20 0.29305 0.82948 
Ethanol Degradation 19 3 24.553 20 0.30024 0.82948 
Tyrosine Metabolism 72 5 23.612 20 0.31591 0.82948 
Galactose Metabolism 38 4 23.695 20 0.31838 0.82948 




Methylhistidine Metabolism 4 1 23.522 20 0.32955 0.82948 
Glucose-Alanine Cycle 13 4 22.837 20 0.33365 0.82948 
Phenylacetate Metabolism 9 2 25.75 20 0.33773 0.82948 
Histidine Metabolism 43 4 23.333 20 0.33814 0.82948 
Fatty acid Metabolism 43 1 22.124 20 0.34649 0.82948 
Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty Acids 28 1 22.124 20 0.34649 0.82948 
Mitochondrial Beta-Oxidation of Medium Chain Saturated Fatty Acids 27 1 22.124 20 0.34649 0.82948 
Mitochondrial Beta-Oxidation of Short Chain Saturated Fatty Acids 27 1 22.124 20 0.34649 0.82948 
Riboflavin Metabolism 20 1 22.124 20 0.34649 0.82948 
Thiamine Metabolism 9 1 22.124 20 0.34649 0.82948 
Aspartate Metabolism 35 8 21.855 20 0.36855 0.84208 
Lysine Degradation 30 2 19.379 20 0.3824 0.84208 
Methionine Metabolism 43 4 22.049 20 0.38373 0.84208 
Lactose Degradation 9 2 17.063 20 0.41967 0.84865 
Sphingolipid Metabolism 40 2 17.063 20 0.41967 0.84865 
Carnitine Synthesis 22 3 20.555 20 0.42557 0.84865 
Beta-Alanine Metabolism 34 4 19.271 20 0.43321 0.84865 
Pyruvaldehyde Degradation 10 1 15.47 20 0.44044 0.84865 
Arachidonic Acid Metabolism 69 1 14.799 20 0.45142 0.84911 
Warburg Effect 58 8 17.591 20 0.4939 0.88415 
Cysteine Metabolism 26 3 17.464 20 0.50433 0.88415 
Betaine Metabolism 21 2 14.209 20 0.5106 0.88415 
Malate-Aspartate Shuttle 10 3 17.737 20 0.51482 0.88415 
Propanoate Metabolism 42 4 17.354 20 0.53454 0.88431 
Nicotinate and Nicotinamide Metabolism 37 4 16.599 20 0.5373 0.88431 




Mitochondrial Electron Transport Chain 19 2 14.966 20 0.58638 0.89959 
Citric Acid Cycle 32 4 14.273 20 0.63258 0.89959 
Gluconeogenesis 35 5 13.647 20 0.63596 0.89959 
Pantothenate and CoA Biosynthesis 21 2 12.537 20 0.64105 0.89959 
Pentose Phosphate Pathway 29 2 11.77 20 0.65431 0.89959 
Glycolysis 25 2 8.7294 20 0.65472 0.89959 
Transfer of Acetyl Groups into Mitochondria 22 2 8.7294 20 0.65472 0.89959 
Pyruvate Metabolism 48 6 15.945 20 0.65675 0.89959 
Amino Sugar Metabolism 33 5 12.162 20 0.67263 0.89959 
Pyrimidine Metabolism 59 3 11.431 20 0.68567 0.89959 
Vitamin K Metabolism 14 1 4.112 20 0.7 0.89959 
Folate Metabolism 29 2 8.2235 20 0.73486 0.89959 
Cardiolipin Biosynthesis 11 1 2.9508 20 0.74487 0.89959 
Phosphatidylinositol Phosphate Metabolism 17 1 2.9508 20 0.74487 0.89959 
Plasmalogen Synthesis 26 1 2.9508 20 0.74487 0.89959 
Butyrate Metabolism 19 3 8.1951 20 0.77293 0.89959 
Fructose and Mannose Degradation 32 2 6.0215 20 0.78238 0.89959 
Lactose Synthesis 20 1 1.9885 20 0.78988 0.89959 
Pterine Biosynthesis 29 2 6.6682 20 0.801 0.89959 
Androgen and Estrogen Metabolism 33 1 1.648 20 0.8085 0.89959 
Androstenedione Metabolism 24 1 1.648 20 0.8085 0.89959 
Steroid Biosynthesis 48 1 1.648 20 0.8085 0.89959 
Phospholipid Biosynthesis 29 1 0.94439 20 0.85469 0.93778 
Starch and Sucrose Metabolism 31 1 0.35471 20 0.91077 0.9557 
Fatty Acid Biosynthesis 35 2 1.6095 20 0.91662 0.9557 




Phosphatidylethanolamine Biosynthesis 12 2 1.9476 20 0.91941 0.9557 
Ketone Body Metabolism 13 1 0.053598 20 0.96528 0.96528 
Oxidation of Branched Chain Fatty Acids 26 1 0.053598 20 0.96528 0.96528 




Table 10.3 Student's T-Test results from metabolomic profile analysis of faeces collected 
from HFD-fed control and α7KO mice 
 t.stat p.value -LOG10(p) FDR 
5-Aminopentanoic acid -2.7474 0.051514 1.2881 0.61268 
Acetate -2.2299 0.089621 1.0476 0.61268 
Succinate -2.1947 0.093206 1.0306 0.61268 
3-Phenylpropionate -2.0889 0.10496 0.97899 0.61268 
Propionate -1.8737 0.13425 0.87208 0.61268 
Taurine 1.6833 0.1676 0.77572 0.61268 
Valerate -1.6481 0.17468 0.75776 0.61268 
Aspartate -1.4877 0.21104 0.67564 0.61268 
Histidine -1.4161 0.2297 0.63884 0.61268 
Pyruvate -1.4055 0.23259 0.63342 0.61268 
Trimethylamine -1.3903 0.23681 0.6256 0.61268 
Uracil -1.2927 0.26573 0.57556 0.61268 
Fumarate -1.2565 0.27732 0.55703 0.61268 
Ornithine -1.2534 0.27832 0.55546 0.61268 
Threonine -1.2265 0.28727 0.5417 0.61268 
Glutamine -1.1844 0.30181 0.52026 0.61268 
AMP -1.1764 0.30467 0.51616 0.61268 
Glutamate -1.1311 0.32123 0.49319 0.61268 
Hypoxanthine -1.1308 0.32133 0.49305 0.61268 
Choline -1.1283 0.32228 0.49176 0.61268 
Glycine -1.1207 0.32517 0.48789 0.61268 
Tyrosine -1.1165 0.32676 0.48578 0.61268 
Valine -1.1101 0.32918 0.48257 0.61268 
Methylamine -1.0909 0.33663 0.47285 0.61268 
Arabinose -1.0673 0.34597 0.46096 0.61268 
Phenylalanine -1.0606 0.34868 0.45758 0.61268 
Xanthine -1.0593 0.34918 0.45695 0.61268 
Asparagine -1.0409 0.35669 0.44771 0.61268 
Lysine -1.0395 0.35727 0.44701 0.61268 
Alanine -1.0268 0.36255 0.44063 0.61268 
Tryptophan -1.0226 0.36432 0.43852 0.61268 
Methionine -1.0167 0.36679 0.43558 0.61268 
Nicotinate -1.0089 0.37012 0.43166 0.61268 
Glycerol -0.98327 0.38114 0.41891 0.61268 
1,3-Dihydroxyacetone 0.97543 0.38458 0.41501 0.61268 
Proline -0.9738 0.3853 0.41421 0.61268 
Galactose -0.95673 0.39288 0.40574 0.61268 
Leucine -0.88706 0.42516 0.37144 0.61268 
Isoleucine -0.87436 0.43128 0.36524 0.61268 
Butyrate -0.86832 0.43421 0.3623 0.61268 




Urocanate -0.83724 0.44957 0.34721 0.61268 
Methanol -0.81054 0.4631 0.33433 0.61268 
Isobutyrate -0.80381 0.46656 0.33109 0.61268 
malic_acid -0.78602 0.47581 0.32257 0.61268 
lactaldehyde_ifr 0.77007 0.48421 0.31496 0.61268 
3-Methyl-2-oxovalerate 0.75509 0.49222 0.30784 0.61268 
Cytidine monophosphate -0.72909 0.50634 0.29556 0.61268 
Ethanol -0.72844 0.5067 0.29525 0.61268 
Ribose -0.72142 0.51057 0.29195 0.61268 
Ferulate -0.70159 0.52161 0.28266 0.61365 
GTP -0.60946 0.57514 0.24023 0.66362 
Fructose -0.45689 0.67146 0.17298 0.76014 
Xylose -0.36784 0.73163 0.13571 0.78678 
Alpha-ketoisovaleric acid 0.35355 0.74152 0.12988 0.78678 
Dimethylamine 0.34394 0.74821 0.12597 0.78678 
2-Oxoisocaproate 0.33806 0.75231 0.1236 0.78678 
Glucose -0.3103 0.77183 0.11248 0.78678 
Lactate -0.3077 0.77367 0.11145 0.78678 




Table 10.4: Results from Metabolite Set Enrichment Analysis of metabolomic profiles of faeces collected from HFD-fed control and α7KO mice 
 Total Cmpd Hits Statistic Q Expected Q Raw p FDR 
Butyrate Metabolism 19 3 32.065 20 0.028035 0.51411 
Mitochondrial Electron Transport Chain 19 2 41.465 20 0.083931 0.51411 
Ketone Body Metabolism 13 1 54.631 20 0.093206 0.51411 
Oxidation of Branched Chain Fatty Acids 26 1 54.631 20 0.093206 0.51411 
Phytanic Acid Peroxisomal Oxidation 26 1 54.631 20 0.093206 0.51411 
Vitamin K Metabolism 14 1 46.744 20 0.13425 0.51411 
Taurine and Hypotaurine Metabolism 12 1 41.465 20 0.1676 0.51411 
Carnitine Synthesis 22 3 33.265 20 0.1828 0.51411 
Citric Acid Cycle 32 4 31.121 20 0.19067 0.51411 
Bile Acid Biosynthesis 65 2 32.68 20 0.19474 0.51411 
Fatty Acid Biosynthesis 35 2 35.64 20 0.19585 0.51411 
Methylhistidine Metabolism 4 1 33.391 20 0.2297 0.51411 
Pyruvaldehyde Degradation 10 1 33.059 20 0.23259 0.51411 
Glutamate Metabolism 49 8 30.496 20 0.23382 0.51411 
Ethanol Degradation 19 3 30.945 20 0.23709 0.51411 
Propanoate Metabolism 42 4 30.059 20 0.24213 0.51411 
Arginine and Proline Metabolism 53 8 29.969 20 0.2438 0.51411 
Amino Sugar Metabolism 33 5 28.727 20 0.24649 0.51411 
Beta-Alanine Metabolism 34 4 30.679 20 0.25126 0.51411 
Aspartate Metabolism 35 8 28.132 20 0.27128 0.51411 
Cysteine Metabolism 26 3 27.666 20 0.27754 0.51411 
Urea Cycle 29 8 27.743 20 0.2787 0.51411 




Tyrosine Metabolism 72 5 26.969 20 0.28916 0.51411 
Ammonia Recycling 32 9 26.455 20 0.293 0.51411 
Phenylacetate Metabolism 9 2 25.835 20 0.30152 0.51411 
Alanine Metabolism 17 5 25.55 20 0.30268 0.51411 
Glycine and Serine Metabolism 59 8 25.477 20 0.30457 0.51411 
Fatty acid Metabolism 43 1 25.704 20 0.30467 0.51411 
Mitochondrial Beta-Oxidation of Long Chain Saturated Fatty Acids 28 1 25.704 20 0.30467 0.51411 
Mitochondrial Beta-Oxidation of Medium Chain Saturated Fatty Acids 27 1 25.704 20 0.30467 0.51411 
Mitochondrial Beta-Oxidation of Short Chain Saturated Fatty Acids 27 1 25.704 20 0.30467 0.51411 
Riboflavin Metabolism 20 1 25.704 20 0.30467 0.51411 
Thiamine Metabolism 9 1 25.704 20 0.30467 0.51411 
Phenylalanine and Tyrosine Metabolism 28 5 24.789 20 0.31386 0.51411 
Malate-Aspartate Shuttle 10 3 24.412 20 0.31584 0.51411 
Histidine Metabolism 43 4 24.56 20 0.31637 0.51411 
Purine Metabolism 74 9 24.261 20 0.31789 0.51411 
Spermidine and Spermine Biosynthesis 18 2 24.368 20 0.3189 0.51411 
Arachidonic Acid Metabolism 69 1 24.234 20 0.32123 0.51411 
Nicotinate and Nicotinamide Metabolism 37 4 24.047 20 0.32216 0.51411 
Phospholipid Biosynthesis 29 1 24.143 20 0.32228 0.51411 
Porphyrin Metabolism 40 1 23.894 20 0.32517 0.51411 
Catecholamine Biosynthesis 20 1 23.759 20 0.32676 0.51411 
Thyroid hormone synthesis 13 1 23.759 20 0.32676 0.51411 
Methionine Metabolism 43 4 23.569 20 0.32849 0.51411 
Selenoamino Acid Metabolism 28 2 23.282 20 0.33227 0.51411 
Pyruvate Metabolism 48 6 22.984 20 0.33279 0.51411 




Warburg Effect 58 8 22.419 20 0.33871 0.51411 
Lysine Degradation 30 2 22.752 20 0.33871 0.51411 
Pyrimidine Metabolism 59 3 22.387 20 0.34176 0.51411 
Betaine Metabolism 21 2 22.339 20 0.34364 0.51411 
Biotin Metabolism 8 1 21.269 20 0.35727 0.51411 
Tryptophan Metabolism 60 4 20.235 20 0.37073 0.51411 
Glucose-Alanine Cycle 13 4 20.126 20 0.37422 0.51411 
Folate Metabolism 29 2 19.679 20 0.37844 0.51411 
Glycerolipid Metabolism 25 1 19.466 20 0.38114 0.51411 
Nucleotide Sugars Metabolism 20 1 18.622 20 0.39288 0.51411 
Pentose Phosphate Pathway 29 2 18.608 20 0.39389 0.51411 
Pantothenate and CoA Biosynthesis 21 2 18.717 20 0.39649 0.51411 
Phosphatidylcholine Biosynthesis 14 2 17.937 20 0.40486 0.51411 
Phosphatidylethanolamine Biosynthesis 12 2 17.937 20 0.40486 0.51411 
Glycolysis 25 2 17.705 20 0.43135 0.52372 
Transfer of Acetyl Groups into Mitochondria 22 2 17.705 20 0.43135 0.52372 
Androgen and Estrogen Metabolism 33 1 15.124 20 0.44607 0.52372 
Androstenedione Metabolism 24 1 15.124 20 0.44607 0.52372 
Steroid Biosynthesis 48 1 15.124 20 0.44607 0.52372 
Valine, Leucine and Isoleucine Degradation 60 8 19.148 20 0.45171 0.52372 
Cardiolipin Biosynthesis 11 1 11.73 20 0.50634 0.55871 
Phosphatidylinositol Phosphate Metabolism 17 1 11.73 20 0.50634 0.55871 
Plasmalogen Synthesis 26 1 11.73 20 0.50634 0.55871 
Pterine Biosynthesis 29 2 11.81 20 0.50982 0.55871 
Gluconeogenesis 35 5 11.92 20 0.54153 0.58345 




Sphingolipid Metabolism 40 2 10.486 20 0.55428 0.58345 
Galactose Metabolism 38 4 11.349 20 0.63243 0.65707 
Starch and Sucrose Metabolism 31 1 4.9599 20 0.67146 0.68868 
Lactose Synthesis 20 1 2.3505 20 0.77183 0.7816 
Fructose and Mannose Degradation 32 2 6.7285 20 0.80509 0.80509 
 
 
